

TRINITY CAPITAL INC.

Supplement No. 4 dated May 13, 2021 to Prospectus dated October 20, 2020

This Supplement No. 4 dated May 13, 2021 (this "Supplement") contains information that amends, supplements or modifies certain information contained in the accompanying prospectus of Trinity Capital Inc. ("we," "us," "our," and the "Company") dated October 20, 2020, as previously supplemented and amended (as so supplemented and amended, the "Prospectus"), and is part of, and should be read in conjunction with, the Prospectus. The Prospectus and this Supplement have been filed with the U.S. Securities and Exchange Commission and are available free of charge at www.sec.gov or by contacting us at 3075 West Ray Road, Suite 525, Chandler, Arizona 85226, calling us at (480) 374-5350 or visiting our corporate website located at www.trincapinvestment.com. Information on our website is not incorporated into or a part of the Prospectus and this Supplement. Capitalized terms used in this Supplement have the same meanings as in the Prospectus, unless otherwise stated herein.

Before investing in our 7.00% Notes due 2025 (the "Notes"), you should read carefully the Prospectus and this Supplement and consider carefully our investment objective, risks and expenses, including the discussion of the material risks of investing in the Notes in "Risk Factors" beginning on page 22 of the Prospectus and any other risk factors included in this Supplement. Investing in the Notes involves a high degree of risk, including credit risk and the risk of the use of leverage, and is highly speculative.

QUARTERLY REPORT ON FORM 10-Q FOR THE FISCAL QUARTER ENDED MARCH 31, 2021

On May 6, 2021, we filed our Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the "Form 10-Q") with the U.S. Securities and Exchange Commission. The Form 10-Q, excluding the exhibits thereto, is attached to this Supplement as <u>Annex A</u> and incorporated herein by reference.

* * * * *

ANNEX A

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended March 31, 2021

OR

□ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 000-56139

TRINITY CAPITAL INC.

(Exact name of registrant as specified in its charter)

Maryland other jurisdiction of incorp

(State or other jurisdiction of incorporation or organization)

3075 West Ray Road Suite 525 Chandler, Arizona (Address of principal executive offices) **35-2670395** (IRS Employer Identification No.)

> 85226 (Zip Code)

(480) 374-5350

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

 Title of Each Class
 Trading Symbol(s)
 Name of each exchange on which registered

 Common Stock, par value \$0.001 per share
 TRIN
 Nasdaq Global Select Market

 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 Yes
 No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes \Box No \Box

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer Non-accelerated filer

 Accelerated filer Smaller reporting company Emerging growth company
Energing growth company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Indicate by check mark whether the registrant is a shell Company (as defined in Rule 12b-2 of the Act). Yes 🛛 No 🖾

As of May 5, 2021, the registrant had 26,491,274 shares of common stock (\$0.001 par value per share) outstanding.

TRINITY CAPITAL INC. FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2021

TABLE OF CONTENTS

		PAGE NO.
PART I	FINANCIAL INFORMATION	3
<u>Item 1.</u>	Consolidated Financial Statements	3
	Consolidated Statements of Assets and Liabilities as of March 31, 2021 (unaudited) and	
	<u>December 31, 2020</u>	3
	Consolidated Statements of Operations for the Three Months Ended March 31, 2021 and 2020	
	(unaudited)	4
	Consolidated Statements of Changes in Net Assets for the Three Months Ended March 31, 2021	
	and 2020 (unaudited)	5
	Consolidated Statement of Cash Flows for the Three Months Ended March 31, 2021 and 2020	6
	(<u>unaudited</u>)	0
	Consolidated Schedule of Investments as of March 31, 2021 (unaudited)	8
	Consolidated Schedule of Investments as of December 31, 2020	22
	Notes to Consolidated Financial Statements (unaudited)	36
<u>Item 2.</u>	Management's Discussion and Analysis of Financial Condition and Results of Operations	63
<u>Item 3.</u>	Quantitative and Qualitative Disclosures About Market Risk	79
<u>Item 4.</u>	Controls and Procedures	80
PART II	OTHER INFORMATION	81
<u>Item 1.</u>	Legal Proceedings	81
<u>Item 1A.</u>	<u>Risk Factors</u>	81
<u>Item 2.</u>	Unregistered Sales of Equity Securities and Use of Proceeds	82
<u>Item 3.</u>	Defaults Upon Senior Securities	82
<u>Item 4.</u>	Mine Safety Disclosures	82
<u>Item 5.</u>	Other Information	82
<u>Item 6.</u>	Exhibits	83
SIGNATU	<u>RES</u>	84

PART I: FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements

TRINITY CAPITAL INC. Consolidated Statements of Assets and Liabilities (In thousands, except share and per share data)

		March 31, 2021	De	cember 31, 2020
ASSETS	(Unaudited)		
Investments at fair value:				
Control investments (cost of \$62,573 and \$57,072, respectively)	\$	46,677	\$	48,730
Affiliate investments (cost of \$20,425 and \$20,653, respectively)		21,110		27,650
Non-control / Non-affiliate investments (cast of \$442.222 and \$420.611, respectively)		467.054		417 271
Non-control / Non-affiliate investments (cost of \$442,233 and \$420,611, respectively)		467,954		417,271
Total investments (cost of \$525,231 and \$498,336, respectively)		535,741		493,651
Cash and cash equivalents		36,026		44,656
Restricted cash		15,259		16,445
		10,200		10,110
Interest receivable		3,924		3,468
Prepaid expenses		1,851		744
Other assets		1,186		744
Total assets	\$	593,987	\$	559,708
LIABILITIES				
Credit Facility, net of \$1,583 and \$2,107, respectively, of unamortized deferred financing costs	\$	43,420	\$	132,893
2025 Notes, net of \$4,406, and \$4,697, respectively, of unamortized deferred financing costs		120,594		120,303
Convertible Notes, net of \$2,887, and \$3,448, respectively, of unamortized deferred				
financing costs and discount		47,113		46,552
Distribution payable		7,396		4,947
Accounts payable and accrued liabilities		3,802		7,309
Other liabilities		10,099	_	8,956
Total liabilities		232,424		320,960

Commitments and contingencies (Note 6)		
NET ASSETS		
Common stock, \$0.001 par value per share (200,000,000 authorized, 26,415,275 and 18,321,274 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively)	26	18
Paid-in capital in excess of par	368,245	263,366
Distributable earnings/(accumulated loss)	 (6,708)	 (24,636)
Total net assets	361,563	 238,748
Total liabilities and net assets	\$ 593,987	\$ 559,708
NET ASSET VALUE PER SHARE	\$ 13.69	\$ 13.03

See accompanying notes to consolidated financial statements.

TRINITY CAPITAL INC. Consolidated Statements of Operations (In thousands, except share and per share data) (Unaudited)

	Three Months Ended March 31, 2021	Three Months Ended March 31, 2020
INVESTMENT INCOME: Interest income:		
Control investments	\$ 1,307	\$ 59
Affiliate investments	438	116
Non-Control / Non-Affiliate investments	14,600	10,639
Total interest income Fee income:	16,345	10,814
Non-Control / Non-Affiliate investments	975	1,434
Total fee income	975	1,434
Total investment income	17,320	12,248
EXPENSES:		
Interest expense and other debt financing costs	4,616	4,259
Compensation and benefits	3,996	1,389
Professional fees	647	479
General and administrative	808	414
Total expenses	10,067	6,541
NET INVESTMENT INCOME	7,253	5,707
NET REALIZED GAIN/(LOSS) FROM INVESTMENTS:		
Control investments		_
Affiliate investments	_	_
Non-Control / Non-Affiliate investments	2,595	(882)
Net realized loss from investments	2,595	(882)
NET CHANGE IN UNREALIZED APPRECIATION/(DEPRECIATION) FROM INVESTMENTS:		
Control investments	(7,554)	(7,128)
Affiliate investments	(6,312)	(1,507)
Non-Control / Non-Affiliate investments	29,342	(15,655)
Net change in unrealized appreciation/(depreciation) from investments	15,476	(24,290)
NET INCREASE/(DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS BEFORE FORMATION COSTS	25,324	(19,465)
Costs related to the acquisition of Trinity Capital Holdings and Legacy Funds		(15,586)
NET INCREASE/(DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS	<u>\$ 25,324</u>	\$ (35,051)
NET INVESTMENT INCOME PER SHARE - BASIC AND DILUTED	\$ 0.31	\$ 0.32
NET INCREASE/(DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS PER SHARE - BASIC AND DILUTED	<u>\$ 1.08</u>	(1.97)
WEIGHTED AVERAGE SHARES OUTSTANDING - BASIC AND DILUTED	23,554,950	17,821,790

See accompanying notes to consolidated financial statements.

TRINITY CAPITAL INC. Consolidated Statements of Changes in Net Assets (In thousands, except share and per share data) (Unaudited)

Three Months Ended March 31, 2021:

nree Months Ended March 31, 2021:			stributable Earnings /				
	Common Stock Shares Par Value		Paid In Capital in Excess of Par		ccumulated Loss)	Total Net Assets	
	Shares	Pdf Vd	iue	<u>III E</u>	access of Par	 LUSS	Net Assets
Balance as of December 31, 2020	18,321,274	\$	18	\$	263,366	\$ (24,636)	\$ 238,748
Impact of adoption of ASU 2020-06	_	-			(462)	_	(462)
Distributions to stockholders	_	-			_	(7,396)	(7,396)
Issuance of common stock in initial public offering, net of issuance costs	8,006,291		8		104,200	_	104,208
Issuance of common stock pursuant to distribution reinvestment plan Net increase/(decrease) in net assets resulting from	87,710				1,141	_	1,141
operations: Net investment income	_	_			_	7,253	7,253
Net realized gain/(loss) from investments	_	_			_	2,595	2,595
Net unrealized appreciation/(depreciation) from investments	_	-			_	15,476	15,476
Balance as of March 31, 2021 (unaudited)	26,415,275	\$ 2	26	\$	368,245	\$ (6,708)	\$ 361,563

Three Months Ended March 31, 2020:

Three Months Ended March 31, 2020:					Distributable	
		Common Shares	Value	Paid In Capital in Excess of Par Value	Earnings / (Accumulated Loss)	Total Net Assets
]	Balance as of December 31, 2019	10	\$ —	\$ —	\$ (524)	\$ (524)
	Issuance of shares related to Formation Transaction (1)	9,716,517	10	145,738	_	145,748
	Issuance of common stock, net of issuance costs	8,333,333	8	114,382	_	114,390
	Distributions to stockholders Net increase/(decrease) in net assets resulting from operations:	_	_	_	_	_
	Net investment income/(loss)	_	_	_	5,707	5,707
	Net realized gain/(loss) from investments	_	_	_	(882)	(882)
	Net unrealized appreciation/(depreciation) from investments	_	_	_	(24,290)	(24,290)
	Costs related to the acquisition of Trinity Capital Holdings and Legacy Funds	_		_		

		 	 	 (15,586)	(15,586)
Balance as of March 31, 2020 (unaudited)	18,049,860	\$ 18	\$ 260,120	\$ (35,575)	\$ 224,563

See accompanying notes to consolidated financial statements.

TRINITY CAPITAL INC. Consolidated Statement of Cash Flows (In thousands) (Unaudited)

	Thr March 31, 2021	Ended March 31, 202	ch 31, 2020	
Cash flows provided by/(used in) operating activities: Net increase/(decrease) in net assets resulting from operations Adjustments to reconcile net decrease in net assets resulting from operations to net cash provided by/(used in) operating activities:	\$ 2	25,324 5	\$ (3	35,051)
Purchase of investments, net of deferred fees	(8	36,694)	(4	17,740)
Proceeds from sales and paydowns of investments	6	56,985	4	4,465
Net change in unrealized depreciation from investments, net of third party participation	()	15,193)	2	24,277
Net realized gain/(loss) from investments		(2,595)		(503)
Accretion of original issue discounts and end of term payments on investments		(4,593)	((2,068)
Costs related to the acquisition of Trinity Capital Holdings and Legacy Funds		_	1	5,586
Amortization of deferred financing costs		917		666
Depreciation of fixed assets Change in operating assets and liabilities		16		9
(Increase)/Decrease in interest receivable		(456)	((2,054)
(Increase)/Decrease in prepaid expenses		(1,107)		13
(Increase)/Decrease in other assets		32		(594)
Increase/(Decrease) in accounts payable and accrued liabilities		(3,507)		3,069
Increase/(Decrease) in other liabilities		1,143		2,091
Increase/(Decrease) in due to related party			((1,058)
Net cash provided by/(used in) operating activities	(1	19,728)		1,108
Cash flows provided by/(used in) investing activities:				
Formation Transactions of Legacy Funds, net of cash acquired (1)		_	(8	89,515)
Acquisition of Trinity Capital Holdings		_	((2,211)
Acquisition of fixed assets		(490)		(10)
Net cash used in investing activities		(490)	(9	91,736)
Cash flows provided by/(used in) financing activities				
Issuance of common stock	11	12,088	12	25,000
Common stock issuance costs		(7,880)	(1	0,610)
Distributions paid, net of stock issued under DRIP of \$1,141 and \$0, respectively		(3,806)		_
Proceeds from issuance of 2025 Notes		_	12	25,000
Financing costs paid related to 2025 Notes		_	((5,542)
Repayments under Credit Facility	2)	90,000)	(6	50,000)
Financing costs paid related to credit facility			((3,735)
Net cash provided by/(used in) financing activities	1	10,402	17	70,113
Net increase/(decrease) in cash, cash equivalents and restricted cash		(9,816)	7	79,485
Cash, cash equivalents and restricted cash at beginning of period	6	51,101		
Cash, cash equivalents and restricted cash at end of period	\$ <u>5</u>	51,285	5 7	79,485
	For the March 31, 2021	Three Mon	ths Ended March 31, 202	20
Supplemental and non-cash investing and financing activities:				
Cash paid for interest	\$	4,200	5	3,583

Suppremental and non-cash investing and manenig activities.		
Cash paid for interest	\$ 4,200	\$ 3,583
Shares issued to Trinity Capital Holdings ⁽¹⁾	\$ _	\$ 8,000
Assumption of severance liability ⁽¹⁾	\$ _	\$ 3,508
Shares issued to the Legacy Investors as part of the Formation Transactions (1)	\$ _	\$ 137,748
Accrued but unpaid distributions	\$ 7,396	\$ _
Value of shares issued in connection with the distribution reinvestment plan	\$ 1,141	\$ _

The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the Consolidated Statements of Assets and Liabilities that sum to the total of the same such amounts on the Consolidated Statement of Cash Flows:

	 March 31, 2021	 March 31, 2020
Cash and cash equivalents	\$ 36,026	\$ 62,602
Restricted cash	 15,259	 16,883
Total cash, cash equivalents and restricted cash shown in the Consolidated Statements of Cash Flows	\$ 51,285	\$ 79,485

(1) See "Note 1 - Organization and Basis of Presentation"

See accompanying notes to consolidated financial statements.

Portfolio Company ⁽¹⁾ Debt Securities	Type of Investment ⁽³⁾	Maturity Date	Interest Rate (4)	Principal Amount ⁽⁵⁾	Cost	Fair V	Value (6)
Administrative and Support and Waste Managen	nent and Remediation (?).						
SeaOn Environmental, LLC	Equipment Financing	January 1, 2023	Fixed interest rate 9.0%; EOT 12.0%	\$ 1,888	\$ 2,165	\$	2,123
Sub-total: Administrative and Support and Wa	ste Management and Ren	ediation (0.6%)*		\$ 1,888	\$ 2,165	\$	2,123
Agriculture, Forestry, Fishing and Hunting (?)							
Bowery Farming, Inc.	Equipment Financing	January 1, 2023	Fixed interest rate 8.5%; EOT 8.5%	\$ 2,193	\$ 2,474	\$	2,305
	Equipment Financing	February 1, 2023	Fixed interest rate 8.7%; EOT 8.5%	2,181	2,408		2,424
	Equipment Financing	May 1, 2023	Fixed interest rate 8.7%; EOT 8.5%	2,756	2,993		3,004
	Equipment Financing	January 1, 2024	Fixed interest rate 7.5%; EOT 8.5%	9,211	9,265		9,312
Total Bowery Farming, Inc.				16,341	17,140		17,045
Robotany, Inc.	Equipment Financing	January 1, 2024	Fixed interest rate 7.6%; EOT 22.0%	\$ 1,587	\$ 1,698	\$	1,748
Sub-total: Agriculture, Forestry, Fishing and H	funting (5.2%)*			\$ 17,928	\$18,838	\$	18,793
Construction							
Dandelion Energy, Inc.	Equipment Financing	April 1, 2024	Fixed interest rate 9.0%; EOT 12.5%	\$ 429	\$ 443	\$	447
	Equipment Financing	November 1, 2024	Fixed interest rate 9.2%; EOT 12.5%	515	529		531
	Equipment Financing ⁽¹²⁾	December 1, 2024	Fixed interest rate 9.1%; EOT 12.5%	522	536		539
	Equipment Financing	January 1, 2025	Fixed interest rate 9.2%; EOT 12.5%	744	756		759
	Equipment Financing (12)	April 1, 2025	Fixed interest rate 9.1%; EOT 12.5%	1,159	1,161		1,163
Total Dandelion Energy, Inc.				3,369	3,425		3,439
Project Frog, Inc. (17)	Secured Loan	May 1, 2023	Fixed interest rate 12.0%	\$ 4,128	\$ 4,058	\$	3,912
Sub-total: Construction (2.0%)*				\$ 7,497	\$ 7,483	\$	7,351
Educational Services (?).							
Medical Sales Training Holding Company (14)	Secured Loan	April 1, 2025	Variable interest rate PRIME + 8.8% or Floor rate 12.0%; EOT 12.5% ⁽⁹⁾	\$ 6,000	\$ 5,929	\$	5,929
Yellowbrick Education, Inc.	Secured Loan	September 1, 2025	Variable interest rate PRIME + 8.3% or Floor rate 11.5%; EOT 5.0% ⁽⁹⁾	\$ 7,500	\$ 7,483	\$	7,483
Sub-total: Educational Services (3.7%)*				\$ 13,500	\$13,412	\$	13,412

Portfolio Company ⁽¹⁾	Type of Investment (3)	Maturity Date	Interest Rate ⁽⁴⁾	Principal Amount ⁽⁵⁾	Cost	Fair Value ⁽⁶
Debt Securities, Continued						
Finance and Insurance (?).						
DailyPay, Inc.	Secured Loan	November 1, 2024	Variable interest rate PRIME + 7.0% or Floor rate 12.0%; EOT 6.0% (9)	\$ 20,000	\$19,924	\$ 20,185
	Secured Loan	January 1, 2025	Variable interest rate PRIME + 7.0% or Floor rate 12.0%; EOT 6.0% ⁽⁹⁾	5,000	4,972	5,018
	Secured Loan	January 1, 2023	valiable interest rate FRIME + 7.076 of Floor rate 12.076, EOT 0.076 (5)	5,000	4,372	5,010
Total DailyPay, Inc.				25,000	24,896	25,203
Petal Card, Inc.	Secured Loan	December 1, 2023	Fixed interest rate 11.0%; EOT 3.0%	\$ 10,000	\$10,036	\$ 10,152
	Secured Loan (14)	January 1, 2024	Variable interest rate PRIME + 7.5% or Floor rate 11.5%	1,115	1,084	1,084
				11,115	11,120	11,236
Sub-total: Finance and Insurance (10.1%)*				\$ 36,115	\$36,016	\$ 36,439
Health Care and Social Assistance (?).						
Lark Technologies, Inc.	Secured Loan	April 1, 2025	Variable interest rate PRIME + 8.3% or Floor rate 11.5%; EOT 4.0% ⁽⁹⁾	\$ 5,000	\$ 4,839	\$ 4,903
Lark rechnologies, inc.	Secured Loan	April 1, 2023	Valiable interest rate FRIME * 0.576 01 Floor rate 11.576, EOT 4.076 (9)	\$ 5,000	\$ 4,035	\$ 4,505
WorkWell Prevention & Care Inc.	Secured Loan	March 1, 2024	Fixed interest rate 8.0%; EOT 10.0%	\$ 3,370	\$ 3,620	\$ 3,580
	6 J.	M 14 2024	T	200	730	c00
	Secured Loan	March 1, 2024	Fixed interest rate 8.0%	700	730	690
Total WorkWell Prevention & Care Inc. (17)				4,070	4,350	4,270
Sub-total: Health Care and Social Assistance (2.5%)*				\$ 9,070	\$ 9,189	\$ 9,173
Information (?).						
Firefly Systems, Inc.	Equipment Financing	February 1, 2023	Fixed interest rate 9.0%; EOT 10.0%	\$ 3,511	\$ 3,734	\$ 3,701
	E	Contract on 1, 2022	First distances and 0.00%, FOT 10.00%	2 0 2 0	2.005	2.070
	Equipment Financing	September 1, 2023	Fixed interest rate 9.0%; EOT 10.0%	2,939	3,085	3,078
	Equipment Financing	October 1, 2023	Fixed interest rate 9.0%; EOT 10.0%	355	371	370
Total Firefly Systems, Inc.				6,805	7,190	7,149
Gobiquity, Inc.	Equipment Financing	April 1, 2022	Fixed interest rate 7.5%; EOT 20.0%	\$ 239	\$ 349	\$ 347
RapidMiner, Inc.	Secured Loan	April 1, 2024	Fixed interest rate 12.0%; EOT 7.5%	\$ 10,000	\$10,179	\$ 10,189
Rigetti & Co, Inc. (14)	Secured Loan	April 1, 2025	Variable interest rate PRIME + 7.5% or Floor rate 11.0%; EOT 2.8% ⁽⁹⁾	\$ 12.000	\$11.735	\$ 11,735
				,		
Smule, Inc.	Secured Loan	January 1, 2022	Fixed interest rate 0.0% (15)	\$ 99	\$ 99	\$ 99
STS Media, Inc. (11)	Secured Loan	May 1, 2022	Fixed interest rate 11.9%; EOT 4.0%	\$ 7,811	\$ 737	\$ 100
Unitas Global, Inc.	Equipment Financing	July 1, 2021	Fixed interest rate 9.0%; EOT 12.0%	\$ 293	\$ 665	\$ 656
	Equipment Financing	April 1, 2021	Fixed interest rate 7.8%; EOT 6.0%		24	24
Total Unitas Global, Inc.				293	689	680
Sub-total: Information (8.4%)*				\$ 37,247	\$30,978	\$ 30,299

Portfolio Company ⁽¹⁾ Debt Securities, Continued	Type of Investment ⁽³⁾	Maturity Date	Interest Rate ⁽⁴⁾		rincipal mount ⁽⁵⁾	_	Cost	Fair Value (
<u>Ianufacturing ^(?)</u>									
AyDeeKay LLC	Secured Loan	August 1, 2024	Variable interest rate PRIME + 7.5% or Floor rate 10.8%; EOT 3.0% ⁽⁹⁾	\$	12,000	\$	11,981	\$	11,988
BHCosmetics, LLC	Equipment Financing	April 1, 2021	Fixed interest rate 8.7%; EOT 5.0% (16)	\$	_	\$	59	\$	59
Footprint International Holding, Inc.	Equipment Financing	March 1, 2024	Fixed interest rate 10.3%; EOT 8.0%	\$	13,771	\$	14,374	\$	14,468
	Secured Loan	July 1, 2024	Fixed interest rate 12.0%; EOT 9.0%		7,000		7,153		7,226
						_		_	
Total Footprint International Holding, Inc.					20,771		21,527		21,694
Happiest Baby, Inc.	Equipment Financing	September 1, 2022	Fixed interest rate 8.4%; EOT 9.5%	\$	794	\$	915	\$	889
	Equipment Financing	November 1, 2022	Fixed interest rate 8.6%; EOT 9.5%		653		739		743
	Equipment Financing	January 1, 2023	Fixed interest rate 8.6%; EOT 9.5%		635		703		711
	Equipment Financing	June 1, 2023	Fixed interest rate 8.2%; EOT 9.5%		816		879		880
	Equipment Financing	January 1, 2024	Fixed interest rate 7.8%; EOT 9.5%		1,156		1,193		1,200
	Equipment Financing	May 1, 2025	Fixed interest rate 8.4%; EOT 9.5%		955		965		965
					- 000				= 000
Total Happiest Baby, Inc.					5,009		5,394		5,388
Health-Ade, LLC	Equipment Financing	February 1, 2022	Fixed interest rate 9.4%; EOT 15.0%	\$	1,059	\$	1,615	\$	1,599
	Equipment Financing	April 1, 2022	Fixed interest rate 8.6%; EOT 15.0%		634		900		894
	-1								
	Equipment Financing	July 1, 2022	Fixed interest rate 9.1%; EOT 15.0%		1,648		2,173		2,165
Total Health-Ade, LLC					3,341		4,688		4,658
			Fixed						
Mainspring Energy, Inc.	Secured Loan	August 1, 2023	interest rate 11.0%; EOT 3.8%	\$	7,889	\$	8,085	\$	8,124
	Secured Loan	December 1, 2024	Fixed interest rate 11.0%; EOT 3.8%		5,500		5,307		5,454
Total Mainspring Energy, Inc.					13,389		13,392		13,578
Miyoko's Kitchen	Equipment Financing	September 1, 2022	Fixed interest rate 8.8%; EOT 9.0%	\$	498	\$	545	\$	546
MIJORO S PERCIEN	Equipment Financing	March 1, 2023	Fixed interest rate 8.9%; EOT 9.0%	Ψ	775	Ψ	812	Ψ	815
	Equipment Financing	September 1, 2023	Fixed interest rate 8.5%; EOT 9.0%		632		639		639
		-		_					
Total Miyoko's Kitchen					1,905		1,996		2,000
Molekule, Inc.	Equipment Financing	January 1, 2024	Fixed interest rate 8.8%; EOT 10.0%	\$	2,340	\$	2,420	\$	2,436
Molekule, Inc.	Equipment Financing	April 1, 2024	Fixed interest rate 9.0%; EOT 10.0%	æ	505	3	520	æ	524
	Equipment Financing	July 1, 2024	Fixed interest rate 8.8%; EOT 10.0%		821		835		839
	1.1.1.1.1.1								
Total Molekule, Inc.					3,666		3,775		3,799
Orig NVC Ing (14)	Comment of the second	A1 1 2020	Variable interest rate PRIME + 8.0% or Floor rate 11.3%; EOT 2.0% ⁽⁹⁾	¢	17 500		17 105	¢	17 105
Quip NYC, Inc. ⁽¹⁴⁾	Secured Loan	April 1, 2026	rate 11.3%; EOT 2.0% (3)	\$	17,500	\$	17,135	\$	17,135
Second Nature Brands, Inc.	Equipment Financing	April 1, 2024	Fixed interest rate 9.7%; EOT 11.50%	\$	2,051	\$	2,050	\$	2,555
Store Intelligence, Inc. (17)	Secured Loan	June 1, 2024	Fixed interest rate 12.0%; EOT 7.8%	\$	12,001	\$	12,310	\$	11,832
The Fynder Group, Inc.	Equipment Financing	May 1, 2024	Fixed interest rate 9.1%; EOT 10.0%	\$	612	\$	613	\$	617
	Equipment 1 manenig	y 1, 2024	Interest fate 517.0, EOT 10.070	Ψ	012	Ţ	013	Ş	017
Vertical Communications, Inc.	Secured Loan	November 1, 2024	Fixed interest rate 9.5%; EOT 26.4%	\$	12,000	\$	13,159	\$	12,968
	Secured Loan	July 1, 2022	Fixed interest rate 9.5%	_	687		687		694
Total Vertical Communications, Inc. (17)				_	12,687	_	13,846	_	13,662
				~	40.000				400
Sub-total: Manufacturing (30.1%)*				\$	104,932	\$	108,766	\$	108,965

Portfolio Company (1)	Type of Investment ⁽³⁾	Maturity Date	Interest Rate ⁽⁴⁾	Pr An	incipal nount ⁽⁵⁾		Cost	Fair	Value ⁽⁶⁾
Debt Securities, Continued									
Pharmaceutical ⁽²⁾ .									
Zosano Pharma Corporation	Equipment Financing	April 1, 2022	Fixed interest rate 9.4%; EOT 12.0%	\$	1,825	\$	2,362	\$	2,193
	Equipment Financing	July 1, 2022	Fixed interest rate 9.7%; EOT 12.0%		1,266		1,546		1,454
	Equipment Financing	January 1, 2023	Fixed interest rate 9.9%; EOT 12.0%		1,424		1,611		1,558
	Equipment Financing	April 1, 2023	Fixed interest rate 9.9%; EOT 12.0%		1,608		1,769		1,735
	Equipment Financing	May 1, 2023	Fixed interest rate 10.5%; EOT 12.0%		1,195		1,314		1,282
Total Zosano Pharma Corporation					7,318		8,602		8,222
						_			
Sub-total: Pharmaceutical (2.3%)*				\$	7,318	\$	8,602	\$	8,222
Professional, Scientific, and Technical Services (?).									
BackBlaze, Inc.	Equipment Financing	January 1, 2023	Fixed interest rate 7.2%; EOT 11.5%	\$	800	\$	949	\$	950
	Equipment Financing	April 1, 2023	Fixed interest rate 7.4%; EOT 11.5%		105		121		121
	Equipment Financing	June 1, 2023	Fixed interest rate 7.4%; EOT 11.5%		819		927		929
	Equipment Financing	August 1, 2023	Fixed interest rate 7.5%; EOT 11.5%		164		183		183
	Equipment Financing	September 1, 2023	Fixed interest rate 7.7%; EOT 11.5%		169		188		187
	Equipment Financing	October 1, 2023	Fixed interest rate 7.5%; EOT 11.5%		170		188		188
	Equipment Financing	November 1, 2023	Fixed interest rate 7.2%; EOT 11.5%		571		628		627
	Equipment Financing	December 1, 2023	Fixed interest rate 7.5%; EOT 11.5%		759		827		826
	Equipment Financing	January 1, 2024	Fixed interest rate 7.4%; EOT 11.5%		663		719		717
	Equipment Financing	February 1, 2024	Fixed interest rate 7.4%; EOT 11.5%		678		731		730
	Equipment Financing	March 1, 2024	Fixed interest rate 7.2%; EOT 11.5%		591		635		634
	Equipment Financing	April 1, 2024	Fixed interest rate 7.4%; EOT 11.5%		179		191		194
	Equipment Financing	May 1, 2024	Fixed interest rate 7.3%; EOT 11.5%		1,162		1,235		1,240
	Equipment Financing	August 1, 2024	Fixed interest rate 7.5%; EOT 11.5%		1,254		1,309		1,311
	Equipment Financing	October 1, 2024	Fixed interest rate 7.2%; EOT 11.5%		225		232		232
	Equipment Financing	April 1, 2025	Fixed interest rate 7.5%; EOT 11.5%		2,784		2,794		2,794
Total BackBlaze, Inc.					11,093		11,857		11,863
Edeniq, Inc.	Secured Loan	September 1, 2021	Fixed interest rate 13.0%; EOT 9.5%	\$	2,328	\$	434	\$	434
	Secured Loan	September 1, 2021	Fixed interest rate 13.0%; EOT 9.5%		1,745		279		279
Total Edeniq, Inc. ⁽¹¹⁾ (17)					4,073		713		713
Emergy, Inc. ⁽¹⁴⁾	Equipment Financing	May 1, 2024	Fixed interest rate 9.1%; EOT 5.0%	\$	554	\$	558	\$	558

Portfolio Company ⁽¹⁾	Type of Investment ⁽³⁾	Maturity Date	Interest Rate (4)	rincipal nount ⁽⁵⁾		Cost	Fai	r Value ⁽⁶⁾
Debt Securities, Continued					_		_	
Professional, Scientific, and Technical Services,	Continued							
Greenlight Biosciences Inc. (14)	Equipment Financing	April 1, 2024	Fixed interest rate 9.7%; EOT 8.0%	\$ 3,341	\$	3,285	\$	3,285
Incontext Solutions, Inc.	Secured Loan	October 1, 2023	Fixed interest rate 11.75%; EOT 11.4%	\$ 7,149	\$	7,479	\$	6,160
Matterport, Inc.	Secured Loan	May 1, 2022	Fixed interest rate 11.5%; EOT 5.0%	\$ 4,301	\$	4,739	\$	4,776
Pendulum Therapeutics, Inc.	Equipment Financing	May 1, 2023	Fixed interest rate 7.7%; EOT 5.0%	\$ 313	\$	310	\$	311
	Equipment Financing Equipment Financing	August 1, 2023 October 1, 2023	Fixed interest rate 7.8%; EOT 5.0% Fixed interest rate 7.7%; EOT 5.0%	1,900 565		1,976 575		1,992 580
	Equipment Financing	February 1, 2024	Fixed interest rate 9.8%; EOT 6.0%	831		840		850
Total Pendulum Therapeutics, Inc.				3,609		3,701		3,733
Reciprocity, Inc.	Secured Loan	October 1, 2024	Variable interest rate PRIME + 8.0% or Floor rate 11.3%; EOT 2.0% ⁽⁹⁾	\$ 10,000	\$	9,888	\$	9,853
Sun Basket, Inc.	Secured Loan	December 1, 2024	Variable interest rate PRIME + 8.5% or Floor rate 11.8%; EOT 5.0% ⁽⁹⁾	\$ 18,375	\$	17,978	\$	18,150
Utility Associates, Inc. (11)	Secured Loan	October 1, 2023	Fixed interest rate 11.0%	\$ 750	\$	830	\$	603
Sub-total: Professional, Scientific, and Technic	al Services (16.5%)*			\$ 63,245	\$	61,028	\$	59,694

Portfolio Company (1)	Type of Investment (3)	Maturity Date	Interest Rate ⁽⁴⁾		rincipal nount ⁽⁵⁾		Cost	Fai	r Value ⁽⁶⁾
Debt Securities, Continued									
Real Estate ⁽²⁾ .									
Knockaway, Inc.	Secured Loan	December 1, 2023	Fixed interest rate 11.0%; EOT 3.0%	\$	9,286	\$	9,416	\$	9,430
	Secured Loan	February 1 , 2024	Fixed interest rate 11.0%; EOT 3.0%		2,441		2,467		2,483
					_,		_,		_,
	Secured Loan	March 1, 2024	Fixed interest rate 11.0%; EOT 3.0%		2,500		2,523		2,541
Total Knockaway, Inc.					14,227		14,406		14,454
Orchard Technologies, Inc. (14)	Secured Loan	April 1, 2026	Variable interest rate PRIME + 7.5% or Floor rate 11.0%; EOT 4.0% ⁽⁹⁾	\$	5,000	\$	4,978	\$	4,978
Wanderjaunt, Inc.	Equipment Financing	June 1, 2023	Fixed interest rate 10.2%; EOT 12.0%	\$	351	\$	364	\$	355
Wanderjaan, ne.	Equipment I manenig	June 1, 2023	Fixed interest fate 10.270, EOT 12.070	Ψ	551	9	504	Ψ	333
	Equipment Financing	August 1, 2023	Fixed interest rate 10.2%; EOT 12.0%		1,124		1,225		1,208
Total Wanderjaunt, Inc.					1,475		1,589		1,563
				_				_	
Sub-total: Real Estate (5.8%)*				\$	20,702	s	20,973	\$	20,995
Rental and Leasing Services ⁽²⁾ .				-		-		-	,
and the starting of victory									
EquipmentShare, Inc.	Equipment Financing	July 1, 2023	Fixed interest rate 10.7%; EOT 5.0%	\$	6,872	\$	7,072	\$	7,117
	Equipment Financing	August 1, 2023	Fixed interest rate 10.1%; EOT 5.0%		790		811		816
	Equipment Financing	September 1, 2023	Fixed interest rate 10.2%; EOT 5.0%		1,750		1,791		1,800
	Equipment Financing	October 1, 2023	Fixed interest rate 10.4%; EOT 5.0%		3,149		3,210		3,224
	Equipment Financing	October 1, 2024	Fixed interest rate 8.3%; EOT 10.0%		404		415		415
	Equipment Financing	November 1, 2023	Fixed interest rate 10.4%; EOT 5.0%		749		761		770
	Equipment Financing	November 1, 2023	Fixed interest rate 10.5%; EOT 5.0%		2,363		2,402		2,428
	Equipment Financing	December 1, 2023	Fixed interest rate 10.1%; EOT 5.0%		2,305		2,337		2,361
	1 1				,		,		
	Equipment Financing	January 1, 2024	Fixed interest rate 10.1%; EOT 5.0%		1,850		1,870		1,887
	Equipment Financing	January 1, 2024	Fixed interest rate 10.5%; EOT 5.0%		736		743		750
	Equipment Financing	February 1, 2024	Fixed interest rate 10.6%; EOT 5.0%		1,363		1,372		1,372
	E automote Financia a	Mauch 1, 2024	Eine distance and 10 CO/+ EOE 5 OO/		1 701		1 700		1 700
	Equipment Financing	March 1, 2024	Fixed interest rate 10.6%; EOT 5.0%		1,791		1,798		1,798
	Equipment Financing	April 1, 2024	Fixed interest rate 10.7%; EOT 5.0%		1,913		1,918		1,918
Total EquipmentShare, Inc.					26,035		26,500		26,656
Total Equipmentonare, met					20,000		20,000		20,000
Maxwell Financial Labs, Inc.	Secured Loan	November 1, 2024	Variable interest rate PRIME + 8.0% or Floor rate 11.25%; EOT 4.0% ⁽⁹⁾	\$	3,000	\$	2,978	\$	3,018
			Variable interest rate PRIME + 8.0% or Floor						
	Secured Loan	January 1, 2025	rate 11.25%; EOT 4.0% ⁽⁹⁾		3,000		2,953		2,981
Total Maxwell Financial Labs, Inc.					6,000		5,931		5,999
								_	
Sub-total: Rental and Leasing Services (9.0%)*				\$	32,035	\$	32,431	\$	32,655
<u>Retail Trade (?).</u>									
Birchbox, Inc. (17)	Secured Loan	July 1, 2024	Fixed interest rate 9.0%; EOT 7.5%	\$	10,000	\$	10,464	\$	9,694
December 2010	Comment of the second	I 1 2022	Variable interest rate PRIME + 7.75% or Floor	¢	5 000		4.050	¢	F 007
Boosted eCommerce, Inc. (14)	Secured Loan	January 1, 2023	rate 11.0%; EOT 3.25% ⁽⁹⁾ Variable interest rate PRIME + 7.75% or Floor	\$	5,000	\$	4,959	\$	5,007
	Secured Loan	January 1, 2023	variable interest rate PRIME + 7.75% or Floor rate 11.0%; EOT 3.25% ⁽⁹⁾		2,500		2,473		2,473
	Secured Loan	January 1, 2023	Variable interest rate PRIME + 7.75% or Floor rate 11.0%; EOT 3.25% ⁽⁹⁾		7,500		7,412		7,412
	Contra Louis	5unuu y 1, 2023			.,500		.,712		,,412
Total Boosted eCommerce, Inc.					15,000		14,844		14,892
Gobble, Inc.	Secured Loan	July 1, 2023	Fixed interest rate 11.3%; EOT 6.0%	\$	3,151	\$	3,276	\$	3,310

	Secured Loan	July 1, 2023	Fixed interest rate 11.5%; EOT 6.0%		1,584		1,646		1,663
Total Gobble Inc.					4,735	-	4,922	-	4,973
Madison Reed, Inc.	Secured Loan	May 1, 2024	Variable interest rate PRIME + 6.0% or Floor rate 10.3%; EOT 4.0% ⁽⁹⁾	\$	17,500	\$	17,539	\$	18,550
Portofino Labs, Inc. (14)	Secured Loan	July 1, 2025	Variable interest rate PRIME + 8.25% or Floor rate 11.5%; EOT 4.0% ⁽⁹⁾	\$	2,000	\$	1,991	\$	2,002
	Secured Loan	October 1, 2025	Variable interest rate PRIME + 8.25% or Floor rate 11.5%; EOT 4.0% ⁽⁹⁾	_	3,000		2,836		2,836
Total Portofino Labs, Inc.					5,000		4,827		4,838
Super73, Inc. (14)	Secured Loan	January 1, 2025	Variable interest rate PRIME + 7.3% or Floor rate 11.8%; EOT 4.0% ⁽⁹⁾	\$	5,500	\$	5,442	\$	5,494
UnTuckIt, Inc.	Secured Loan	June 1, 2024	Fixed interest rate 12.0%; EOT 5.0%	\$	20,000	\$	21,079	\$	19,430
Sub-total: Retail Trade (21.5%)*				\$	77,735	\$	79,117	\$	77,871

Portfolio Company (1)	Type of Investment ⁽³⁾	Maturity Date	Interest Rate (4)	Principal Amount ⁽⁵⁾	Cost	Fair Value ⁽⁶⁾
Debt Securities, Continued						
<u>Utilities</u> (?)						
Invenia, Inc.	Secured Loan	January 1, 2023	Fixed interest rate 11.5%; EOT 5.0%	\$ 5,862	\$ 6,327	\$ 6,288
	Secured Loan	May 1, 2023	Fixed interest rate 11.5%; EOT 5.0%	3,023	3,231	3,243
	Secured Loan	January 1, 2024	Fixed interest rate 11.5%; EOT 5.0%	2,859	2,930	2,991
	Secured Loan	February 1, 2024	Fixed interest rate 11.5%; EOT 5.0%	3,906	4,024	4,081
	Secured Loan	July 1, 2024	Fixed interest rate 11.5%: EOT 5.0%	4,000	4,060	4,177
	Secured Loan	November 1, 2024	Fixed interest rate 11.5%: EOT 5.0%	5,000	5,037	5,182
Total Invenia, Inc. ⁽⁸⁾				24,650	25,609	25,962
				\$ 24,650	\$ 25,609	\$ 25,962
Sub-total: Utilities (7.2%)*				\$ 24,030	3 23,003	\$ 23,302
Wholesale Trade						
BaubleBar, Inc. ⁽¹⁸⁾	Secured Loan	March 1, 2023	Fixed interest rate 11.5%; EOT 7.3%	\$ 5,184	\$ 6,030	\$ 5,665
Combad Inc	Equipment Financing	Inc. 1, 2022	Fined interest and 10 COV. FOT 5 00/	\$ 2,633	\$ 2,666	\$ 2,686
Grandpad, Inc.	Equipment Financing	June 1, 2023	Fixed interest rate 10.6%; EOT 5.0%	\$ 2,033	\$ 2,000	\$ 2,000
	Equipment Financing	July 1, 2023	Fixed interest rate 10.8%; EOT 5.0%	3,327	3,354	3,379
	Equipment Financing	July 1, 2023	Fixed interest fate 10.0%, EO1 5.0%		5,554	3,373
Total Crandrad Inc. (14)				5.060	6.020	6.065
Total Grandpad, Inc. (14)				5,960	6,020	6,065
Sub-total: Wholesale Trade (3.2%)*				\$ 11,144	\$ 12,050	\$ 11,730
				<u> </u>		
Total: Debt Securities (128.2%)* (13)				\$ 465,006	\$ 466,657	\$ 463,684

Portfolio Company ⁽¹⁾ Warrant Investments	Type of Investment ⁽³⁾	Expiration Date	Series	Shares	Str	ike Price		Cost	Fair	r Value ⁽⁶⁾
Agriculture, Forestry, Fishing and Hunting (2)										
Bowery Farming, Inc.	Warrant	June 10, 2029	Common Stock	68,863	\$	5.08	\$	410	\$	537
	Warrant	December 22, 2030	Common Stock	29,925	\$	6.24	\$	160	\$	234
Total Bowery Farming, Inc.								570		771
Robotany, Inc.	Warrant	July 19, 2029	Common Stock	262,870	\$	0.26	\$	128	\$	173
Sub-Total: Agriculture, Forestry, Fishing and Hunting ((0.3%)*						\$	698	\$	944
Construction (?).										
Project Frog, Inc. (17)	Warrant	July 26, 2026	Preferred Series AA	391,990	\$	0.19	\$	18	\$	3
Sub-Total: Construction (0.0%)*							\$	18	\$	3
Educational Services (?)										
Medical Sales Training Holding Company	Warrant	March 18, 2031	Common Stock	3,232	\$	7.74	\$	21	\$	20
Yellowbrick Education, Inc.	Warrant	September 28, 2028	Common Stock	222,222	\$	0.90	\$	120	\$	582
Sub-Total: Educational Services (0.2%)*							\$	141	\$	602
Finance and Insurance (?).										
DailyPay, Inc.	Warrant	September 30, 2030	Common Stock	89,264	\$	3.00	\$	151	\$	268
Petal Card, Inc.	Warrant	November 27, 2029	Preferred Series B	250,268	\$	1.32	\$	147	\$	394
Tatel Datel Card Jac	Warrant	January 11, 2031	Common Stock (14)	135,835		0.01		312		343
Total Petal Card, Inc.								459		737
Realty Mogul	Warrant	December 18, 2027	Preferred Series B	234,421	\$	3.88	\$	285	\$	23
Sub-Total: Finance and Insurance (0.3%)*							\$	895	\$	1,028
Health Care and Social Assistance (?)										
Lark Technologies, Inc.	Warrant	September 30, 2030	Common Stock	76,231	\$	1.76	\$	177	\$	189
Sub-Total: Health Care and Social Assistance (0.1%)*							\$	177	\$	189
Information (?).										
Convercent, Inc.	Warrant	November 30, 2025	Preferred Series 1	3,139,579	\$	0.16	\$	924	\$	1,637
Figg, Inc. (7)	Warrant	March 31, 2028	Common Stock	935,198	\$	0.07	\$	_	\$	_
Everalbum, Inc.	Warrant	July 29, 2026	Preferred Series A	851,063	\$	0.10	\$	24	\$	4
	¥47	1 20 2020	0 0 1	100.445	¢		¢	202	¢	440
Firefly Systems, Inc.	Warrant	January 29, 2030	Common Stock	133,147	\$	1.14	\$	282	\$	113
Gtxcel, Inc.	Warrant	September 24, 2025	Preferred Series C	1,000,000	\$	0.21	\$	83	\$	11
Total Gtxcel, Inc.	Warrant	September 24, 2025	Preferred Series D	1,000,000	\$	0.21		83 166		
								200		
Lucidworks, Inc.	Warrant	June 27, 2026	Preferred Series D	619,435	\$	0.77	\$	806	\$	1,659
Oto Analytics, Inc.	Warrant	August 31, 2028	Preferred Series B	1,018,718	\$	0.79	\$	295	\$	187
RapidMiner, Inc.	Warrant	March 25, 2029	Preferred Series C-1	11,624	\$	60.22	\$	528	\$	113
Rigetti & Co, Inc. (14)	Warrant	March 10, 2031	Common Stock	398,040	\$	0.21	\$	217	\$	195
STS Media, Inc. ⁽⁷⁾	Warrant	March 15, 2028	Preferred Series C	20,210	\$	24.74	\$	_	\$	_

Sub-Total: Information (1.1%)*

\$ 3,242 \$ 3,919

Portfolio Company ⁽¹⁾ Warrant Investments, Continued	Type of Investment ⁽³⁾	Expiration Date	Series	Shares	Sti	ike Price	_	Cost	Fai	r Value ⁽⁶⁾
Manufacturing (?).										
AyDeeKay LLC	Warrant	March 30, 2028	Preferred Series G	6,250	\$	35.42	\$	31	\$	865
Footprint International Holding, Inc.	Warrant	February 14, 2030	Common Stock	26,852	\$	0.31	\$	5	\$	90
	Warrant	June 22, 2030	Common Stock	10,836	\$	0.31		4		36
Total Footprint International Holding, Inc.								9		126
Happiest Baby, Inc.	Warrant	May 16, 2029	Common Stock	182,554	\$	0.33	\$	193	\$	162
Lensvector, Inc.	Warrant	December 30, 2021	Preferred Series C	85,065	\$	1.18	\$	32	\$	_
Mainspring Energy, Inc.	Warrant	July 9, 2029	Common Stock	140,186	\$	1.15	\$	283	\$	580
	Warrant	November 20, 2030	Common Stock	81,294	\$	1.15		226		336
Total Mainspring Energy, Inc.								509		916
Molekule, Inc.	Warrant	June 19, 2030	Preferred Series C-1	32,051	\$	3.12	\$	16	\$	17
Quip NYC, Inc. ⁽¹⁴⁾	Warrant	March 9, 2031	Preferred Series A-1	10,833	\$	48.46	\$	203	\$	187
SBG Labs, Inc.	Warrant	June 29, 2023	Preferred Series A-1	42,857	\$	0.70	\$	13	\$	_
	Warrant	September 18, 2024	Preferred Series A-1	25,714	\$	0.70		8		_
	Warrant	January 14, 2024	Preferred Series A-1	21,492	\$	0.70		7		_
	Warrant	March 24, 2025	Preferred Series A-1	12,155	\$	0.70		4		_
	Warrant	October 10, 2023	Preferred Series A-1	11,150	\$	0.70		4		_
	Warrant	May 6, 2024	Preferred Series A-1	11,145	\$	0.70		4		_
	Warrant	June 9, 2024	Preferred Series A-1	7,085	\$	0.70		2		_
	Warrant	May 20, 2024	Preferred Series A-1	342,857	\$	0.70		110		_
	Warrant	March 26, 2025	Preferred Series A-1	200,000	\$	0.70		65		_
Total SBG Labs, Inc.								217		_
The Fynder Group, Inc.	Warrant	October 14, 2030	Common Stock	107,190	\$	0.49	\$	202	\$	222
Vertical Communications, Inc. ⁽⁷⁾ (17)	Warrant	July 11, 2026	Preferred Series A	828,479	\$	1.00	\$	_	\$	_
Sub-Total: Manufacturing (0.7%)*							\$	1,412	\$	2,495

Portfolio Company ⁽¹⁾ Warrant Investments, Continued	Type of Investment ⁽³⁾	Expiration Date	Series	Shares	Str	ike Price		Cost	Fai	r Value ⁽⁶⁾
Pharmaceutical (?).										
Ology Biosciences, Inc. (17)	Warrant	November 14, 2021	Common Stock	67,961	\$	1.03	\$	1,122	\$	1,357
	117	G . 1 05 0005		75.000	¢	2.50	¢	CO	~	
Zosano Pharma Corporation	Warrant	September 25, 2025	Common Stock	75,000	\$	3.59	\$	69	\$	77
Sub-Total: Pharmaceutical (0.4%)*							\$	1,191	\$	1,434
Professional, Scientific, and Technical Services (?).										
Augmedix, Inc.	Warrant	September 3, 2029	Preferred Series B	580,383	\$	2.88	\$	449	\$	1,008
Castinuity Inc	Warrant	Maush 20, 2020	Preferred Series C	1 500 000	¢	0.25	\$	21	\$	33
Continuity, Inc.	warrant	March 29, 2026	Preferred Series C	1,588,806	\$	0.25	Э	21	3	33
Crowdtap, Inc.	Warrant	December 16, 2025	Preferred Series B	442,233	\$	1.09	\$	42	\$	116
	Warrant	November 30, 2027	Preferred Series B	100,000	\$	1.09		9		26
Total Crowdtap, Inc.								51		142
Dynamics, Inc.	Warrant	March 10, 2024	Common Stock	17,000	\$	10.59	\$	86	\$	_
E La Carte, Inc.	Warrant	July 28, 2027	Common Stock	497,183	\$	0.30	\$	186	\$	101
	Warrant	July 28, 2027	Preferred Series A	104,284	\$	7.49		15		22
	Warrant	July 28, 2027	Preferred Series AA-1	106,841	\$	7.49		15		21
Total E La Carte, Inc.								216		144
Edonia Inc	Monost	December 22, 2026	Destaward Cavias D	2.695 501	¢	0.22	\$		\$	
Edeniq, Inc.	Warrant	December 23, 2026	Preferred Series B	2,685,501	\$		æ	_	3	_
	Warrant	December 23, 2026	Preferred Series B	2,184,672	\$	0.01		-		_
	Warrant	March 12, 2028	Preferred Series C	5,106,972	\$	0.44		-		-
	Warrant	October 15, 2028	Preferred Series C	3,850,294	\$	0.01				_
Total Edeniq, Inc. ⁽⁷⁾⁽¹⁷⁾								_		_
Greenlight Biosciences Inc. (14)	Warrant	March 29, 2031	Common Stock	219,839	\$	0.81	\$	138	\$	139
Hologram, Inc.	Warrant	January 27, 2030	Common Stock	193,054	\$	0.26	\$	49	\$	50
Hospitalists Now, Inc.	Warrant	March 30, 2026	Preferred Series D2	135,807	\$	5.89	\$	71	\$	265
	Warrant	December 6, 2026	Preferred Series D2	750,000	\$	5.89		391		1 402
Total Hospitalists Now, Inc.	warrant	December 6, 2026	Preferred Series D2	/50,000	Ф	5.89	-	462		1,462 1,727
Incontext Solutions, Inc.	Warrant	September 28, 2028	Preferred Series AA-1	332,858	\$	1.47	\$	34	\$	47
Matterport, Inc.	Warrant	April 20, 2028	Common Stock	143,813	\$	1.43	\$	434	\$	4,008
Pendulum Therapeutics, Inc.	Warrant Warrant	October 9, 2029 July 15, 2030	Preferred Series B Preferred Series B	55,263 36,842	\$ \$	1.90 1.90	\$	44 36	\$	85 57
Total Pendulum Therapeutics, Inc.	Wallant	5ury 15, 2000	Fictured Series D	30,042	Ψ	1.50		80		142
Reciprocity, Inc.	Warrant	September 25, 2030	Common Stock	114,678	\$	4.17	\$	99	\$	126
Resilinc, Inc.	Warrant	December 15, 2025	Preferred Series A	589,275	\$	0.51	\$	40	\$	47
Saylent Technologies, Inc.	Warrant	March 31, 2027	Preferred Series C	24,096	\$	9.96	\$	108	\$	166
Sun Basket, Inc.	Warrant	October 5, 2027	Preferred Series C-2	249,306	\$	6.02	\$	111	\$	203
	Warrant	December 31, 2030	Common Stock	118,678	\$	0.89		545		440
				.,			-		_	

						656		643
Utility Associates, Inc.	Warrant	June 30, 2025	Preferred Series A	92,511	\$ 4.54	\$ 55	\$	3
	Warrant	May 1, 2026	Preferred Series A	60,000	\$ 4.54	36		6
	Warrant	May 22, 2027	Preferred Series A	200,000	\$ 4.54	120		1
Total Utility Associates, Inc.						211		10
Sub-Total: Professional, Scientific, and Te	chnical Services (2.3%)*					\$ 3,134	\$	8,432
	· /						_	

Portfolio Company ⁽¹⁾	Type of Investment ⁽³⁾	Expiration Date	Series	Shares	Str	ike Price		Cost	Fai	r Value ⁽⁶⁾
Warrant Investments, Continued										
<u>Real Estate ⁽²⁾.</u>										
Egomotion Corporation	Warrant	December 10, 2028	Preferred Series A	60,786	\$	1.32	\$	-	\$	30
	¥17 .	I 20 2020		101 551	¢	4.00		210		50
	Warrant	June 29, 2028	Preferred Series A	121,571	\$	1.32		219		59
Total Egomotion Corporation								219		89
Knockaway, Inc.	Warrant	May 24, 2029	Preferred Series B	87,955	\$	8.53	\$	209	\$	185
							_		_	
Sub-Total: Real Estate (0.1%)*							\$	428	\$	274
<u>Rental and Leasing Services (?).</u>										
Maxwell Financial Labs, Inc.	Warrant	October 7, 2030	Common Stock	106,735	\$	0.29	\$	21	\$	282
	Warrant	December 22, 2030	Common Stock	110,860	\$	0.29		34		270
Total Maxwell Financial Labs, Inc.								55		552
Sub-Total: Rental and Leasing Services (0.1%)*							\$	55	\$	552
							\$	33	9	332
Retail Trade (?).										
Boosted eCommerce, Inc. (14)	Warrant	December 14, 2030	Preferred Series A-1	759,263	\$	0.84	\$	259	\$	179
Gobble, Inc.	Warrant	May 9, 2028	Common Stock	74,635	\$	1.20	\$	73	\$	57
	Warrant	December 27, 2029	Common Stock	10,000	\$	1.22		617		425
Total Gobble, Inc.								690		482
Madison Reed, Inc.	Warrant	March 23, 2027	Preferred Series C	194,553	\$	2.57	\$	185	\$	375
	Warrant	July 18, 2028	Common Stock	43,158	\$	0.99		71		83
	Warrant	May 19, 2029	Common Stock	36,585	\$	1.23		56		71
Total Madison Reed, Inc.								312		529
Portofino Labs, Inc. (14)	Warrant	December 31, 2030	Common Stock	39,659	\$	1.53	\$	160	\$	242
Portonino Labs, nic. (14)	wallalit	December 51, 2050	Common Stock	39,039	æ	1.55	æ	100	¢	242
с тэл (14)	¥17 .	D 1 21 2020		155 205	¢	2.46	¢	105	¢	425
Super73, Inc. (14)	Warrant	December 31, 2030	Common Stock	177,305	\$	3.16	\$	105	\$	135
	¥.7	1 10 . 2020		245 500	¢		¢	222	¢	100
Trendly, Inc.	Warrant	August 10, 2026	Preferred Series A	245,506	\$	1.14	\$	222	\$	136
Sub-Total: Retail Trade (0.5%)*							\$	1,748	\$	1,703
Wholesale Trade (?).										
wholesale Trade s.v.										
BaubleBar, Inc.	Warrant	March 29, 2027	Preferred Series C	531,806	\$	1.96	\$	638	\$	216
	Warrant	April 20, 2028	Preferred Series C	60,000	\$	1.96		72		24
Total BaubleBar, Inc.								710		240
GrubMarket, Inc.	Warrant	June 15, 2030	Common Stock	405,000	\$	1.10	\$	116	\$	623
							_		_	
Sub-Total: Wholesale Trade (0.2%)*							\$	826	\$	863
Total: Warrant Investments (6.2%)* (13)							\$	13,965	\$	22,438
							_		_	

Portfolio Company (1)	Type of Investment ⁽³⁾	Shares / Principal	Series		Cost	Fai	r Value ⁽⁶⁾
Equity Investments Construction (2)							
Project Frog, Inc.	Equity	8,118,527	Preferred Series AA-1	\$	702	\$	161
	Equity	6,300,134	Preferred Series BB		2,667		920
Total Project Frog, Inc. (17)	1 0				3,369		1,081
Sub-Total: Construction (0.3%)*				\$	3,369	\$	1,081
Health Care and Social Assistance (?).							
WorkWell Prevention & Care Inc.	Equity	7,000,000	Common Stock	\$	51	\$	_
	Equity	3,450	Preferred Series P		3,450		_
	Equity	\$ 2,470	Convertible Notes (10)		2,519		2,450
Total WorkWell Prevention & Care Inc. (17)	1.5				6,020		2,450
					0,020		2,100
Sub-Total: Health Care and Social Assistance (0.7%)*				\$	6,020	\$	2,450
Manufacturing (?).							
Atieva, Inc. ⁽⁸⁾	Equity	585,022	Preferred Series E	\$	7,600	\$	26,772
	• •						
Store Intelligence, Inc. (17)	Equity	1,430,000	Preferred Series A	\$	608	\$	260
Vertical Communications, Inc.	Equity	3,892,485	Preferred Series 1 (7)	\$	_	\$	_
vertical communications, ne.	Equity	\$ 5,500,000	Convertible Notes (10)	Ψ	3,966	Ψ	3,659
	Equity	\$ 3,300,000	Convertible Profes ()				
Total Vertical Communications, Inc. (17)					3,966		3,659
Sub-Total: Manufacturing (8.5%)*				\$	12,174	\$	30,691
Pharmaceutical (?).							
	1	264 702	0 0 1	¢	6 205	¢	7.001
Ology Biosciences, Inc. (17)	Equity	364,792	Common Stock	\$	6,385	\$	7,661
Sub-Total: Pharmaceutical (2.1%)*				\$	6,385	\$	7,661
Professional, Scientific, and Technical Services (?).		17 720	Durfamed Caulor A	¢	200	¢	
Dynamics, Inc.	Equity	17,726	Preferred Series A	\$	390	\$	_
	Equity	15,000	Common Stock (7)				
Total Dynamics, Inc.					390		_
Edeniq, Inc.	Equity	7,807,499	Preferred Series B (7)	\$	_	\$	_
	Equity	2,441,082	Preferred Series C (7)		_		_
	Equity	\$ 1,303,373	Convertible Notes (7)(10)		_		_
Total Edeniq, Inc. (17)					_		_
Sub-Total: Professional, Scientific, and Technical	Services (0.0%)*			\$	390	\$	_
Rental and Leasing Services (?).							
Maxwell Financial Labs, Inc (14)	Equity	135,641	Preferred Series B	\$	500	\$	500
	-4						
Sub-Total: Rental and Leasing Services (0.1%)*				\$	500	\$	500
<u>Retail Trade (?).</u>							
Birchbox, Inc.	Equity	3,140,927	Preferred Series D	\$	10,271	\$	3,295
	Equity	2,002,416	Preferred Series E		5,500		3,941
Total Birchbox, Inc. (17)	1.0				15,771		7,236
Iotal Difeibox, inc.					13,771		7,230
Sub-Total: Retail Trade (2.0%)*				\$	15,771	\$	7,236
Total: Equity Investments (13.7%)* (13)				\$	44,609	\$	49,619
Total Investment in Securities (148.2%)*				\$	525,231	\$	535,741
Cash, Cash Equivalents, and Restricted Cash							
Goldman Sachs Financial Square Government Instit	utional Fund			\$	39,842	\$	39,842
Other cash accounts					11,443	_	11,443
Cash, Cash Equivalents, and Restricted Cash (14.2%)*					51,285		51,285
Total Portfolio Investments and Cash and Cash							
					576,516	\$	587,026

- (1) All portfolio companies are located in North America. As of March 31, 2021, the Company had two foreign domiciled portfolio companies one in Canada and one in Cayman Islands. The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the "Securities Act"). These investments are generally subject to certain limitations on resale and may be deemed to be "restricted securities" under the Securities Act.
- ⁽²⁾ The Company uses the North American Industry Classification System ("NAICS") code for classifying the industry grouping of its portfolio companies.
- (3) All debt investments are income producing unless otherwise noted. All equity and warrant investments are non-income producing unless otherwise noted. Equipment financed under our equipment financing investments relates to operational equipment essential to revenue production for the portfolio company in the industry noted.
- (4) Interest rate is the fixed or variable rate of the debt investments and does not include any original issue discount, end-of-term ("EOT") payment, or any additional fees related to such investments, such as deferred interest, commitment fees, prepayment fees or exit fees. EOT payments are contractual payments due in cash at the maturity date of the loan, including upon prepayment, and are a fixed rate determined at the inception of the loan. At the end of the term of certain equipment financings, the borrower has the option to purchase the underlying assets at fair market value in certain cases subject to a cap, or return the equipment and pay a restocking fee. The fair values of the financed assets have been estimated as a percentage of original cost for purpose of the EOT payment value. The EOT payment is amortized and recognized as non-cash income over the loan or equipment financing prior to its payment and is included as a component of the cost basis of the Company's current debt securities
- ⁽⁵⁾ Principal is net of repayments, if any, as per the terms of the debt instrument's contract.
- ⁽⁶⁾ All investments were valued at fair value using Level 3 significant unobservable inputs as determined in good faith by the Company's board of directors.
- (7) Investment has zero cost basis as it was purchased at a fair market value of zero as part of the Formation Transaction.
- (8) Indicates a "non-qualifying asset" under section 55(a) by the Investment Company Act of 1940, as amended. The Company's percentage of non-qualifying assets represents 5.1% of the Company's total assets as of March 31, 2021. Qualifying assets must represent at least 70% of the Company's total assets at the time of acquisition of any additional non-qualifying assets.
- ⁽⁹⁾ The interest rate on variable interest rate investments represents a benchmark rate plus spread. The benchmark interest rate is subject to an interest rate floor. The benchmark rate PRIME was 3.25% as of March 31, 2021.
- (10) Convertible notes represent investments through which the Company will participate in future equity rounds at preferential rates. There are no principal or interest payments made against the note unless conversion does not take place.
- ⁽¹¹⁾ Debt is on non-accrual status as of March 31, 2021 and is therefore considered non-income producing.
- (12) Investment has an unfunded commitment as of March 31, 2021 (see "Note 6 Commitments and Contingencies"). The fair value of the investment includes the impact of the fair value of any unfunded commitments.

- ⁽¹³⁾ All of the Company's debt, warrant and equity securities are pledged as collateral supporting the amounts outstanding under the credit facility with Credit Suisse AG (see "Note 5 Borrowings"), except as noted.
- ⁽¹⁴⁾ Investment is not pledged as collateral supporting amounts outstanding under the credit facility with Credit Suisse AG.
- ⁽¹⁵⁾ Investment is considered non-income producing.
- ⁽¹⁶⁾ Investment principal has been fully repaid. Remaining cost relates to EOT receivable.
- (17) This

investment is deemed to be a "Control Investment" or an "Affiliate Investment." The Company classifies its investment

portfolio in accordance with the requirements of the 1940 Act. Control Investments are defined by the Investment Company Act of 1940,

as amended, as investments in companies in which the Company owns more than 25% of the voting securities or maintains greater than 50%

of the board representation. Affiliate Investments are defined by the Investment Company Act of 1940, as amended, as investments in companies

in which the Company owns between 5% and 25% (inclusive) of the voting securities and does not have rights to maintain greater than 50%

of the board representation. As defined in the Investment Company Act, the Company is deemed to be an "Affiliated Person"

of this portfolio company. Fair value as of March 31, 2021 along with transactions during the three months ended March 31, 2021 in these

control or affiliated investments are as follows:

	Beginning Fair Value		Gross Additions ⁽¹⁾	Gross Reductions ⁽²⁾	Realized Gain/(Loss)	Net change in Unrealized (Depreciation)/ Appreciation		Ending Fair Value			Interest Income
For the Three Months Ended March 31, 2021											
Control Investments											
Birchbox, Inc.	\$ 19,369	\$	5,531	\$ _	\$ _	\$	(7,970)	\$	16,930	\$	256
Edeniq, Inc.	1,507		97	(1,248)	_		356		712		302
Project Frog, Inc.	4,516		13	_	_		466		4,995		137
Vertical Communications, Inc.	16,953		221	(120)	_		267		17,321		523
WorkWell Prevention and Care Inc.	6,385		1,007	 _	 _		(673)	_	6,719		89
Total Control Investments	\$ 48,730	<u>\$</u>	6,869	\$ (1,368)	\$ 	\$	(7,554)	<u>\$</u>	46,677	\$	1,307
Affiliate Investments											
Ology Biosciences, Inc.	\$ 15,072	\$	_	\$ (306)	\$ _	\$	(5,748)	\$	9,018	\$	_
Store Intelligence, Inc.	 12,578		78	_	_		(564)		12,092	_	438
Total Affiliate Investments	\$ 27,650	\$	78	\$ (306)	\$ 	\$	(6,312)	\$	21,110	\$	438
Total Control and Affiliate Investments	\$ 76,380	\$	6,947	\$ (1,674)	\$ 	\$	(13,866)	\$	67,787	\$	1,745

(1) Gross additions may include increases in the cost basis of investments resulting from new portfolio investments, PIK interest, the accretion of discounts, the exchange of one or more existing securities for one or more new securities and the movement of an existing portfolio company into this category from a different category.

(2) Gross

reductions may include decreases in the cost basis of investments resulting from principal collections related to investment repayments

or sales, the exchange of one or more existing securities for one or more new securities and the movement of an existing portfolio company

out of this category into a different category.

Portfolio Company ⁽¹⁾	Type of Investment ⁽³⁾	Maturity Date	Interest Rate ⁽⁴⁾	Principal Amount ⁽⁵⁾			Cost	Fair	r Value ⁽⁶⁾
Debt Securities	Type of Investment ()	Maturity Date	Interest Kate ()		nount (*)		Cust	Fai	value
Administrative and Support and Waste Manageme	nt and Remediation (?).								
SeaOn Environmental, LLC	Equipment Financing	January 1, 2023	Fixed interest rate 9.0%; EOT 12.0%	\$	1,888	\$	2,165	\$	2,123
Sub-total: Administrative and Support and Wast	te Management and Reme	liation (0.6%)*		\$	1,888	\$	2,165	\$	2,123
Agriculture, Forestry, Fishing and Hunting (?).									
Bowery Farming, Inc.	Equipment Financing	January 1, 2023	Fixed interest rate 8.5%; EOT 8.5%	\$	2,193	\$	2,474	\$	2,305
	Equipment Financing	February 1, 2023	Fixed interest rate 8.7%; EOT 8.5%		2,181		2,408		2,424
	Equipment Financing	May 1, 2023	Fixed interest rate 8.7%; EOT 8.5%		2,756		2,993		3,004
	Equipment Financing	January 1, 2024	Fixed interest rate 7.5%; EOT 8.5%		9,211		9,265		9,312
Total Bowery Farming, Inc.					16,341		17,140		17,045
Robotany, Inc.	Equipment Financing	January 1, 2024	Fixed interest rate 7.6%; EOT 22.0%	\$	1,587	\$	1,698	\$	1,748
Sub-total: Agriculture, Forestry, Fishing and Hu	nting (5.2%)*			\$	17,928	\$	18,838	\$	18,793
Construction									
Dandelion Energy, Inc.	Equipment Financing	April 1, 2024	Fixed interest rate 9.0%; EOT 12.5%	\$	429	\$	443	\$	447
	Equipment Financing	November 1, 2024	Fixed interest rate 9.2%; EOT 12.5%		515		529		531
	Equipment Financing (12)	December 1, 2024	Fixed interest rate 9.1%; EOT 12.5%		522		536		539
	Equipment Financing	January 1, 2025	Fixed interest rate 9.2%; EOT 12.5%		744		756		759
	Equipment Financing	April 1, 2025	Fixed interest rate 9.1%; EOT 12.5%		1,159		1,161		1,163
Total Dandelion Energy, Inc.					3,369		3,425		3,439
Project Frog, Inc. (17)	Secured Loan	May 1, 2023	Fixed interest rate 12.0%	\$	4,128	\$	4,058	\$	3,912
Sub-total: Construction (2.0%)*				\$	7,497	\$	7,483	\$	7,351
Educational Services (?).				_					
Medical Sales Training Holding Company (14)	Secured Loan	April 1, 2025	Variable interest rate PRIME + 8.8% or Floor rate 12.0%; EOT 12.5% ⁽⁹⁾	\$	6,000	s	5,929	\$	5,929
Yellowbrick Education, Inc.	Secured Loan	September 1, 2025	Variable interest rate PRIME + 8.3% or Floor rate 11.5%; EOT 5.0% ⁽⁹⁾	\$	7,500	\$	7,483	\$	7,483
Sub-total: Educational Services (3.7%)*				\$	13,500	\$	13,412	\$	13,412

Portfolio Company (1)	Type of Investment ⁽³⁾	Maturity Date	Interest Rate ⁽⁴⁾		incipal iount ⁽⁵⁾		Cost	Fai	r Value ⁽⁶⁾
Debt Securities, Continued									
Finance and Insurance (?)									
DailyPay, Inc.	Secured Loan	November 1, 2024	Variable interest rate PRIME + 7.0% or Floor rate 12.0%; EOT 6.0% ⁽⁹⁾	\$	20,000	\$	19,924	\$	20,185
	Secured Loan	January 1, 2025	Variable interest rate PRIME + 7.0% or Floor rate 12.0%; EOT 6.0% ⁽⁹⁾		5,000		4,972		5,018
Total DailyPay, Inc.					25,000		24,896		25,203
Petal Card, Inc.	Secured Loan	December 1, 2023	Fixed interest rate 11.0%; EOT 3.0%	\$	10,000	\$	10,036	\$	10,152
	Secured Loan (14)	January 1, 2024	Variable interest rate PRIME + 7.5% or Floor rate 11.5%		1,115		1,084		1,084
					11,115		11,120		11,236
Sub-total: Finance and Insurance (10.1%)*				\$	36,115	\$	36,016	\$	36,439
Health Care and Social Assistance (?).									
Lark Technologies, Inc.	Secured Loan	April 1, 2025	Variable interest rate PRIME + 8.3% or Floor rate 11.5%; EOT 4.0% ⁽⁹⁾	\$	5,000	\$	4,839	\$	4,903
WorkWell Prevention & Care Inc.	Secured Loan	March 1, 2024	Fixed interest rate 8.0%; EOT 10.0%	\$	3,370	\$	3,620	\$	3,580
	Secured Loan	March 1, 2024	Fixed interest rate 8.0%		700		730		690
Total WorkWell Prevention & Care Inc. (17)					4,070		4,350		4,270
Sub-total: Health Care and Social Assistance (2.5%)*				\$	9,070	s	9,189	\$	9,173
Information ^[2] .						_			
Firefly Systems, Inc.	Equipment Financing	February 1, 2023	Fixed interest rate 9.0%; EOT 10.0%	\$	3,511	\$	3,734	\$	3,701
	Equipment Financing	September 1, 2023	Fixed interest rate 9.0%; EOT 10.0%		2,939		3,085		3,078
	Equipment Financing	October 1, 2023	Fixed interest rate 9.0%; EOT 10.0%		355		371		370
Total Firefly Systems, Inc.					6,805		7,190		7,149
Gobiquity, Inc.	Equipment Financing	April 1, 2022	Fixed interest rate 7.5%; EOT 20.0%	\$	239	\$	349	\$	347
RapidMiner, Inc.	Secured Loan	April 1, 2024	Fixed interest rate 12.0%; EOT 7.5%	\$	10,000	\$	10,179	\$	10,189
Rigetti & Co, Inc. (14)	Secured Loan	April 1, 2025	Variable interest rate PRIME + 7.5% or Floor rate 11.0%; EOT 2.8% ⁽⁹⁾	\$	12,000	\$	11,735	\$	11,735
Smule, Inc.	Secured Loan	January 1, 2022	Fixed interest rate 0.0% (15)	\$	99	\$	99	\$	99
STS Media, Inc. ⁽¹¹⁾	Secured Loan	May 1, 2022	Fixed interest rate 11.9%; EOT 4.0%	\$	7,811	\$	737	\$	100
Unitas Global, Inc.	Equipment Financing	July 1, 2021	Fixed interest rate 9.0%; EOT 12.0%	\$	293	\$	665	\$	656
	Equipment Financing	April 1, 2021	Fixed interest rate 7.8%; EOT 6.0%		_		24		24
Total Unitas Global, Inc.					293		689		680
				_	0.7.0	_	00.070	¢	00.007
Sub-total: Information (8.4%)*				\$	37,247	\$	30,978	\$	30,299

Portfolio Company ⁽¹⁾ Debt Securities, Continued	Type of Investment ⁽³⁾	Maturity Date	Interest Rate (4)		Principal Amount ⁽⁵⁾				Fair Value ⁽⁶⁾		
<u>Manufacturing (?)</u>											
AyDeeKay LLC	Secured Loan	August 1, 2024	Variable interest rate PRIME + 7.5% or Floor rate 10.8%; EOT 3.0% ⁽⁹⁾	\$	12,000	\$	11,893	\$	11,779		
BHCosmetics, LLC	Equipment Financing	March 1, 2021	Fixed interest rate 8.9%; EOT 5.0%	\$	106	\$	165	\$	165		
	Equipment Financing	April 1, 2021	Fixed interest rate 8.7%; EOT 5.0%		159		217		218		
Total BHCosmetics, LLC					265		382		383		
Footprint International Holding, Inc.	Equipment Financing	March 1, 2024	Fixed interest rate 10.3%; EOT 8.0%	\$	14,771	\$	15,244	\$	15,352		
	Secured Loan	July 1, 2024	Fixed interest rate 12.0%; EOT 9.0%		7,000		7,095		7,177		
Total Footprint International Holding, Inc.					21,771		22,339		22,529		
Happiest Baby, Inc.	Equipment Financing	September 1, 2022	Fixed interest rate 8.4%; EOT 9.5%	\$	924	\$	1,031	\$	998		
	Equipment Financing	November 1, 2022	Fixed interest rate 8.6%; EOT 9.5%		748		822		830		
	Equipment Financing	January 1, 2023	Fixed interest rate 8.6%; EOT 9.5%		719		775		786		
	Equipment Financing	June 1, 2023	Fixed interest rate 8.2%; EOT 9.5%		901		953		955		
	Equipment Financing	January 1, 2024	Fixed interest rate 7.8%; EOT 9.5%		1,248		1,270		1,278		
Total Happiest Baby, Inc.					4,540		4,851		4,847		
Health-Ade, LLC	Equipment Financing	February 1, 2022	Fixed interest rate 9.4%; EOT 15.0%	\$	1,361	s	1,887	\$	1,877		
Health-Aut, ELC	Equipment Financing	April 1, 2022	Fixed interest rate 8.6%; EOT 15.0%	φ	784	ų	1,007	φ	1,077		
	Equipment Financing	July 1, 2022	Fixed interest rate 9.1%; EOT 15.0%	-	1,956	_	2,436		2,441		
Total Health-Ade, LLC					4,101		5,354		5,348		
Mainspring Energy, Inc.	Secured Loan	August 1, 2023	Fixed interest rate 11.0%; EOT 3.8%	\$	8,592	\$	8,759	\$	8,801		
	Secured Loan	December 1, 2024	Fixed interest rate 11.0%; EOT 3.8%		5,500		5,267		5,267		
Total Mainspring Energy, Inc.					14,092		14,026		14,068		
Miyoko's Kitchen	Equipment Financing	September 1, 2022	Fixed interest rate 8.8%; EOT 9.0%	\$	580	\$	617	\$	618		
wiyoko s Kitchen	Equipment Financing	March 1, 2023	Fixed interest rate 8.9%; EOT 9.0%	æ	867	J.	889	J	896		
	Equipment I maileing	March 1, 2025	1 Act Interest face 0.570, 101 5.070								
Total Miyoko's Kitchen					1,447		1,506		1,514		
Molekule, Inc.	Equipment Financing	January 1, 2024	Fixed interest rate 8.8%; EOT 10.0%	\$	2,526	\$	2,571	\$	2,588		
	Equipment Financing	April 1, 2024	Fixed interest rate 9.0%; EOT 10.0%		542		550		554		
	Equipment Financing	July 1, 2024	Fixed interest rate 8.8%; EOT 10.0%		879		879		881		
Total Molekule, Inc.					3,947		4,000		4,023		
Second Nature Brands, Inc.	Equipment Financing	April 1, 2024	Fixed interest rate 9.7%; EOT 11.50%	\$	2,196	\$	2,157	\$	2,144		
Store Intelligence, Inc. (17)	Secured Loan	June 1, 2024	Fixed interest rate 12.0%; EOT 7.8%	\$	12,001	\$	12,232	\$	11,884		
The Fynder Group, Inc.	Equipment Financing	May 1, 2024	Fixed interest rate 9.1%; EOT 10.0%	\$	612	\$	604	\$	604		
Varial Communications Inc	Secured Loan	Novomber 1, 2024	Eived interact rate 0.59/. FOT 36.49/	\$	12 000	ç	12 027	¢	10 707		
Vertical Communications, Inc.	Secured Loan	November 1, 2024 July 1, 2022	Fixed interest rate 9.5%; EOT 26.4% Fixed interest rate 9.5%	\$	12,000 807	\$	12,937 807	\$	12,787 816		
	Jecureu Ludii	July 1, 2022	1 INCU INTEREST 1618 3.370		007		007		010		
Total Vertical Communications, Inc. (17)				_	12,807		13,744		13,603		
Sub-total: Manufacturing (38.9%)*				\$	89,779	<u>\$</u>	93,088	\$	92,726		
				_		_		_			

Pharmaceutical ?? Zosano Pharma Corporation Equipment Financing April 1, 202 Fixed interest rate 9.4%; EOT 12.0% \$ 2,256 \$ 2,756 \$ 2,530 Equipment Financing July 1, 2022 Fixed interest rate 9.7%; EOT 12.0% 1,501 1,757 1,642 Equipment Financing January 1, 2023 Fixed interest rate 9.9%; EOT 12.0% 1,608 1,769 1,710 Equipment Financing April 1, 2023 Fixed interest rate 9.9%; EOT 12.0% 1,787 1,919 1,884 Equipment Financing May 1, 2023 Fixed interest rate 9.9%; EOT 12.0% 1,316 1,420 1,384 Total Zosano Pharma Corporation 8,468 9,621 9,150 9,150 Sub-total: Pharmaceutical (3.8%)* Equipment Financing May 1, 2023 Fixed interest rate 10.5%; EOT 12.0% 1,316 1,420 1,384	Portfolio Company ⁽¹⁾	Type of Investment ⁽³⁾	Maturity Date	Interest Rate ⁽⁴⁾		incipal 10unt ⁽⁵⁾		Cost	Fair Value ⁽⁶⁾		
Zasano Parma Corporation Repipment Financing April 1,202 Fixed interest rate 57% EOT 12.0% -1.50 -1.70 -1.402 Repipment Financing April 1,202 Fixed interest rate 57% EOT 12.0% -1.608 -1.709 -1.402 Repipment Financing April 1,202 Fixed interest rate 57% EOT 12.0% -1.608 -1.608 -1.608 -1.608 Total Zosano Pharma Corporation May 1, 202 Fixed interest rate 57% EOT 12.0% -1.608 <	Debt Securities, Continued										
Experiment Financing May 1, 2022 Faued interest nate 9.7%, EOT 12.0% 1.501 1.757 1.662 Experiment Financing Ammary 1, 2023 Faued interest nate 9.5%, EOT 12.0% 1.608 1.709 1.710 Experiment Financing Angl 1, 2023 Faued interest nate 9.5%, EOT 12.0% 1.316 1.429 1.844 Experiment Financing May 1, 2023 Faued interest nate 9.5%, EOT 12.0% 1.316 1.429 1.844 Total Zoamo Pherms Corporation Image 1.2023 Faued interest nate 9.5%, EOT 12.0% 1.468 9.521 9.159 Stotacti : Phermacentical (0.5%): Superation, Inc. Secured Loan Appl 1, 2023 Faued interest nate 7.5%, EOT 1.5% S 9.42 S 9.623 9.623 BackBlate, Inc. Experiment Financing Angerl 1.2023 Fauel interest nate 7.5%, EOT 1.5% S 9.423 S 9.623	Pharmaceutical ⁽²⁾										
Augustent Financing Jamany 1, 2023 Faed interest are 9.9%, EOT 12.0% 1.688 1.769 1.789 Toal Zosano Pharma Corporation Explanment Financing May 1, 2023 Faed interest are 9.9%, EOT 12.0% 1.216 1.260 1.384 Toal Zosano Pharma Corporation Explanment Financing May 1, 2023 Faed interest are 10.5%; EOT 12.0% 1.848 9.621 9.1384 Toal Zosano Pharma Corporation Explanment Financing May 1, 2023 Faed interest are 12.0%; EOT 12.0% 5 9.422 5 9.629 9 9.029 9 9.029 5 9.029 5 9.029 9 9.029 9 9.029 9 9.029 9	Zosano Pharma Corporation	Equipment Financing	April 1, 2022	Fixed interest rate 9.4%; EOT 12.0%	\$	2,256	\$	2,756	\$	2,530	
Augustent Financing Jamany 1, 2023 Faed interest are 9.9%, EOT 12.0% 1.688 1.769 1.789 Toal Zosano Pharma Corporation Explanment Financing May 1, 2023 Faed interest are 9.9%, EOT 12.0% 1.216 1.260 1.384 Toal Zosano Pharma Corporation Explanment Financing May 1, 2023 Faed interest are 10.5%; EOT 12.0% 1.848 9.621 9.1384 Toal Zosano Pharma Corporation Explanment Financing May 1, 2023 Faed interest are 12.0%; EOT 12.0% 5 9.422 5 9.629 9 9.029 9 9.029 5 9.029 5 9.029 9 9.029 9 9.029 9 9.029 9											
Equipment Financing April 1, 2023 Fixed interest rate 3.9%, EOT 12.0%, 1.767 1.919 1.884 Toril Zoono Phoma Corporation		Equipment Financing	July 1, 2022	Fixed interest rate 9.7%; EOT 12.0%		1,501		1,757		1,642	
Againance Financing Agril 1, 2023 Fixed interest rate 39%; EOT 12.0% 1,707 1,919 1,844 Total Zoomo Pharma Corporation		Equipment Financing	January 1, 2023	Fixed interest rate 9.9%; EOT 12.0%		1,608		1,769		1,710	
Equipment Financing May 1, 2023 Fixed interest rate 10.5%, EOT 12.0% 1.316 1.420 1.344 Total Zosano Pharma Corporation 8.468 9.621 9.130 Sub-testi: Fharmacentical (1.3%)+ 5 6.468 9.621 5 9.629 5 1.626 5 1.626 5 1.626 5 1.626 1.626 1.626 1.626 1.626 1.626 1.626 1.626 1.626 6.671 6.671											
Total Zosano Pharma Corporation 8,463 9,021 9,150 Sub-total: Pharmaceutical (3.9%)* S 6,463 9,621 8 9,621 8 9,150 Sub-total: Pharmaceutical (3.9%)* Secured Loan April 1,2023 Fourd interest rate (2.0%, EOT 6.5% S 9,462 S 9,602 S 1,603 S 1,604 S 1,604 1,604 S		Equipment Financing	April 1, 2023	Fixed interest rate 9.9%; EOT 12.0%		1,787		1,919		1,884	
Sub-tool: Planmaceutical (3.0%)* Secured Loan April 1, 2023 Field interest are 12.0%, EOT 6.5% \$ 9.420 \$ 9.600 \$ 9.600 Augmedix, Inc. Secured Loan April 1, 2023 Field interest are 7.2%, EOT 11.5% \$ 9.420 \$ 9.600 \$ 0.600		Equipment Financing	May 1, 2023	Fixed interest rate 10.5%; EOT 12.0%		1,316		1,420		1,384	
Sub-tool: Planmaceutical (3.9%)* Secured Laan April 1, 2023 Field interest rate 7.2%, EOT 15.5% S 9.422 S 9.602 S 9.629 BackBlace, Inc. Equipment Financing January 1, 2023 Field interest rate 7.2%, EOT 11.5% S 9.422 S 9.602 S 0.602 BackBlace, Inc. Equipment Financing January 1, 2023 Field interest rate 7.2%, EOT 11.5% S 9.42 S 9.602 S 0.403 S 0.403 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>											
Projectional, Scientific and Technical Services Secured Loan April 1, 2023 Fixed interest rate 12.0%; EOT 6.5% S 9.422 S 9.602 S 9.629 BackBlaze, Inc. Equipment Financing January 1, 2023 Fixed interest rate 7.2%; EOT 11.5% S 9.67 S 1.046 S 1.046 Fixed interest rate 7.2%; EOT 11.5% S 9.67 S 1.046 S 1.046 Fixed interest rate 7.2%; EOT 11.5% S 9.67 S 1.046 Fixed interest rate 7.2%; EOT 11.5% S 9.67 S 1.046 Fixed interest rate 7.2%; EOT 11.5% S 9.67 S 1.046 Fixed interest rate 7.2%; EOT 11.5% S 9.67 S 1.046 Fixed interest rate 7.5%; EOT 11.5% 1.065 2.021 Fixed interest rate 7.5%; EOT 11.5% Fixed interest	Total Zosano Pharma Corporation					8,468		9,621		9,150	
Projectional, Scientific and Technical Services Secured Loan April 1, 2023 Fixed interest rate 12.0%; EOT 6.5% S 9.422 S 9.600 S 9.629 BackBlare, Inc. Equipment Financing January 1, 2023 Fixed interest rate 7.2%; EOT 11.5% S 9.07 S 1.046 S 1.046 1.046 Equipment Financing January 1, 2023 Fixed interest rate 7.4%; EOT 11.5% 100 S 1.006 Equipment Financing January 1, 2023 Fixed interest rate 7.4%; EOT 11.5% 100 S 0.006 Equipment Financing June 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 108 2.001 1.006 Equipment Financing Socember 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 108 2.001 2.011 Equipment Financing October 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 108 2.001 2.001 2.001 2.001 2.001 2.001 2.001 2.001 2.001 2.001 2.001 2.001 2.001 2.001 2.001 2.001 2.001 2.001											
R4 Augmedia, Inc. Secured Loan April 1, 2023 Fixed interest rate 7.2%, EOT 11.5%, S 9, 422 S 9, 602 S 1, 004 Equipment Financing April 1, 2023 Fixed interest rate 7.2%, EOT 11.5%, S 9, 005 S 1, 001 1, 1023 Equipment Financing Agaust 1, 2023 Fixed interest rate 7.3%, EOT 11.5%, 9, 005 1, 001 1, 006 Equipment Financing September 1, 2023 Fixed interest rate 7.3%, EOT 11.5%, 185 2,01 2,01 Equipment Financing Cotober 1, 2023 Fixed interest rate 7.3%, EOT 11.5%, 186 2,01 6,00 Equipment Financing Doctober 1, 2023 Fixed interest rate 7.3%, EOT 11.5%, 6,21 6,70 6,70 Equipment Financing Doctober 1, 2024 Fixed interest rate 7.3%, EOT 11.5%, 7,17 7,76 7,75 Equipment Financing March 1, 2024 Fixed interest rate 7,3%, EOT 11.5%, 1,22 1,303 1,311	Sub-total: Pharmaceutical (3.8%)*				\$	8,468	\$	9,621	\$	9,150	
Augmedia, Inc. Secured Loan April 1, 2023 Fixed interest rate 12.0%; EOT 65% S 9.422 S 9.602 S 9.602 BackBlaze, Inc. Equipment Financing Jamaay 1. 2023 Fixed interest rate 7.2%; EOT 11.5% S 9.07 S 1.042 S 1.042 S 1.042 S 1.042 S 1.042 S 1.013 1.013 1.013 1.013 1.010	Professional, Scientific, and Technical Services										
BackBlaze, Inc. Equipment Financing January 1, 2023 Fixed interest rate 7.2%; EOT 11.5% S 907 S 1.042 S 1.046 Equipment Financing April 1, 2023 Fixed interest rate 7.2%; EOT 11.5% 117 131 132 Equipment Financing Augus 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 168 200 201 Equipment Financing September 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 186 200 201 Equipment Financing Oxober 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 186 200 201 Equipment Financing Oxober 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 186 200 201 Equipment Financing Doxember 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 186 200 201 Equipment Financing Doxember 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 126 670 670 Equipment Financing Doxember 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 717 764 773 Equipment Financing March 1, 2024 Fixed interest rate 7.4%; EOT 11.5% 712 715 715 Eq	(2)										
Heat Equipment Financing April 1, 2023 Fixed interest rate 7.4%; EOT 11.5% 117 131 132 Equipment Financing June 1, 2023 Fixed interest rate 7.4%; EOT 11.5% 905 1,001 1,006 Equipment Financing August 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 186 201 201 Equipment Financing October 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 186 200 201 Equipment Financing October 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 186 200 201 Equipment Financing October 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 621 670 670 Equipment Financing December 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 621 670 775 Equipment Financing December 1, 2024 Fixed interest rate 7.5%; EOT 11.5% 717 764 763 Equipment Financing March 1. 2024 Fixed interest rate 7.5%; EOT 11.5% 763 762 763 Equipment Financing Mary 1. 2024 Fixed interest rate 7.5%; EOT 11.5% 1,303 1,313 1,313 Equipment Financing August 1, 2024 <td< td=""><td>Augmedix, Inc.</td><td>Secured Loan</td><td>April 1, 2023</td><td>Fixed interest rate 12.0%; EOT 6.5%</td><td>\$</td><td>9,422</td><td>\$</td><td>9,602</td><td>\$</td><td>9,629</td></td<>	Augmedix, Inc.	Secured Loan	April 1, 2023	Fixed interest rate 12.0%; EOT 6.5%	\$	9,422	\$	9,602	\$	9,629	
Heat Equipment Financing April 1, 2023 Fixed interest rate 7.4%; EOT 11.5% 117 131 132 Equipment Financing June 1, 2023 Fixed interest rate 7.4%; EOT 11.5% 905 1,001 1,006 Equipment Financing August 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 186 201 201 Equipment Financing October 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 186 200 201 Equipment Financing October 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 186 200 201 Equipment Financing October 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 621 670 670 Equipment Financing December 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 621 670 775 Equipment Financing December 1, 2024 Fixed interest rate 7.5%; EOT 11.5% 717 764 763 Equipment Financing March 1. 2024 Fixed interest rate 7.5%; EOT 11.5% 763 762 763 Equipment Financing Mary 1. 2024 Fixed interest rate 7.5%; EOT 11.5% 1,303 1,313 1,313 Equipment Financing August 1, 2024 <td< td=""><td>PackPlane Inc.</td><td>Equipment Financing</td><td>January 1, 2022</td><td>Eined interest rate 7.2%, EOT 11.5%</td><td>¢</td><td>007</td><td>¢</td><td>1.042</td><td>¢</td><td>1.046</td></td<>	PackPlane Inc.	Equipment Financing	January 1, 2022	Eined interest rate 7.2%, EOT 11.5%	¢	007	¢	1.042	¢	1.046	
Equipment FinanciaJune 1, 202Fixed interest ate 7.4%, EOT 11.5%9051.0011.001Equipment FinanciaAugus 1, 202Fixed interest ate 7.5%, EOT 11.5%180197Equipment FinanciaOctober 1, 202Fixed interest ate 7.5%, EOT 11.5%1862.001Equipment FinanciaOctober 1, 202Fixed interest ate 7.5%, EOT 11.5%1862.001Equipment FinanciaOctober 1, 202Fixed interest ate 7.5%, EOT 11.5%1862.001Equipment FinanciaDecember 1, 202Fixed interest ate 7.5%, EOT 11.5%7.023.001Equipment FinanciaJanuary 1, 204Fixed interest ate 7.4%, EOT 11.5%7.023.001Equipment FinanciaJanuary 1, 204Fixed interest ate 7.4%, EOT 11.5%7.023.001Equipment FinanciaApril 1, 204Fixed interest ate 7.4%, EOT 11.5%7.023.001Equipment FinanciaApril 1, 204Fixed interest ate 7.4%, EOT 11.5%7.023.001Equipment FinanciaMarch 1, 204Fixed interest ate 7.4%, EOT 11.5%7.023.001Equipment FinanciaMarch 1, 204Fixed interest ate 7.5%, EOT 11.5%7.023.001Equipment FinanciaApril 1, 204Fixed interest ate 7.5%, EOT 11.5%1.0243.001Equipment FinanciaApril 1, 204Fixed interest ate 7.5%, EOT 11.5%1.0243.001Equipment FinanciaApril 1, 204Fixed interest ate 7.5%, EOT 11.5%1.3243.031Cuebiq, Inc.Equipment FinanciaApril 1, 204Fixed interest ate 7.5%, EOT 11.5	васквиаze, inc.				\$		3		Э		
Equipment Financing August 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 180 196 197 Equipment Financing September 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 186 201 201 Equipment Financing October 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 186 200 200 Equipment Financing October 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 621 620 670 Equipment Financing December 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 717 764 753 Equipment Financing December 1, 2024 Fixed interest rate 7.5%; EOT 11.5% 712 775 775 Equipment Financing March 1, 2024 Fixed interest rate 7.5%; EOT 11.5% 712 701 701 Equipment Financing March 1, 2024 Fixed interest rate 7.5%; EOT 11.5% 712 703 701 Equipment Financing March 1, 2024 Fixed interest rate 7.5%; EOT 11.5% 712 713 713 713 713 713 713 713 713 713 713 713 713 713 713 713 713 713 713											
Equipment Financing September 1, 2023 Fixed interest rate 7.7%; EOT 11.5% 185 201 Equipment Financing October 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 621 670 Equipment Financing November 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 622 881 881 Equipment Financing December 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 622 881 881 Equipment Financing January 1, 2024 Fixed interest rate 7.4%; EOT 11.5% 732 775 764 763 Equipment Financing March 1, 2024 Fixed interest rate 7.4%; EOT 11.5% 732 775 775 Equipment Financing March 1, 2024 Fixed interest rate 7.3%; EOT 11.5% 124 1.303 1.311 Equipment Financing May 1, 2024 Fixed interest rate 7.5%; EOT 11.5% 1.246 1.333 1.374 1.378 Equipment Financing August 1, 2024 Fixed interest rate 7.5%; EOT 11.5% 1.36 1.374 1.378 Cuebiq, Inc. Secured Loan April 1, 2024 Fixed interest rate 7.5%; EOT 11.5% 1.36 5.030 5 5.030 5 5.030 5											
Equipment Financing October 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 186 200 201 Equipment Financing November 1, 2023 Fixed interest rate 7.2%; EOT 11.5% 621 670 670 Equipment Financing December 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 822 881 881 Equipment Financing January 1, 2024 Fixed interest rate 7.4%; EOT 11.5% 717 764 763 Equipment Financing March 1, 2024 Fixed interest rate 7.4%; EOT 11.5% 723 775 775 Equipment Financing March 1, 2024 Fixed interest rate 7.4%; EOT 11.5% 732 733 751 Equipment Financing March 1, 2024 Fixed interest rate 7.4%; EOT 11.5% 126 1,303 1,311 Equipment Financing Mary 1, 2024 Fixed interest rate 7.3%; EOT 11.5% 1,246 1,303 1,374 1,378 Equipment Financing August 1, 2024 Fixed interest rate 7.2%; EOT 11.5% 2,39 2,43 2,377 Total BackBlaze, Inc. Secured Loan April 1, 2024 Fixed interest rate 7.2%; EOT 11.5% 5,500 5 5,676 Edeniq, Inc.			<u> </u>								
Equipment Financing November 1,2023 Fixed interest rate 7.2%; EOT 11.5% 621 670 670 Equipment Financing December 1,2023 Fixed interest rate 7.5%; EOT 11.5% 722 881 881 Equipment Financing January 1,2024 Fixed interest rate 7.4%; EOT 11.5% 717 764 775 Equipment Financing February 1,2024 Fixed interest rate 7.4%; EOT 11.5% 712 775 775 Equipment Financing March 1,2024 Fixed interest rate 7.4%; EOT 11.5% 636 6673 672 Equipment Financing March 1,2024 Fixed interest rate 7.4%; EOT 11.5% 192 201 206 Equipment Financing March 1,2024 Fixed interest rate 7.3%; EOT 11.5% 1,246 1,303 1,311 Equipment Financing May 1,2024 Fixed interest rate 7.5%; EOT 11.5% 1,336 1,374 1,313 Forol BackBlaze, Inc. Equipment Financing August 1,2024 Fixed interest rate 7.5%; EOT 11.5% 239 243 237 Total BackBlaze, Inc. Secured Loan April 1,2024 Fixed interest rate 7.2%; EOT 4.5% of Floor 9,055 9,056 9,056 9,056											
Image: Antipener Financing December 1, 2023 Fixed interest rate 7.5%; EOT 11.5% 822 881 881 Image: Antipener Financing January 1, 2024 Fixed interest rate 7.4%; EOT 11.5% 712 775 Image: Antipener Financing March 1, 2024 Fixed interest rate 7.4%; EOT 11.5% 732 775 775 Image: Antipener Financing March 1, 2024 Fixed interest rate 7.4%; EOT 11.5% 732 775 775 Image: Antipener Financing March 1, 2024 Fixed interest rate 7.4%; EOT 11.5% 732 733 733 Image: Antipener Financing March 1, 2024 Fixed interest rate 7.3%; EOT 11.5% 736 733 733 Image: Antipener Financing May 1, 2024 Fixed interest rate 7.3%; EOT 11.5% 736 733 733 733 Image: Antipener Financing May 1, 2024 Fixed interest rate 7.3%; EOT 11.5% 733 733 733 733 Image: Antipener Financing August 1, 2024 Fixed interest rate 7.5%; EOT 11.5% 733 733 733 733 Image: Antipener Financing Corober 1, 2024 Fixed interest rate 7.5%; EOT 11.5% 7336 530 5 530											
Equipment Financing January 1,2024 Fixed interest rate 7.4%; EOT 11.5% 717 764 717 Equipment Financing February 1,2024 Fixed interest rate 7.4%; EOT 11.5% 732 775 775 Equipment Financing March 1,2024 Fixed interest rate 7.2%; EOT 11.5% 102 201 201 Equipment Financing April 1,202 Fixed interest rate 7.3%; EOT 11.5% 128 1,303 1,314 Equipment Financing May 1,2024 Fixed interest rate 7.3%; EOT 11.5% 1,246 1,303 1,314 Equipment Financing May 1,2024 Fixed interest rate 7.3%; EOT 11.5% 1,326 1,337 1,317 Equipment Financing May 1,2024 Fixed interest rate 7.5%; EOT 11.5% 1,336 1,374 1,318 Equipment Financing October 1,2024 Fixed interest rate 7.5%; EOT 11.5% 1,336 1,374 1,317 Total BackBlaze, Inc. Equipment Financing October 1,2024 Fixed interest rate 7.3%; EOT 11.5% 9,021 9,055 9,056 Cuebiq, Inc. Secured Loan April 1,202 Variable interest rate 7.3%; EOT 15.5% 5,030 \$ 5,030 \$ 5,030 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>											
Equipment Financing February 1, 2024 Fixed interest rate 7.4%; EOT 11.5% 732 775 775 Equipment Financing March 1, 2024 Fixed interest rate 7.2%; EOT 11.5% 636 673 672 Equipment Financing April 1, 2024 Fixed interest rate 7.4%; EOT 11.5% 192 201 206 Equipment Financing May 1, 2024 Fixed interest rate 7.4%; EOT 11.5% 1,246 1,303 1,311 Equipment Financing May 1, 2024 Fixed interest rate 7.3%; EOT 11.5% 1,246 1,303 1,311 Equipment Financing May 1, 2024 Fixed interest rate 7.3%; EOT 11.5% 1,336 1,374 1,378 Total BackBlaze, Inc. Equipment Financing August 1, 2024 Fixed interest rate 7.2%; EOT 11.5% 239 243 237 Total BackBlaze, Inc. Secured Loan April 1, 2024 Variable interest rate PRIME + 7.3% or Floor 5,000 \$ 5,030 \$ 4,963 Edeniq, Inc. Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% \$ 3,039 \$ 1,102 \$ 859 Edeniq, Inc. Secured Loan September 1, 2021											
Equipment Financing March 1, 2024 Fixed interest rate 7.2%; EOT 11.5% 636 673 622 Equipment Financing April 1, 2024 Fixed interest rate 7.4%; EOT 11.5% 192 1,303 1,311 Equipment Financing May 1, 2024 Fixed interest rate 7.3%; EOT 11.5% 1,326 1,333 1,313 Equipment Financing May 1, 2024 Fixed interest rate 7.5%; EOT 11.5% 1,336 1,374 1,378 Equipment Financing August 1, 2024 Fixed interest rate 7.5%; EOT 11.5% 1,336 1,374 1,378 Equipment Financing August 1, 2024 Fixed interest rate 7.5%; EOT 11.5% 1,336 1,374 1,378 Total BackBlaze, Inc. October 1, 2024 Fixed interest rate PRIME + 7.3% or Floor \$ 9,055 9,055 9,056 Cuebiq, Inc. Secured Loan April 1,202 Fixed interest rate 13.0%; EOT 9.5% \$ \$ 5,030 \$ 4,963 Edeniq, Inc. Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% \$ 3,039 \$ 1,102 \$ Edeniq, Inc. Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9											
Equipment Financing April 1, 2024 Fixed interest rate 7.4%; EOT 11.5% 192 201 206 Equipment Financing May 1, 2024 Fixed interest rate 7.3%; EOT 11.5% 1,246 1,303 1,311 Equipment Financing August 1, 2024 Fixed interest rate 7.5%; EOT 11.5% 1,336 1,374 1,378 Equipment Financing August 1, 2024 Fixed interest rate 7.5%; EOT 11.5% 1,336 1,374 1,378 Equipment Financing October 1, 2024 Fixed interest rate 7.2%; EOT 11.5% 239 243 237 Total BackBlaze, Inc. 9,021 9,655 9,655 9,676 Cuebiq, Inc. Secured Loan April 1, 2024 Yariable interest rate PRIME + 7.3% or Floor rate 12.0%; EOT 4.5% (9) \$ 5,000 \$ 5,030 \$ 4,963 Edeniq, Inc. Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% \$ 3,039 \$ 1,102 \$ 859 Edeniq, Inc. Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% \$ 3,039 \$ 1,102 \$ 859 Secured Loan September 1, 2021		Equipment Financing	February 1, 2024	Fixed interest rate 7.4%; EOT 11.5%						775	
Equipment Financing May 1, 2024 Fixed interest rate 7.3%; EOT 11.5% 1,246 1,303 1,311 Equipment Financing August 1, 2024 Fixed interest rate 7.3%; EOT 11.5% 1,366 1,374 1,378 Equipment Financing August 1, 2024 Fixed interest rate 7.2%; EOT 11.5% 239 243 237 Total BackBlaze, Inc. 9,021 9,655 9,656 9,656 Cuebiq, Inc. Secured Loan April 1, 2024 Fixed interest rate 13.0%; EOT 9.5% \$ 5,000 \$ 5,030 \$ 4,963 Edeniq, Inc. Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% \$ 3,039 \$ 1,102 \$ 859 Edeniq, Inc. Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% \$ 3,039 \$ 1,102 \$ 859 Edeniq, Inc. Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% \$ 3,039 \$ 1,102 \$ 859 Edeniq, Inc. Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% \$ 2,282 762 648		Equipment Financing	March 1, 2024	Fixed interest rate 7.2%; EOT 11.5%		636				672	
Equipment Financing August 1, 2024 Fixed interest rate 7.5%; EOT 11.5% 1,336 1,374 1,378 Equipment Financing October 1, 2024 Fixed interest rate 7.2%; EOT 11.5% 239 243 237 Total BackBlaze, Inc. 9,021 9,655 9,655 9,676 Cuebiq, Inc. Secured Loan April 1, 2024 Yariable interest rate PRIME + 7.3% or Floor rate 12.0%; EOT 4.5% ⁽⁹⁾ \$ 5,000 \$ 5,030 \$ 4,963 Edeniq, Inc. Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% \$ 3,039 \$ 1,102 \$ 859 Edeniq, Inc. Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% \$ 3,039 \$ 1,102 \$ 859 Edeniq, Inc. Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% \$ 3,039 \$ 1,102 \$ 859 Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% 2,282 762 648		Equipment Financing	April 1, 2024	Fixed interest rate 7.4%; EOT 11.5%		192		201		206	
Equipment Financing August 1, 2024 Fixed interest rate 7.5%; EOT 11.5% 1,336 1,374 1,378 Equipment Financing October 1, 2024 Fixed interest rate 7.2%; EOT 11.5% 239 243 237 Total BackBlaze, Inc. 9,021 9,655 9,655 9,656 Cuebiq, Inc. Secured Loan April 1, 2024 Fixed interest rate PRIME + 7.3% or Floor rate 12.0%; EOT 4.5% ⁽⁹⁾ \$ 5,000 \$ 5,030 \$ 4,963 Edeniq, Inc. Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% \$ 3,039 \$ 1,102 \$ 8 Edeniq, Inc. Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% \$ 3,039 \$ 1,102 \$ 8 Edeniq, Inc. Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% \$ 3,039 \$ 1,102 \$ 6 Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% 2,282 762 648		Equipment Financing	May 1, 2024	Fixed interest rate 7.3%; EOT 11.5%		1,246		1,303		1,311	
Equipment Financing October 1, 2024 Fixed interest rate 7.2%; EOT 11.5% 239 243 237 Total BackBlaze, Inc.											
FinancingOctober 1, 2024Fixed interest rate 7.2%; EOT 11.5%239243237Total BackBlaze, Inc.9,0219,6559,676Cuebiq, Inc.Secured LoanApril 1, 2024Variable interest rate PRIME + 7.3% or Floor rate 12.0%; EOT 4.5% ⁽⁹⁾ \$ 5,000\$ 5,030\$ 4,963Edeniq, Inc.Secured LoanSeptember 1, 2021Fixed interest rate 13.0%; EOT 9.5%\$ 3,039\$ 1,102\$ 859Secured LoanSeptember 1, 2021Fixed interest rate 13.0%; EOT 9.5%2,282762648		Equipment Financing	August 1, 2024	Fixed interest rate 7.5%; EOT 11.5%		1,336		1,374		1,378	
Total BackBlaze, Inc. 9,021 9,655 9,676 Cuebiq, Inc. Secured Loan April 1, 2024 Variable interest rate PRIME + 7.3% or Floor rate 2.5,000 \$ 5,030 \$ 4,963 Edeniq, Inc. Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% \$ 3,039 \$ 1,102 \$ 859 Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% 2,282 762 648			October 1, 2024	Fixed interest rate 7.2%; EOT 11.5%		239		243		237	
Cuebiq, Inc. Secured Loan April 1, 2024 Variable interest rate PRIME + 7.3% or Floor \$ 5,000 \$ 5,030 \$ 4,963 Edeniq, Inc. Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% \$ 3,039 \$ 1,102 \$ 8 8859 Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% 2,282 762 648											
Cuebiq, Inc. Secured Loan April 1, 2024 rate 12.0%; EOT 4.5% ⁽⁹⁾ \$ 5,000 \$ 5,030 \$ 4,963 Edeniq, Inc. Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% \$ 3,039 \$ 1,102 \$ 859 Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% \$ 2,282 762 648	Total BackBlaze, Inc.					9,021		9,655		9,676	
Cuebiq, Inc. Secured Loan April 1, 2024 rate 12.0%; EOT 4.5% ⁽⁹⁾ \$ 5,000 \$ 5,030 \$ 4,963 Edeniq, Inc. Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% \$ 3,039 \$ 1,102 \$ 859 Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% \$ 2,282 762 648				Variable interest rate PRIME + 7.3% or Floor							
Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% 2,282 762 648	Cuebiq, Inc.	Secured Loan	April 1, 2024		\$	5,000	\$	5,030	\$	4,963	
Secured Loan September 1, 2021 Fixed interest rate 13.0%; EOT 9.5% 2,282 762 648											
	Edeniq, Inc.	Secured Loan	September 1, 2021	Fixed interest rate 13.0%; EOT 9.5%	\$	3,039	\$	1,102	\$	859	
		Secured Loan	Sentember 1 2021	Fixed interest rate 13 0% · FOT 9 5%		2 282		762		648	
Total Edeniq, Inc. (11) (17) 5,321 1,864 1,507		Secure Loui	September 1, 2021	interest tate 15/0/0, EO1 5/5/0		2,202		/ 02		0+0	
	Total Edeniq, Inc. (11) (17)					5,321		1,864		1,507	

Portfolio Company ⁽¹⁾ Debt Securities, Continued	Type of Investment ⁽³⁾	Maturity Date	Interest Rate ⁽⁴⁾		Principal Amount ⁽⁵⁾		Cost	Fai	r Value ⁽⁶⁾
Professional, Scientific, and Technical Services, C	ontinued								
Incontext Solutions, Inc.	Secured Loan	October 1, 2023	Fixed interest rate 11.75%; EOT 11.4%	\$	7,149	\$	7,401	\$	6,998
Matterport, Inc.	Secured Loan	May 1, 2022	Fixed interest rate 11.5%; EOT 5.0%	\$	4,870	\$	5,560	\$	5,599
Pendulum Therapeutics, Inc.	Equipment Financing	May 1, 2023	Fixed interest rate 7.7%; EOT 5.0%	\$	347	\$	338	\$	338
	Equipment Financing	August 1, 2023	Fixed interest rate 7.8%; EOT 5.0%		2,084		2,147		2,164
	Equipment Financing	October 1, 2023	Fixed interest rate 7.7%; EOT 5.0%		616		620		626
	Equipment Financing	February 1, 2024	Fixed interest rate 9.8%; EOT 6.0%		894		895		881
Total Pendulum Therapeutics, Inc.					3,941		4,000		4,009
Reciprocity, Inc.	Secured Loan	October 1, 2024	Variable interest rate PRIME + 8.0% or Floor rate 11.3%; EOT 2.0% ⁽⁹⁾	\$	10,000	\$	9,862	\$	9,805
Sun Basket, Inc.	Secured Loan	December 1, 2024	Variable interest rate PRIME + 8.5% or Floor rate 11.8%; EOT 5.0% ⁽⁹⁾		18,375		17,831		17,831
Utility Associates, Inc. (11)	Secured Loan	October 1, 2023	Fixed interest rate 11.0%	\$	750	\$	830	\$	604
Sub-total: Professional, Scientific, and Technica	Services (29.6%)*			5	73,849	5	71,635	5	70,621
				-	- /	-	1	-	

Portfolio Company (1)	Type of Investment (3)	Maturity Date	Interest Rate (4)		rincipal nount ⁽⁵⁾		Cost	Fair	r Value ⁽⁶⁾
Debt Securities, Continued									
<u>Real Estate (?)</u>									
Knockaway, Inc.	Secured Loan	December 1, 2023	Fixed interest rate 11.0%; EOT 3.0%	\$	10,000	\$	10,103	\$	10,112
	Secured Loan	February 1 , 2024	Fixed interest rate 11.0%; EOT 3.0%		2,500		2,519		2,549
	Secured Loan	March 1, 2024	Fixed interest rate 11.0%; EOT 3.0%		2,500		2,516		2,548
Total Knockaway, Inc.					15,000		15,138		15,209
Wanderjaunt, Inc.	Equipment Financing	June 1, 2023	Fixed interest rate 10.2%; EOT 12.0%	\$	387	\$	388	\$	380
	Equipment Financing	August 1, 2023	Fixed interest rate 10.2%; EOT 12.0%		1,230		1,313		1,296
Total Wanderjaunt, Inc.					1,617		1,701		1,676
Sub-total: Real Estate (9.6%)*				\$	16,617	\$	16,839	\$	16,885
Rental and Leasing Services ⁽²⁾				_		_			
<u></u>									
EquipmentShare, Inc.	Equipment Financing	July 1, 2023	Fixed interest rate 10.7%; EOT 5.0%	\$	7,538	\$	7,685	\$	7,730
	Equipment Financing	August 1, 2023	Fixed interest rate 10.1%; EOT 5.0%		864		879		884
	Equipment Financing	September 1, 2023	Fixed interest rate 10.2%; EOT 5.0%		1,908		1,935		1,944
	Equipment Financing	October 1, 2023	Fixed interest rate 10.4%; EOT 5.0%		3,422		3,458		3,470
	Equipment Financing	October 1, 2024	Fixed interest rate 8.3%; EOT 10.0%		429		435		435
	Equipment Financing	November 1, 2023	Fixed interest rate 10.4%; EOT 5.0%		811		818		818
	Equipment Financing	November 1, 2023	Fixed interest rate 10.5%; EOT 5.0%		2,560		2,581		2,581
	Equipment Financing	December 1, 2023	Fixed interest rate 10.1%; EOT 5.0%		2,491		2,506		2,506
	Equipment Financing	January 1, 2024	Fixed interest rate 10.1%; EOT 5.0%		1,995		2,002		2,002
	Equipment Financing	January 1, 2024	Fixed interest rate 10.5%; EOT 5.0%		797		799	. <u> </u>	799
Total EquipmentShare, Inc.					22,815		23,098		23,169
Maxwell Financial Labs, Inc.	Secured Loan	November 1, 2024	Variable interest rate PRIME + 8.0% or Floor rate 11.25%; EOT 4.0% ⁽⁹⁾	\$	3,000	\$	2,964	\$	2,964
nativen i manear 2005, net	Secured Loan	January 1, 2025	Variable interest rate PRIME + 8.0% or Floor rate 11.25%; EOT 4.0% ⁽⁹⁾	Ŷ	3,000	Ĵ	2,938	¢	2,938
Total Maxwell Financial Labs, Inc.				_	6,000		5,902		5,902
four Maxwell Financial Eads, file.				_	0,000	_	5,502	_	5,502
Sub-total: Rental and Leasing Services (12.2%)*				\$	28,815	\$	29,000	\$	29,071
<u>Retail Trade (?)</u>									
Birchbox, Inc. (17)	Secured Loan	July 1, 2024	Fixed interest rate 9.0%; EOT 7.5%	\$	10,000	\$	10,433	\$	9,924
Boosted eCommerce, Inc. (14)	Secured Loan	January 1, 2023	Variable interest rate PRIME + 7.75% or Floor rate 11.0%; EOT 3.25% ⁽⁹⁾	\$	5,000	\$	4,933	\$	4,933
Gobble, Inc.	Secured Loan	July 1, 2023	Fixed interest rate 11.3%; EOT 6.0%	\$	3,443	\$	3,544	\$	3,556
	Secured Loan	July 1, 2023	Fixed interest rate 11.5%; EOT 6.0%		1,730		1,781		1,795
Total Gobble Inc.					5,173		5,325		5,351
Madison Reed, Inc.	Secured Loan	May 1, 2024	Variable interest rate PRIME + 6.0% or Floor rate 10.3%; EOT 4.0% ⁽⁹⁾	\$	17,500	\$	17,471	\$	17,835
Portofino Labs, Inc. (14)	Secured Loan	July 1, 2025	Variable interest rate PRIME + 8.25% or Floor rate 11.5%; EOT 4.0% $^{(9)}$	\$	2,000	\$	1,984	\$	1,984
Super73, Inc. (14)	Secured Loan	January 1, 2025	Variable interest rate PRIME + 7.3% or Floor rate 11.8%; EOT 4.0% ⁽⁹⁾	\$	5,500	\$	5,416	\$	5,416
UnTuckIt, Inc.	Secured Loan	June 1, 2024	Fixed interest rate 12.0%; EOT 5.0%	\$		\$		\$	

	20,	.000	21,098	19	9,230
					_
ub-total: Retail Trade (27.1%)*	\$ 65,	173 \$	66,660	\$ 64	,673

Portfolio Company (1)	Type of Investment ⁽³⁾	Maturity Date	Interest Rate (4)	Principal Amount ⁽⁵⁾		Cost	Fai	r Value ⁽⁶⁾
Debt Securities, Continued								
<u>Utilities (?)</u>								
Invenia, Inc.	Secured Loan	January 1, 2023	Fixed interest rate 11.5%; EOT 5.0%	\$ 6,570	\$	7,042	\$	6,991
	Secured Loan	May 1, 2023	Fixed interest rate 11.5%; EOT 5.0%	3,326		3,537		3,550
	Secured Loan	January 1, 2024	Fixed interest rate 11.5%; EOT 5.0%	3,000		3,058		3,165
	Secured Loan	February 1, 2024	Fixed interest rate 11.5%; EOT 5.0%	4,000		4,103		4,200
	Secured Loan	July 1, 2024	Fixed interest rate 11.5%: EOT 5.0%	4,000		4,043		4,160
	Secured Loan	November 1, 2024	Fixed interest rate 11.5%: EOT 5.0%	5,000		5,017		5,017
Total Invenia, Inc. (13)				25,896		26,800		27,083
Sub-total: Utilities (11.4%)*				\$ 25,896	\$	26,800	\$	27,083
							-	
Wholesale Trade								
BaubleBar, Inc. (17)	Secured Loan	March 1, 2023	Fixed interest rate 11.5%; EOT 7.3%	\$ 5,752	\$	6,576	\$	6,148
Grandpad, Inc.	Equipment Financing	June 1, 2023	Fixed interest rate 10.6%; EOT 5.0%	\$ 2,899	\$	2,907	\$	2,907
	Equipment Financing	July 1, 2023	Fixed interest rate 10.8%; EOT 5.0%	3,672		3,667		3,667
Total Grandpad, Inc. (14)				6,571		6,574		6,574
GrubMarket, Inc.	Secured Loan	July 1, 2024	Fixed interest rate 10.5%; EOT 3.0%	\$ 10,000	s	9,875	\$	10,114
Giubwarket, nic.	Secureu Loan	July 1, 2024	Fixed intelest fate 10.5%, EOT 5.0%	\$ 10,000	ф.	9,675	Ф	10,114
Sub total: Mibalasala Tuada (0.6%))*				\$ 22,323	\$	23,025	\$	22,836
Sub-total: Wholesale Trade (9.6%)*				φ 22,323	φ	20,020	φ	22,000
Total, Daht Securities (196.09/)* (12)				\$ 448,010	\$	447,510	\$	443,219
Total: Debt Securities (186.0%)* ⁽¹³⁾				φ 440,010	ą		9	443,413

Portfolio Company (1)	Type of Investment ⁽³⁾	Expiration Date	Series	Shares	Strike Price			Cost	Fair	Value (6)
Warrant Investments										
<u>Agriculture, Forestry, Fishing and Hunting ⁽²⁾</u>										
Bowery Farming, Inc.	Warrant	June 10, 2029	Common Stock	68,863	\$	5.08	\$	410	\$	403
	Warrant	December 22, 2030	Common Stock	29,925	\$	6.24	\$	160	\$	160
Total Bowery Farming, Inc.								570		563
Robotany, Inc.	Warrant	July 19, 2029	Common Stock	262,870	\$	0.26	\$	128	\$	92
Sub-Total: Agriculture, Forestry, Fishing and Hunting	(0.3%)*						\$	698	\$	655
Construction (?).										
Depinet Event Type (17)	Momont	Intr 26, 2026	Disformed Covies A A	391,990	\$	0.19	\$	18	\$	2
Project Frog, Inc. (17)	Warrant	July 26, 2026	Preferred Series AA	391,990	2	0.19	\$	18	ə	2
Sub-Total: Construction (0.0%)*							\$	18	\$	2
Educational Services (?).										
Qubed, Inc. dba Yellowbrick	Warrant	September 28, 2028	Common Stock	222,222	\$	0.90	\$	120	\$	593
Sub Tatal: Educational Services (0.00/*							\$	120	\$	593
Sub-Total: Educational Services (0.2%)*							φ	120	φ	393
Finance and Insurance ⁽²⁾						_	~			
DailyPay, Inc.	Warrant	September 30, 2030	Common Stock	89,264	\$	3.00	\$	151	\$	206
Petal Card, Inc.	Warrant	November 27, 2029	Preferred Series B	250,268	\$	1.32	\$	147	\$	350
Realty Mogul, Co	Warrant	December 18, 2027	Preferred Series B	234,421	\$	3.88	\$	285	\$	25
Sub-Total: Finance and Insurance (0.2%)*							\$	583	\$	581
Health Care and Social Assistance (?).										
Lark Technologies, Inc.	Warrant	September 30, 2030	Common Stock	76,231	\$	1.76	\$	177	\$	163
Lark reemologies, ne.	Warrant	September 30, 2030	Common Stock	70,201	Ψ	1.70	-	1//	-	105
Sub-Total: Health Care and Social Assistance (0.1%)*							\$	177	\$	163
Information (?)										
Convercent, Inc.	Warrant	November 30, 2025	Preferred Series 1	3,139,579	\$	0.16	\$	924	\$	610
Figg, Inc. (12)	Warrant	March 31, 2028	Common Stock	935,198	\$	0.07	\$	-	\$	—
Everalbum, Inc.	Warrant	July 29, 2026	Preferred Series A	851,063	\$	0.10	\$	24	\$	6
Firefly Systems, Inc.	Warrant	January 29, 2030	Common Stock	133,147	\$	1.14	\$	282	\$	132
Gtxcel, Inc.	Warrant	September 24, 2025	Preferred Series C	1,000,000	\$	0.21	\$	83	\$	4
	Warrant	September 24, 2025	Preferred Series D	1,000,000	\$	0.21		83		12
Total Gtxcel, Inc.								166		16
Hytrust, Inc.	Warrant	June 23, 2026	Preferred Series D2	424,808	\$	0.82	\$	172	\$	_
Lucidworks, Inc.	Warrant	June 27, 2026	Preferred Series D	619,435	\$	0.77	\$	806	\$	1,509
Oto Analytics, Inc.	Warrant	August 31, 2028	Preferred Series B	1,018,718	\$	0.79	\$	295	\$	221
RapidMiner, Inc.	Warrant	March 25, 2029	Preferred Series C-1	11,624	\$	60.22	\$	528	\$	357
STS Media, Inc. ⁽¹²⁾	Warrant	March 15, 2028	Preferred Series C	20,210	\$	24.74	\$	_	\$	_
Sub-Total: Information (1.2%)*							\$	3,197	\$	2,851
							-	3,107		_,001

Portfolio Company (1)	Type of Investment ⁽³⁾	Expiration Date	Series	Shares	Str	ike Price		Cost	Fair	r Value (6)
Warrant Investments, Continued										
<u>Manufacturing (?)</u>										
Atieva, Inc. (13)	Warrant	March 31, 2027	Preferred Series D	390,016	\$	5.13	\$	3,067	\$	1,053
	Warrant	September 8, 2027	Preferred Series D	195,008	\$	5.13		1,533		526
Total Atieva, Inc.								4,600		1,579
AyDeeKay LLC	Warrant	March 30, 2028	Preferred Series G	6,250	\$	35.42	\$	31	\$	32
Footprint International Holding, Inc.	Warrant	February 14, 2030	Common Stock	26,852	\$	0.31	\$	5	\$	81
	Warrant	June 22, 2030	Common Stock	10,836	\$	0.31		4		33
Total Footprint International Holding, Inc.								9		114
Happiest Baby, Inc.	Warrant	May 16, 2029	Common Stock	182,554	\$	0.33	\$	193	\$	126
Hexatech, Inc. (12)	Warrant	April 2, 2022	Preferred Series A	226	\$	2.77	\$	_	\$	_
Lauranten Ing	Warrant	December 30, 2021	Durafarma d Carriera C	05.005	\$	1.10	\$	32	\$	
Lensvector, Inc.	warrant	December 30, 2021	Preferred Series C	85,065	\$	1.18	\$	32	Э	
Mainspring Energy, Inc.	Warrant	July 9, 2029	Common Stock	140,186	\$	1.15	\$	283	\$	394
Manspring Energy, Inc.	Warrant	November 20, 2030	Common Stock	81,294	\$	1.15	φ	226	φ	229
Total Mainspring Energy, Inc.	warant	1000cmbcr 20, 2000	Common Stock	01,254	Ψ	1.15		509		623
Total Manispring Energy, Inc.								309		023
Molekule, Inc.	Warrant	June 19, 2030	Preferred Series C-1	32,051		3.12	\$	16	\$	23
SBG Labs, Inc.	Warrant	June 29, 2023	Preferred Series A-1	42,857	\$	0.70	\$	13	\$	10
	Warrant	September 18, 2024	Preferred Series A-1	25,714	\$	0.70	Ŷ	8	Ŷ	6
	Warrant	January 14, 2024	Preferred Series A-1	21,492	\$	0.70		7		5
	Warrant	March 24, 2025	Preferred Series A-1	12,155	\$	0.70		4		3
	Warrant	October 10, 2023	Preferred Series A-1	11,150	\$	0.70		4		3
	Warrant	May 6, 2024	Preferred Series A-1	11,145	\$	0.70		4		3
	Warrant	June 9, 2024	Preferred Series A-1	7,085	\$	0.70		2		2
	Warrant	May 20, 2024	Preferred Series A-1	342,857	\$	0.70		110		80
	Warrant	March 26, 2025	Preferred Series A-1	200,000	\$	0.70		65		48
Total SBG Labs, Inc.								217		160
The Fynder Group, Inc.	Warrant	October 14, 2030	Common Stock	107,190	\$	0.49	\$	201	\$	282
Vertical Communications, Inc. (12)(17)	Warrant	July 11, 2026	Preferred Series A	828,479	\$	1.00	\$	_	\$	_
							_		_	
Sub-Total: Manufacturing (1.2%)*							\$	5,808	\$	2,939

Varrant Investments, Continued	Investment (3)	Expiration Date	Series	Shares	Str	ike Price		Cost	Fair	r Value (6)
Pharmaceutical (?).										
Ology Biosciences, Inc. (17)	Warrant	November 14, 2021	Common Stock	67,961	\$	1.03	\$	1,122	\$	2,216
Zosano Pharma Corporation	Warrant	September 25, 2025	Common Stock	75,000	\$	3.59	\$	69	\$	18
							_			
Sub-Total: Pharmaceutical (0.9%)*							\$	1,191	\$	2,234
Professional, Scientific, and Technical Services (?).										
Augmedix, Inc.	Warrant	September 3, 2029	Preferred Series B	580,383	\$	2.88	\$	449	\$	379
Continuity, Inc.	Warrant	March 29, 2026	Preferred Series C	1,588,806	\$	0.25	\$	21	\$	45
Continuity, mc.	wdiidiit	Maicii 29, 2020	Preferred Series C	1,300,000	3	0.25	æ	21	φ	43
Crowdtap, Inc.	Warrant	December 16, 2025	Preferred Series B	442,233	\$	1.09	\$	42	\$	140
	Warrant	November 30, 2027	Preferred Series B	100,000	\$	1.09		9		32
Total Crowdtap, Inc.				,	Ĩ			51		172
				-=	•					
Dynamics, Inc.	Warrant	March 10, 2024	Common Stock	17,000	\$	10.59	\$	86	\$	_
E La Carte, Inc.	Warrant	July 28, 2027	Common Stock	497,183	\$	0.30	\$	186	\$	123
	¥17 .	L 1 00 0007		101 201	¢	5.40		15		24
	Warrant	July 28, 2027	Preferred Series A	104,284	\$	7.49		15		34
	Warrant	July 28, 2027	Preferred Series AA-1	106,841	\$	7.49		15		1
Total E La Carte, Inc.								216		158
Edeniq, Inc.	Warrant	December 23, 2026	Preferred Series B	2,685,501	\$	0.22	\$	_	\$	_
							Ť		-	
	Warrant	December 23, 2026	Preferred Series B	2,184,672	\$	0.01		—		_
	Warrant	March 12, 2028	Preferred Series C	5,106,972	\$	0.44		-		-
	Warrant	October 15, 2028	Preferred Series C	3,850,294	\$	0.01				_
Total Edeniq, Inc. (12)(17)								_		_
Fingerprint Digital, Inc.	Warrant	April 29, 2026	Preferred Series B	48,102	\$	10.39	\$	165	\$	84
0. r - 0 ,		r .,								
Hologram, Inc.	Warrant	January 27, 2030	Common Stock	193,054	\$	0.26	\$	49	\$	33
Hospitalists Now, Inc.	Warrant	March 30, 2026	Preferred Series D2	135,807	\$	5.89	\$	71	\$	272
	Warrant	December 6, 2026	Preferred Series D2	750,000	\$	5.89		391		1,505
Total Hospitalists Now, Inc.								462		1,777
Incontext Solutions, Inc.	Warrant	September 28, 2028	Preferred Series AA-1	332,858	\$	1.47	\$	34	\$	47
Matterport, Inc.	Warrant	April 20, 2028	Common Stock	143,813	\$	1.43	\$	434	\$	603
Pendulum Therapeutics, Inc.	Warrant	Ortober 0, 2020	Desfamed Carica D	55 262	¢	1.90	\$	44	\$	65
Pendulum Therapeutics, Inc.	Warrant	October 9, 2029 July 15, 2030	Preferred Series B Preferred Series B	55,263 36,842	\$ \$	1.90	2	44 36	э	43
Total Pendulum Therapeutics, Inc.								80		108
Reciprocity, Inc.	Warrant	September 25, 2030	Common Stock	114,678	\$	4.17	\$	99	\$	145
					c					
Resilinc, Inc.	Warrant	December 15, 2025	Preferred Series A	589,275	\$	0.51	\$	40	\$	100
Saylent Technologies, Inc.	Warrant	March 31, 2027	Preferred Series C	24,096	\$	9.96	\$	108	\$	94
Sun Basket, Inc.	Warrant	October 5, 2027	Preferred Series C-2	249,306	\$	6.02	\$	111	\$	343
	Warrant	December 31, 2030	Common Stock	118,678	\$	0.89		545	_	546

Utility Associates, Inc.	Warrant	June 30, 2025	Preferred Series A	92,511	\$ 4.54	\$ 55	s	4
	Warrant	May 1, 2026	Preferred Series A	60,000	\$ 4.54	36		3
	Warrant	May 22, 2027	Preferred Series A	200,000	\$ 4.54	120		8
Total Utility Associates, Inc.						211		15
Sub-Total: Professional, Scientific, and Tecl	nnical Services (2.0%)*					\$ 3,161	\$	4,649

Portfolio Company (1) Warrant Investments, Continued	Type of Investment ⁽³⁾	Expiration Date	Series	Shares	Strike Price		_	Cost	Fair	r Value ⁽⁶⁾
<u>Real Estate (?).</u>	1 47	D 1 40 2020	D 6 10 1 4	co 7 00	¢	4.00	¢		¢	50
Egomotion Corporation	Warrant	December 10, 2028	Preferred Series A	60,786	\$	1.32	\$	-	\$	53
	Warrant	June 29, 2028	Preferred Series A	121,571	\$	1.32		219		106
Total Egomotion Corporation								219		159
Knockaway, Inc.	Warrant	May 24, 2029	Preferred Series B	87,955	\$	8.53	\$	209	\$	272
Knockuway, nc.	Warrant	Muy 24, 2023	Treatment Series B	07,355	Ψ	0.55	.	205		2/2
Sub-Total: Real Estate (0.2%)*							\$	428	\$	431
<u>Rental and Leasing Services 🕀</u>										
Maxwell Financial Labs, Inc.	Warrant	October 7, 2030	Common Stock	106,735	\$	0.29	\$	21	\$	33
	X 47 .	D 1 00 0000		110.000	¢	0.00		24		24
	Warrant	December 22, 2030	Common Stock	110,860	\$	0.29		34		34
Total Maxwell Financial Labs, Inc.							_	55		67
Sub-Total: Rental and Leasing Services (0.0%)*							\$	55	\$	67
Retail Trade 🕀										
Boosted eCommerce, Inc. (14)	Warrant	December 14, 2030	Preferred Series A-1	759,263	\$	0.84	\$	259	\$	259
Gobble, Inc.	Warrant	May 9, 2028	Common Stock	74,635	\$	1.20	\$	73	\$	63
	Warrant	December 27, 2029	Common Stock	10,000	\$	1.22		617		467
Total Gobble, Inc.								690		530
Madison Reed, Inc.	Warrant	March 23, 2027	Preferred Series C	194,553	\$	2.57	\$	185	\$	241
	Warrant	July 18, 2028	Common Stock	43,158	\$	0.99		71		78
	Warrant	May 19, 2029	Common Stock	36,585	\$	1.23		56		62
Total Madison Reed, Inc.								312		381
5 6 5 1 5 (14)			· ·	20.080						
Portofino Labs, Inc. (14)	Warrant	December 31, 2030	Common Stock	39,659	\$	1.53	\$	15	\$	15
Super73, Inc. (14)	Warrant	December 21, 2020	Common Stock	177 205	¢	3.16	\$	105	\$	105
Supervs, nic. (19)	waitalit	December 31, 2030	Common Stock	177,305	\$	5.10	æ	105	Э	105
Trendly, Inc.	Warrant	August 10, 2026	Preferred Series A	245,506	\$	1.14	\$	222	\$	256
Tendiy, Inc.	Warrant	August 10, 2020	Treating Series A	243,300	Ψ	1.14	ų.		φ	230
Sub-Total: Retail Trade (0.6%)*							\$	1,603	\$	1,546
Wholesale Trade (?)										
BaubleBar, Inc.	Warrant	March 29, 2027	Preferred Series C	531,806	\$	1.96	\$	638	\$	207
	Warrant	April 20, 2028	Preferred Series C	60,000	\$	1.96		72		23
Total BaubleBar, Inc.								710		230
Carb) (adat Inc	147	L. 15 0000	Common St. 1	105 000	¢	4.40	¢		¢	005
GrubMarket, Inc.	Warrant	June 15, 2030	Common Stock	405,000	\$	1.10	\$	116	\$	837
Sub-Total: Wholesale Trade (0.4%)*							\$	826	\$	1,067
Total: Warrant Investments (7.4%)* (13)							s	17,865	\$	17,778
Total, waitant investments (7.470)" (***)							-	1,005	*	1,,,,,

Portfolio Company (1)	Type of Investment ⁽³⁾	Shares / Principal	Series		Cost	Fa	ir Value ⁽⁶⁾
Equity Investments Construction (?).							
Project Frog, Inc.	Equity	8,118,527	Preferred Series AA-1	\$	702	\$	36
rioject riog, ne.	Equity	6,300,134	Preferred Series BB	Ψ	2,667	Ψ	449
Total Project Frog, Inc. (17)	Equity	0,500,134	Fielened Selies DD				
Iotal Project Frog, Inc. (27)					3,369		485
Sub-Total: Construction (0.2%)*				\$	3,369	\$	485
Health Care and Social Assistance (?).							
WorkWell Prevention & Care Inc.	Equity	7,000,000	Common Stock	\$	51	\$	_
	Equity	3,450	Preferred Series P		3,450		657
	a. 5	\$ 1,470	Convertible Notes (10)		1,519		1,542
Total WorkWell Prevention & Care Inc. (17)		,			5,020		2,199
					5,020		2,155
Sub-Total: Health Care and Social Assistance (0.9%)*				\$	5,020	\$	2,199
<u>Manufacturing (?)</u>							
Store Intelligence, Inc. (17)	Equity	1,430,000	Preferred Series A	\$	608	\$	694
	1.5	,,					
Vertical Communications, Inc.	Equity	3,892,485	Preferred Series 1 ⁽⁷⁾	\$	_	\$	_
	Equity	\$ 5,500,000	Convertible Notes (10)		3,966		3,350
Total Vertical Communications, Inc. (17)					3,966		3,350
Sub-Total: Manufacturing (1.7%)*				\$	4,574	\$	4,044
<u>Pharmaceutical</u> (?). Ology							
Biociences, Inc. (17)	Equity	382,277	Common Stock (16)	\$	6,691	\$	12,856
Sub-Total: Pharmaceutical (5.4%)*				\$	6,691	\$	12,856
Professional, Scientific, and Technical Services	(?)						
Dynamics, Inc.	Equity	17,726	Preferred Series A	\$	390	\$	-
	Equity	15,000	Common Stock				_
Total Dynamics, Inc.					390		_
	1	E 005 400		¢		¢	
Edeniq, Inc.	Equity	7,807,499	Preferred Series B (7)	\$	_	\$	_
	Equity	2,441,082	Preferred Series C (7)		_		_
	Equity	\$ 1,303,373	Convertible Notes (7)(10)				
Total Edeniq, Inc. (17)					—		—
Instart Logic, Inc.	Equity	\$ 2,600,000	Convertible Notes (10)	\$	2,646	\$	3,625
Sub-Total: Professional, Scientific, and Techni	cal Services (1.5%)*			\$	3,036	\$	3,625
<u>Retail Trade (?).</u>							
Birchbox, Inc. (17)	Equity	3,140,927	Preferred Series D	\$	10,271	\$	9,445
Sub-Total: Retail Trade (4.0%)*				\$	10,271	\$	9,445
						-	
Total: Equity Investments (13.7%)* (13)				\$	32,961	\$	32,654
Total Investment in Securities (207.2%)*				\$	498,336	\$	493,651
					.50,550	<u>-</u>	100,001
Cash, Cash Equivalents, and Restricted Cash							
Goldman Sachs Financial Square Government In	stitutional Fund			\$	60,284	\$	60,284
Other cash accounts Cash, Cash Equivalents, and Restricted Cash					817		817
(25.6%)*					61,101		61,101
Total Portfolio Investments and Cash and Cash Equivalents (232.9% of net assets)				¢	559,437	\$	554,752
Equivalents (252.3/0 0) rice ussels)				φ	000,407	÷	JJ4,7J2

- (1) All portfolio companies are located in North America. As of December 31, 2020, the Company had one foreign domiciled portfolio in Canada. The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the "Securities Act"). These investments are generally subject to certain limitations on resale and may be deemed to be "restricted securities" under the Securities Act.
- ⁽²⁾ The Company uses the North American Industry Classification System ("NAICS") code for classifying the industry grouping of its portfolio companies.
- (3) All debt investments are income producing unless otherwise noted. All equity and warrant investments are non-income producing unless otherwise noted. Equipment financed under our equipment financing investments relates to operational equipment essential to revenue production for the portfolio company in the industry noted.
- (4) Interest rate is the fixed or variable rate of the debt investments and does not include any original issue discount, end-of-term ("EOT") payment, or any additional fees related to such investments, such as deferred interest, commitment fees, prepayment fees or exit fees. EOT payments are contractual payments due in cash at the maturity date of the loan, including upon prepayment, and are a fixed rate determined at the inception of the loan. At the end of the term of certain equipment financings, the borrower has the option to purchase the underlying assets at fair market value in certain cases subject to a cap, or return the equipment and pay a restocking fee. The fair values of the financed assets have been estimated as a percentage of original cost for purpose of the EOT payment value. The EOT payment is amortized and recognized as non-cash income over the loan or equipment financing prior to its payment and is included as a component of the cost basis of the Company's current debt securities
- ⁽⁵⁾ Principal is net of repayments, if any, as per the terms of the debt instrument's contract.
- ⁽⁶⁾ All investments were valued at fair value using Level 3 significant unobservable inputs as determined in good faith by the Company's board of directors.
- (7) Investment has zero cost basis as it was purchased at a fair market value of zero as part of the Formation Transaction.
- ⁽⁸⁾ Indicates a "non-qualifying asset" under section 55(a) by the Investment Company Act of 1940, as amended. The Company's percentage of non-qualifying assets represents 5.1% of the Company's total assets as of December 31, 2020. Qualifying assets must represent at least 70% of the Company's total assets at the time of acquisition of any additional non-qualifying assets.
- ⁽⁹⁾ The interest rate on variable interest rate investments represents a benchmark rate plus spread. The benchmark interest rate is subject to an interest rate floor. The benchmark rate PRIME was 3.25% as of December 30, 2020.
- (10) Convertible notes represent investments through which the Company will participate in future equity rounds at preferential rates. There are no principal or interest payments made against the note unless conversion does not take place.
- ⁽¹¹⁾ Debt is on non-accrual status as of December 30, 2020 and is therefore considered non-income producing.
- (12) Investment has an unfunded commitment as of December 31, 2020 (see "Note 6 Commitments and Contingencies"). The fair value of the investment includes the impact of the fair value of any unfunded commitments.



- (13) All of the Company's debt, warrant and equity securities are pledged as collateral supporting the amounts outstanding under the credit facility with Credit Suisse AG (see "Note 5 – Borrowings"), except as noted.
- ⁽¹⁴⁾ Investment is not pledged as collateral supporting amounts outstanding under the credit facility with Credit Suisse AG.
- ⁽¹⁵⁾ Investment is considered non-income producing.
- (16) Certain third parties have rights to 17,485 shares of Ology Biosciences common stock at a fair value of approximately \$0.6 million as of December 31, 2020.
- (17) This

investment is deemed to be a "Control Investment" or an "Affiliate Investment." The Company classifies its investment

portfolio in accordance with the requirements of the 1940 Act. Control Investments are defined by the Investment Company Act of 1940,

as amended, as investments in companies in which the Company owns more than 25% of the voting securities or maintains greater than 50%

of the board representation. Affiliate Investments are defined by the Investment Company Act of 1940, as amended, as investments in companies

in which the Company owns between 5% and 25% (inclusive) of the voting securities and does not have rights to maintain greater than 50%

of the board representation. As defined in the Investment Company Act, the Company is deemed to be an "Affiliated Person"

of this portfolio company. Fair value as of December 31, 2020 along with transactions during the three months ended December 31, 2020

in these control or affiliated investments are as follows:

									Net change in Unrealized				
	Beg	inning	Gross		Gross		Realized		(Depreciation)/		Ending		Interest
	Fair	· Value	 Additions (1)]	Reductions (2)	_	Gain/(Loss)	_	Appreciation	_	Fair Value	_	Income
For the Year Ended December 31, 2020													
Control Investments													
Birchbox, Inc.	\$	_	\$ 20,704	\$		\$	_	\$	(1,335)	\$	19,369	\$	1,289
Edeniq, Inc.		_	3,278		(1,414)		_		(357)		1,507		_
Project Frog, Inc.		—	7,432				_		(2,916)		4,516		552
Vertical Communications, Inc.		_	17,904		(194)		_		(757)		16,953		1,425
WorkWell Prevention and Care Inc.		<u> </u>	 9,362						(2,977)		6,385	_	395
Total Control Investments	<u>\$</u>		\$ 58,680	\$	(1,608)	\$		\$	(8,342)	\$	48,730	\$	3,661
Affiliate Investments													
Ology Biosciences, Inc.	\$	_	\$ 7,813	\$		\$	_	\$	7,259	\$	15,072	\$	_
Store Intelligence, Inc.			 12,840			_		_	(262)		12,578	_	1,191
Total Affiliate Investments	\$		\$ 20,653	\$		\$		\$	6,997	\$	27,650	\$	1,191
Total Control and Affiliate Investments	\$	_	\$ 79,333	\$	(1,608)	\$		\$	(1,345)	\$	76,380	\$	4,852

(1) Gross additions may include increases in the cost basis of investments resulting from new portfolio investments, PIK interest, the accretion of discounts, the exchange of one or more existing securities for one or more new securities and the movement of an existing portfolio company into this category from a different category.

(2) Gross reductions may include decreases in the cost basis of investments resulting from principal collections related to investment repayments or sales, the exchange of one or more existing securities for one or more new securities and the movement of an existing portfolio company out of this category into a different category.

TRINITY CAPITAL INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Note 1. Organization and Basis of Presentation

Trinity Capital Inc., ("Trinity Capital" and, together with its subsidiary, the "Company") is a specialty lending company focused on providing debt, including loans and equipment financings, to growth stage companies, including venture-backed companies and companies with institutional equity investors. Trinity Capital was formed on August 12, 2019 as a Maryland corporation and commenced operations on January 16, 2020. Prior to January 16, 2020, Trinity Capital had no operations, except for matters relating to its formation and organization as a business development company ("BDC").

Trinity Capital is an internally managed, closed-end, non-diversified management investment company that has elected to be regulated as a BDC under the Investment Company Act of 1940, as amended (the "1940 Act"). Trinity Capital intends to elect to be treated, and intends to qualify annually thereafter, as a regulated investment company (a "RIC") under Subchapter M of the Internal Revenue Code of 1986, as amended (the "Code"), for U.S. federal income tax purposes. This election will be made in conjunction with the filing of the Company's 2020 tax return.

On September 27, 2019, Trinity Capital was initially capitalized with the issuance of 10 shares of its common stock for \$150 to its sole stockholder. On January 16, 2020, Trinity Capital completed a series of transactions, including a private equity offering, a private debt offering, and the acquisition of Trinity Capital Investment, LLC ("TCI"), Trinity Capital Fund II, L.P. ("Fund II"), Trinity Capital Fund III, L.P. ("Fund III"), Trinity Capital Fund IV, L.P. ("Fund IV"), and Trinity Sidecar Income Fund, L.P. ("Sidecar Fund") (collectively the "Legacy Funds") through mergers of the Legacy Funds with and into Trinity Capital as well as Trinity Capital's acquisition of Trinity Capital Holdings, LLC ("Trinity Capital Holdings") (collectively, the "Formation Transactions").

Trinity Capital's common stock began trading on the Nasdaq Global Select Market on January 29, 2021 under the symbol "TRIN" in connection with its initial public offering of shares of its common stock ("IPO").

Basis of Presentation

The Company's interim consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Articles 6, 10 and 12 of Regulation S-X. Accordingly, certain disclosures accompanying annual financial statements prepared in accordance with GAAP are omitted. In the opinion of management, the unaudited financial results included herein contain all adjustments, consisting solely of normal accruals, considered necessary for the fair statement of the results for the interim period included herein. The current period's consolidated results of operations are not necessarily indicative of results that may be achieved for the year. The interim consolidated financial statements and notes thereto should be read in conjunction with the consolidated financial statements and notes thereto should be read in conjunction with the company follows accounting and reporting guidance determined by the Financial Accounting Standards Board ("FASB"), in Accounting Standards Codification, as amended ("ASC") Topic 946 - *Financial Services – Investment Companies* ("ASC 946").

Formation Transactions

The Formation Transactions were accounted for as a business combination in accordance with FASB ASC 805, *Business Combinations* ("ASC 805"), and as a result the assets acquired, and liabilities assumed were recorded at fair values as of January 16, 2020. Transaction costs related to the acquisition of a business are expensed as incurred and excluded from the fair value of the consideration transferred.

On January 16, 2020, the Company completed a private offering of shares of its common stock (the "Private Common Stock Offering") in reliance upon the available exemptions from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), pursuant to which the Company issued and sold 7,000,000 shares of its common stock for aggregate gross proceeds of approximately \$105.0 million. Keefe, Bruyette & Woods, Inc. ("KBW") acted as the initial purchaser and placement agent in connection with the Private Common Stock Offering pursuant to a purchase/placement agreement, dated January 8, 2020, by and between the Company and KBW. KBW exercised in full its option to purchase or place additional shares and on January 29, 2020 the Company issued and sold an additional 1,333,333 shares of its common stock for gross proceeds of approximately \$20.0 million. As a result, the Company issued and sold a total of 8,333,333 shares of its common stock Offering for aggregate net proceeds of approximately \$114.4 million, net of offering costs of approximately \$10.6 million.

On January 16, 2020, concurrent with the initial closing of the Private Common Stock Offering, the Company completed a private debt offering (the "144A Note Offering" and together with the Private Common Stock Offering, the "Private Offerings") of \$105.0 million in aggregate principal amount of the Company's unsecured 7.00% Notes due 2025 (the "2025 Notes"). On January 29, 2020, an over-allotment option related to the 144A Note Offering was exercised in full and on the Company issued and sold an additional \$20.0 million in aggregate principal amount of the Notes. As a result, the Company issued and sold \$125.0 million in aggregate principal amount of the Notes. See "Note 5 - Borrowings" and "Note 7 – Stockholder's Equity."

On January 16, 2020, immediately following the consummation of the Private Offerings, the Company used a portion of the proceeds of the Private Offerings to acquire, through the Formation Transactions, the Legacy Funds and Trinity Capital Holdings. Each member/limited partner of the Legacy Funds was given the option to elect to receive cash and or shares of the Company's common stock in exchange for its limited partner interests or membership interests, as applicable. The general partners, managers or managing members of the Legacy Funds received only shares in exchange for their interests held in such capacities. As a result of the Formation Transactions, the Legacy Funds were merged with and into the Company and Trinity Capital Holdings became a wholly owned subsidiary of the Company.

As consideration for the partnership and membership interests in the Legacy Funds, the Company issued 9,183,185 shares of its common stock at \$15.00 per share for a total value of approximately \$137.7 million and paid approximately \$108.7 million in cash to the Legacy Funds' investors, which included the general partners/managers of the Legacy Funds (the "Legacy Investors"). The acquisition consideration of the Formation Transactions was based on valuations as of September 30, 2019, as adjusted for assets that were disposed of by the Legacy Funds, as well as earnings, capital contributions and distributions paid to the members/limited partners, and material events affecting the portfolio companies of the Legacy Funds subsequent to September 30, 2019 and through the closing date of the Formation Transactions.

Investments acquired	\$ 417,023
Interest receivable and other assets acquired	1,191
Accounts payable and accrued liabilities assumed	(680)
Customer deposits assumed	(4,250)
Credit facility assumed	(190,000)
Financing fees related to credit facility acquired	1,900
Cash acquired	19,183
Total net assets acquired	\$ 244,367

A summary of the fair value of the assets acquired and liabilities assumed from the Legacy Funds as of the acquisition date is as follows (in thousands):

The total merger consideration of the Legacy Funds of approximately \$246.4 million exceeded the fair value of the net assets acquired as of the acquisition date, and as a result, the Company included a loss of approximately \$2.1 million in Costs related to the acquisition of Trinity Capital Holdings and Legacy Funds in the Consolidated Statements of Operations. During the quarter ended December 31, 2020, upon filing the final tax returns for the Legacy Funds, the Company reversed approximately \$0.4 million of accrued liabilities assumed related to expected tax expense of the Legacy Funds.

Additionally, as part of the Formation Transactions, the Company also used a portion of the proceeds of the Private Offerings to acquire 100% of the equity interests of Trinity Capital Holdings, the sole member of Trinity Management IV, LLC, the investment manager to Fund IV and the sub-adviser to Fund II and Fund III, the Company issued 533,332 shares of common stock at \$15.00 per share for a total value of approximately \$8.0 million and paid approximately \$2.0 million in cash. In connection with the acquisition of Trinity Capital Holdings, the Company also assumed a \$3.5 million severance related liability with respect to a former member of certain general partners of certain Legacy Funds. Prior to the completion of the Formation Transactions, Trinity Capital Holdings acquired approximately \$0.2 million of certain net assets from Trinity SBIC Management, LLC, the investment manager to Fund II and Fund III.

In connection with the acquisition of Trinity Capital Holdings, approximately \$13.5 million (consisting of the aggregate purchase price and severance related liability assumed) was expensed to Costs related to the acquisition of Trinity Capital Holdings and Legacy Funds in the Consolidated Statements of Operations. Under ASC 805, such amount represents the settlement price, based on the estimated fair value of the future profits and cash flows that would otherwise have been contractually due to Trinity Capital Holdings, had the underlying management agreements with each of the Legacy Funds not been canceled in order to enter into the Formation Transactions and operate the Company as an internally managed BDC.

Principles of Consolidation

Under ASC 946, the Company is precluded from consolidating portfolio company investments, including those in which it has a controlling interest, unless the portfolio company is another investment company. An exception to this general principle occurs if the Company holds a controlling interest in an operating company that provides all or substantially all of its services directly to the Company or to its portfolio companies. None of the portfolio investments made by the Company qualify for this exception. Therefore, the Company's investment portfolio is carried on the Consolidated Statements of Assets and Liabilities at fair value, as discussed further in "Note 3 - Investments," with any adjustments to fair value recognized as "Net unrealized appreciation (depreciation) from investments" on the Consolidated Statements of Operations.

The Company's consolidated operations include the activities of its wholly owned subsidiary, Trinity Funding 1, LLC ("TF1"). On January 16, 2020, in connection with the Formation Transactions, the Company acquired TF1 through Fund II and became a party to, and assumed, a \$300 million credit agreement (as amended, the "Credit Facility") with Credit Suisse AG ("Credit Suisse") through TF1. TF1 was formed on August 14, 2019 as a Delaware limited liability company with Fund II as its sole equity member. TF1 is a special purpose bankruptcy-remote entity and is a separate legal entity from the Company. Any assets conveyed to TF1 are not available to creditors of the Company or any other entity other than TF1's lenders. TF1 is consolidated for financial reporting purposes and in accordance with GAAP, and the portfolio investments held by this subsidiary are included in the Company's consolidated financial statements and recorded at fair value. All intercompany balances and transactions have been eliminated.

In accordance with Rule 10-01(b)(1) of Regulation S-X, as amended, Trinity Capital must determine which of its unconsolidated controlled portfolio companies, if any, are considered "significant subsidiaries." In evaluating these unconsolidated controlled portfolio companies, there are two significance tests utilized per Rule 1-02(w) of Regulation S-X to determine if any of Trinity Capital's Control Investments (as defined in "Note 2 - Summary of Significant Accounting Policies") are considered significant subsidiaries: the investment test, and the income test. As of March 31, 2021 and December 31, 2020, Trinity Capital had no single investment that met either of these two tests.

Note 2. Summary of Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. These estimates and assumptions also affect the reported amounts of revenues, costs

and expenses during the reporting period. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ materially from those estimates.

Investment Transactions

Loan originations are recorded on the date of the legally binding commitment. Realized gains or losses are recorded using the specific identification method as the difference between the net proceeds received, excluding prepayment fees, if any, and the amortized cost basis of the investment without regard to unrealized gains or losses previously recognized, and include investments written off during the period, net of recoveries. The net change in unrealized gains or losses primarily reflects the change in investment fair values as of the last business day of the reporting period and also includes the reversal of previously recorded unrealized gains or losses with respect to investments realized during the period.

Valuation of Investments

The most significant estimate inherent in the preparation of the Company's consolidated financial statements is the valuation of investments and the related amounts of unrealized appreciation and depreciation of investments recorded.

The Company's investments are carried at fair value in accordance with the 1940 Act and ASC 946 and measured in accordance with ASC 820, *Fair Value Measurements and Disclosures* ("ASC 820"). ASC 820 defines fair value, establishes a framework for measuring fair value, establishes a fair value hierarchy based on the observability of inputs used to measure fair value, and provides disclosure requirements for fair value measurements. ASC 820 requires the Company to assume that each of the portfolio investments is sold in a hypothetical transaction in the principal or, as applicable, most advantageous market using market participant assumptions as of the measurement date. Market participants are defined as buyers and sellers in the principal market that are independent, knowledgeable and willing and able to transact. The Company values its investments at fair value as determined in good faith pursuant to a consistent valuation policy by the Company's Board of Directors (the "Board") in accordance with the provisions of ASC 820 and the 1940 Act.

While the Board is ultimately and solely responsible for determining the fair value of the Company's investments, the Company has engaged independent valuation firms to provide the Company with valuation assistance with respect to its investments. The Company engages independent valuation firms on a discretionary basis. Specifically, on a quarterly basis, the Company will identify portfolio investments with respect to which an independent valuation firm will assist in valuing. The Company selects these portfolio investments based on a number of factors, including, but not limited to, the potential for material fluctuations in valuation results, size, credit quality and the time lapse since the last valuation of the portfolio investment by an independent valuation firm.

Investments recorded on the Company's Consolidated Statements of Assets and Liabilities are categorized based on the inputs to the valuation techniques as follows:

- Level 1 Investments whose values are based on unadjusted quoted prices for identical assets in an active market that the Company has the ability to access (examples include investments in active exchange-traded equity securities and investments in most U.S. government and agency securities).
- Level 2 Investments whose values are based on quoted prices in markets that are not active or model inputs that are observable either directly or indirectly for substantially the full term of the investment.
- Level 3 Investments whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement (for example, investments in illiquid securities issued by privately held companies). These inputs reflect management's own assumptions about the assumptions a market participant would use in pricing the investment.

Given the nature of lending to venture capital-backed growth stage companies, substantially all of the Company's investments in these portfolio companies are considered Level 3 assets under ASC 820 because there is no known or

accessible market or market indexes for these investment securities to be traded or exchanges. The Company uses an internally developed portfolio investment rating system in connection with its investment oversight, portfolio management and analysis and investment valuation procedures. This system takes into account both quantitative and qualitative factors of the portfolio companies. Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company's investments may fluctuate from period to period. Because of the inherent uncertainty of valuation, these estimated values may differ significantly from the values that would have been reported had a ready market for the investments existed, and it is reasonably possible that the difference could be material.

Debt Securities

The debt securities identified on the Consolidated Schedule of Investments are secured loans and equipment financings made to growth stage companies. For portfolio investments in debt securities for which the Company has determined that third-party quotes or other independent pricing are not available, the Company generally estimates the fair value based on the assumptions that hypothetical market participants would use to value the investment in a current hypothetical sale using an income approach.

In its application of the income approach to determine the fair value of debt securities, the Company bases its assessment of fair value on projections of the discounted future free cash flows that the security will likely generate, including analyzing the discounted cash flows of interest and principal amounts for the security, as set forth in the associated loan and equipment financing agreements, as well as market yields and the financial position and credit risk of the portfolio company (the "Hypothetical Market Yield Method"). The discount rate applied to the future cash flows of the security is based on the calibrated yield implied by the terms of the Company's investment adjusted for changes in market yields and performance of the subject company. The Company's estimate of the expected repayment date of its loans and equipment financings securities is either the maturity date of the instrument or the anticipated pre-payment date, depending on the facts and circumstances. The Hypothetical Market Yield Method analysis also considers changes in leverage levels, credit quality, portfolio company performance, market yield movements, and other factors. If there is deterioration in credit quality or if a security is in workout status, the Company may consider other factors in determining the fair value of the security, including, but not limited to, the value attributable to the security from the enterprise value of the portfolio company or the proceeds that would most likely be received in a liquidation analysis.

Equity-Related Securities and Warrants

Often the Company is issued warrants by issuers as yield enhancements. These warrants are recorded as assets at estimated fair value on the grant date. Depending on the facts and circumstances, the Company usually utilizes a combination of one or several forms of the market approach as well as contingent claim analyses (a form of option analysis) to estimate the fair value of the securities as of the measurement date. As part of its application of the market approach, the Company estimates the enterprise value of a portfolio company utilizing customary pricing multiples, based on the development stage of the underlying issuers, or other appropriate valuation methods, such as considering recent transactions in the equity securities of the portfolio company or third-party valuations that are assessed to be indicative of fair value of the respective portfolio company, and, if appropriate based on the facts and circumstances performs an allocation of the enterprise value to the equity securities utilizing a contingent claim analysis and/or other waterfall calculation by which it allocates the enterprise value across the portfolio company's securities in order of their preference relative to one another.

Fair value estimates are made at discrete points in time based on relevant information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. The carrying amounts of the Company's financial instruments, consisting of cash, investments, receivables, payables and other liabilities approximate the fair values of such items due to the short-term nature of these instruments. Refer to "Note 4 – Fair Value of Financial Instruments" for further discussion.

Cash, Cash Equivalents and Restricted Cash

Cash, cash equivalents and restricted cash consist of funds deposited with financial institutions and short-term (original maturity of three months or less) liquid investments in money market deposit accounts. Cash equivalents are classified as Level 1 assets and are valued using the Net Asset Value ("NAV") per share of the money market fund. As of March 31, 2021 and December 31, 2020, cash, cash equivalents and restricted cash consisted of \$51.3 million and \$61.1 million, respectively, of which \$39.7 and \$60.3 million, respectively, is held in the Goldman Sachs Financial Square Government Institutional Fund. Cash held in demand deposit accounts may exceed the Federal Deposit Insurance Corporation ("FDIC") insured limit and therefore is subject to credit risk. All of the Company's cash deposits are held at large established high credit quality financial institutions, and management believes that the risk of loss associated with any uninsured balances is remote. As of March 31, 2021 and December 31, 2020, restricted cash consisted of approximately \$15.3 million and \$15.7 million, respectively, related to the Credit Facility covenants (See "Note 5 – Borrowings"), and an additional amount of approximately \$0.7 million as of December 31, 2020 was held in escrow related to the payout of a severance related liability assumed as part of the Formation Transactions with respect to a former member of certain general partners of certain Legacy Funds.

Other Assets

Other assets generally consist of fixed assets net of accumulated depreciation, right of use asset, security deposits and other assets.

Equity Offering Costs

Equity offering costs consist of fees and expenses incurred in connection with the sale of the Company's common stock, including legal, accounting and printing fees. These costs are deferred at the time of incurrence and are subsequently charged as a reduction to capital when the offering takes place or as shares are issued. Deferred costs are periodically reviewed and expensed if the related registration is no longer active.

Debt Financing Costs

The Company records costs related to the issuance of debt obligations as deferred debt financing costs. These costs are deferred and amortized using the straight-line method over the stated maturity life of the obligations.

Other Liabilities

Other liabilities generally consist of equipment financing security deposits, unallocated commitment fees, lease liability and other liabilities.

Income Recognition

Interest Income

The Company recognizes interest income on an accrual basis and recognizes it as earned in accordance with the contractual terms of the loan agreement to the extent that such amounts are expected to be collected. Original issue discount ("OID") initially includes the estimated fair value of detachable warrants obtained in conjunction with the origination of debt securities and is accreted into interest income over the term of the loan as a yield enhancement based on the effective yield method. In addition, the Company may also be entitled to an end-of-term ("EOT") fee. EOT fees to be paid at the termination of the debt agreements are accreted into interest income over the contractual life of the debt based on the effective yield method. As of March 31, 2021 and December 31, 2020, the EOT payment receivable of approximately \$36.1 million and \$37.9 million, respectively, is included as a component of the cost basis of the Company's current debt securities.

The Company had a limited number of debt investments in its portfolio that contain a payment-in-kind ("PIK") provision. Contractual PIK interest, which represents contractually deferred interest added to the loan balance that is

generally

due at the end of the loan term, is generally recorded on an accrual basis to the extent such amounts are expected to be collected. The

Company will generally cease accruing PIK interest if there is insufficient value to support the accrual or management does not expect

the portfolio company to be able to pay all principal and interest due. No PIK interest income was recorded during the three months ended

March 31, 2021. The Company recorded approximately \$0.4 million in PIK interest income during the three months ended March 31, 2020.

Income related to application or origination payments, net of related expenses, and generally collected in advance, includes loan commitment and facility fees for due diligence, as well as fees for transaction services rendered by the Company to borrowers. Loan and commitment fees in excess of the related expenses are amortized into interest income over the contractual life of the loan. In certain loan arrangements, warrants or other equity interests are received from the borrower as additional origination fees. The Company recognizes nonrecurring fees over the remaining term of the loan commencing in the quarter relating to specific loan modifications.

When

a portfolio company pre-pays their indebtedness prior to the scheduled maturity date, then the acceleration of the unaccreted OID and

EOT is recognized as interest income.

Fee Income

The

Company recognizes one-time fee income, including, but not limited to, structuring fees, prepayment penalties, and exit fees related to

a change in ownership of the portfolio company, as other income when earned. These fees are generally earned when the portfolio company

enters into an equipment financing arrangement or pays off their outstanding indebtedness prior to the scheduled maturity.

Non-Accrual Policy

When a debt security becomes 90 days or more past due, or if management otherwise does not expect that principal, interest, and other obligations due will be collected in full, the Company will generally place the debt security on non-accrual status and cease recognizing interest income on that debt security until all principal and interest due has been paid or the Company believes the borrower has demonstrated the ability to repay its current and future contractual obligations. Any uncollected interest is reversed from income in the period that collection of the interest receivable is determined to be doubtful. However, the Company make exceptions to this policy if the investment has sufficient collateral value and is in the process of collection.

As of March 31, 2021, loans to three portfolio companies were on non-accrual status with a total cost of approximately \$2.3 million, and a total fair market value of approximately \$1.4 million, or 0.3%, of the fair value of the Company's investment portfolio. As of December 31, 2020, loans to three portfolio companies were on non-accrual status with a total cost of approximately \$3.4 million, and a total fair value of approximately \$2.2 million, or 0.5%, of the total fair value of the Company's investment portfolio.

Net Realized Gains / (Losses)

Realized gains / (losses) are measured by the difference between the net proceeds from the sale or redemption of an investment or a financial instrument and the cost basis of the investment or financial instrument, without regard to unrealized appreciation or depreciation previously recognized, and includes investments written-off during the period net of recoveries and realized gains or losses from in-kind redemptions. Net proceeds excludes any prepayment penalties, exit fees, and OID and EOT acceleration. Prepayment penalties and exit fees received at the time of sale or redemption are included in fee income on the Consolidated Statements of Operations. OID and EOT acceleration is included in interest income on the Consolidated Statements of Operations.

Net Unrealized Appreciation / (Depreciation)

Net change in unrealized appreciation / (depreciation) reflects the net change in the fair value of the investment portfolio and financial instruments and the reclassification of any prior period unrealized appreciation or depreciation on exited investments and financial instruments to realized gains or losses.

Earnings Per Share

Basic earnings per share ("EPS") is computed by dividing net income available to common stockholders by the weighted-average number of common shares outstanding for the period. Other potentially dilutive common shares, and the related impact to earnings are considered when calculating earnings per share on a diluted basis. Potential common shares associated with the conversion option embedded in the Convertible Notes are anti-dilutive when the Company's average NAV is below the conversion price.

Income Taxes

The Company intends to elect to be treated for U.S. federal tax purposes as a RIC under Subchapter M of the Code and operate in a manner so as to qualify annually thereafter for the tax treatment applicable to RICs. As a RIC, the Company generally will not pay corporate-level income tax on the portion of its taxable income distributed to stockholders, generally required to be at least 90% of its investment company taxable income (which is generally its net ordinary taxable income and realized net short-term capital gains in excess of realized net long-term capital losses) and 90% of its tax-exempt income to maintain its RIC status (pass-through tax treatment for amounts distributed).

The Company evaluates tax positions taken in the course of preparing the Company's tax returns to determine whether the tax positions are "more-likely-than-not" to be sustained by the applicable tax authority in accordance with ASC Topic 740, *Income Taxes* ("ASC 740"), as modified by ASC 946. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, would be recorded as tax expense in the current year. It is the Company's policy to recognize accrued interest and penalties related to uncertain tax benefits in income tax expense. The Company has no material uncertain tax positions as of March 31, 2021 and December 31, 2020. All the Company's tax returns remain subject to examination by U.S. federal and state tax authorities.

In order for the Company not to be subject to federal excise taxes, it must distribute annually an amount at least equal to the sum of (i) 98% of its ordinary income (taking into account certain deferrals and elections), (ii) 98.2% of its net capital gains from the current year and (iii) any undistributed ordinary income and net capital gains from preceding year on which it paid corporate-level U.S. federal income tax. The Company, at its discretion, may carry forward taxable income in excess of calendar year distributions and pay a 4% excise tax on this income. If the Company chooses to do so, this generally would increase expenses and reduce the amount available to be distributed to stockholders. The Company will accrue excise tax on estimated undistributed taxable income as required on an annual basis.

Distributions

Distributions to common stockholders are recorded on the record date. The amount to be paid out as a distribution is determined by the Board each quarter and is generally based upon the earnings estimated by management. Net realized capital gains, if any, are distributed at least annually, although the Company may decide to retain such capital gains for investment.

Reclassification

Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. Included in interest income for the three months ended March 31, 2020 is the acceleration of OID and EOT of approximately \$0.4 million, which was reclassified from net realized gain/(loss) on investments. Included in one-time fee income for the three months ended March 31, 2020 is non-recurring fees of approximately \$1.4 million for the three months then ended of which \$0.9 million were reclassified from net realized gain/(loss) on investment and \$0.5 million were reclassified from interest income. These reclassifications had no effect on the previously reported net increase (decrease) in net assets.

Note 3. Investments

The Company provides debt, including loans and equipment financings, to growth stage companies, including venture capital-backed companies and companies with institutional equity investors, primarily in the United States. The Company's investment strategy includes making investments consisting primarily of term loans and equipment financings, and, to a lesser extent, working capital loans, equity and equity-related investments. In addition, the Company may obtain warrants or contingent exit fees at funding from many of the portfolio companies.

Debt Securities

The Company's debt securities primarily consist of direct investments in interest-bearing secured loans and equipment financings to privately held companies based in the United States. Secured loans are generally secured by a blanket first lien or a blanket second lien on the assets of the portfolio company. Equipment financings typically include a specific asset lien on mission critical assets as well as a second lien on the assets of the portfolio company. These debt securities typically have a term of between three and five years from the original investment date. Certain of the debt securities are "covenant-lite" loans, which generally are loans that do not have a complete set of financial maintenance covenants and have covenants that are incurrence-based, meaning they are only tested and can only be breached following an affirmative action of the borrower rather than by a deterioration in the borrower's financial condition. The equipment financings in the investment portfolio generally have fixed interest rates. The loans in the investment portfolio generally have fixed interest rates or floating interest rates subject to interest rate floors. Both equipment financings and loans generally include an EOT payment.

The specific terms of each debt security vary depending on the creditworthiness of the portfolio company and the projected value of the financed assets. Companies with stronger creditworthiness may receive an initial period of lower financing factor, which is analogous to an interest-only period on a traditional term loan. Equipment financings may include upfront interim payments and security deposits. Equipment financing arrangements have various structural protections, including customary default penalties, information and reporting rights, material adverse change or investor abandonment provisions, consent rights for any additions or changes to senior debt, and, as needed, intercreditor agreements with cross-default provisions to protect the Company's second lien positions.

Warrant Investments

In connection with the Company's debt investments, the Company may receive warrants in the portfolio company. Warrants received in connection with a debt investment typically include a potentially discounted contract price to exercise, and thus, as a portfolio company appreciates in value, the Company may achieve additional investment return from this equity interest. The warrants typically contain provisions that protect the Company as a minority-interest holder, as well as secured or unsecured put rights, or rights to sell such securities back to the portfolio company, upon the occurrence of specified events. In certain cases, the Company may also obtain follow-up rights in connection with these equity interests, which allow the Company to participate in future financing rounds.

Equity Investments

In specific circumstances, the Company may seek to make direct equity investments in situations where it is appropriate to align the interests of the Company with key management and stockholders of the portfolio company, and to allow for participation in the appreciation in the equity values of portfolio company. These equity investments are generally made in connection with debt investments. The Company seeks to maintain fully diluted equity positions in the portfolio companies of 5% to 50% and may have controlling equity interests in some instances.

Portfolio Industry Classification

The Company's portfolio investments are in companies conducting business in a variety of industries. The following table summarizes the composition of the Company's portfolio investments by industry at cost and fair value and as a percentage of the total portfolio as of March 31, 2021 and December 31, 2020 (dollars in thousands):

		March 31, 2021				December 31, 2020					
	Cos	st	Fair V	alue	Cos	st	Fair V	alue			
Industry	Amount	%	Amount	%	Amount	<u>%</u>	Amount	%			
Manufacturing	\$ 122,352	23.3%	\$ 142,151	26.5%	\$ 103,471	20.8%	\$ 99,709	20.2%			
Retail Trade	96,636	18.4%	86,810	16.2%	78,534	15.7%	75,664	15.4%			
Professional, Scientific, and Technical Services	64,552	12.3%	68,126	12.7%	77,831	15.6%	78,893	16.0%			
Finance and Insurance	36,911	7.0%	37,467	7.0%	35,320	7.0%	35,699	7.2%			
Information	34,220	6.5%	34,218	6.4%	31,843	6.4%	30,709	6.2%			
Rental and Leasing Services	32,986	6.3%	33,707	6.3%	29,055	5.8%	29,138	5.9%			
Utilities	25,609	4.9%	25,962	4.8%	26,800	5.4%	27,083	5.5%			
Real Estate	21,401	4.1%	21,269	4.0%	17,267	3.5%	17,316	3.5%			
Agriculture, Forestry, Fishing and Hunting	19,536	3.7%	19,737	3.7%	20,981	4.2%	20,837	4.2%			
Pharmaceutical	16,178	3.1%	17,317	3.2%	17,503	3.5%	24,240	4.9%			
Educational Services	13,553	2.6%	14,014	2.6%	9,359	1.9%	9,816	2.0%			
Wholesale Trade	12,876	2.5%	12,593	2.4%	23,850	4.8%	23,903	4.8%			
Health Care and Social Assistance	15,386	2.8%	11,812	2.2%	14,348	2.9%	11,422	2.3%			
Construction Administrative and Support and Waste	10,870	2.1%	8,435	1.6%	9,804	2.0%	6,894	1.4%			
Management and Remediation Services	2,165	0.4%	2,123	0.4%	2,370	0.5%	2,328	0.5%			
Total	\$ 525,231	100.0%	\$ 535,741	100.0%	\$ 498,336	100.0%	\$ 493,651	100.0%			

The geographic composition is determined by the location of the corporate headquarters of the portfolio company. The following table summarizes the composition of the Company's portfolio investments by geographic region of the United States and other countries at cost and fair value and as a percentage of the total portfolio as of March 31, 2021 and December 31, 2020 (dollars in thousands):

		March	31, 2021			December 31, 2020				
	Cost		Fair Va	alue	Cost	t	Fair V	alue		
Geographic Region	Amount	%	Amount	%	Amount	%	Amount	%		
United States:										
West	\$	46.2%	\$	49.3%	\$	49.6%	\$	48.8%		

	242,488		264,372		247,204		241,096	
Northeast	154,790	29.5%	143,175	26.7%	131,692	26.4%	127,801	25.9%
	E1 06E	0.00/	46 535	0.50/	45 00 4	0.5%	44,000	0.00/
Midwest	51,267	9.8%	46,535	8.7%	47,324	9.5%	44,092	8.9%
Mountain	40,017	7.6%	41,784	7.8%	33,842	6.8%	33,969	6.9%
Contheast	10 500	2.00/	10,100	2 20/	11 011	2 20/	17.024	2.00/
Southeast	10,598	2.0%	12,186	2.3%	11,011	2.2%	17,834	3.6%
South	462	0.1%	1,727	0.3%	463	0.1%	1,777	0.4%
Canada	25,609	4.8%	25,962	4.9%	26,800	5.4%	27,082	5.5%
China da								
Total	\$ 525,231	100.0%	\$ 535,741	100.0%	\$ 498,336	100.0%	\$ 493,651	100.0%

		March	31, 2021			Decembe	er 31, 2020	
	Cos		Fair V	alue	Cos	st	Fair V	alue
Investment	Amount	%	Amount	%	Amount	%	Amount	%
Secured Loan	\$ 338,940	64.5%	\$ 335,663	62.6%	\$ 324,544	65.1%	\$ 320,718	65.0%
Equipment Financing	127,717	24.3%	128,021	23.9%	122,966	24.7%	122,501	24.8%
Equity	44,609	8.5%	49,619	9.3%	32,961	6.6%	32,654	6.6%
Warrants	13,965	2.7%	22,438	4.2%	17,865	3.6%	17,778	3.6%
Total	\$ 525,231	100.0%	\$ 535,741	100.0%	\$ 498,336	100.0%	\$ 493,651	100.0%

The following table summarizes the composition of the Company's portfolio investments by investment type at cost and fair value and as a percentage of the total portfolio as of March 31, 2021 and December 31, 2020 (dollars in thousands):

Certain Risk Factors

In the ordinary course of business, the Company manages a variety of risks including market risk, credit risk and liquidity risk. The Company identifies, measures and monitors risk through various control mechanisms, including trading limits and diversifying exposures and activities across a variety of instruments, markets and counterparties.

Market risk is the risk of potential adverse changes to the value of financial instruments because of changes in market conditions, including as a result of changes in the credit quality of a particular issuer, credit spreads, interest rates, and other movements and volatility in security prices or commodities. In particular, the Company may invest in issuers that are experiencing or have experienced financial or business difficulties (including difficulties resulting from the initiation or prospect of significant litigation or bankruptcy proceedings), which involves significant risks. The Company manages its exposure to market risk through the use of risk management strategies and various analytical monitoring techniques.

The Company's investments may, at any time, include securities and other financial instruments or obligations that are illiquid or thinly traded, making purchase or sale of such securities and financial instruments at desired prices or in desired quantities difficult. Furthermore, the sale of any such investments may be possible only at substantial discounts, and it may be extremely difficult to value any such investments accurately.

The Company's investments consist of growth stage companies, many of which have relatively limited operating histories and also may experience variation in operating results. Many of these companies conduct business in regulated industries and could be affected by the changes in government regulations. Most of the Company's borrowers will need additional capital to satisfy their continuing working capital needs and other requirements, and in many instances, to service the interest and principal payments on the debt.

Note 4. Fair Value of Financial Instruments

ASC 820 defines fair value, establishes a framework for measuring fair value, and establishes a fair value hierarchy based on the quality of inputs used to measure fair value and enhances disclosure requirements for fair value measurements. The Company accounts for its investments at fair value.

In accordance with ASC 820, the Company has categorized its investments based on the priority of the inputs to the valuation technique into a three-level fair value hierarchy. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical investments (Level 1) and the lowest priority to unobservable inputs (Level 3). See "Note 2 - Summary of Significant Accounting Policies."

As required by ASC 820, when the inputs used to measure fair value fall within different levels of the hierarchy, the level within which the fair value measurement is categorized is based on the lowest level input that is significant to the fair value measurement in its entirety. For example, a Level 3 fair value measurement may include inputs that are observable (Levels 1 and 2) and unobservable (Level 3). Therefore, unrealized appreciation and depreciation related to

such investments categorized within the Level 3 tables below may include changes in fair value that are attributable to both observable inputs (Levels 1 and 2) and unobservable inputs (Level 3).

As of March 31, 2021 and December 31, 2020, the Company's portfolio investments consisted primarily of investments in secured loans and equipment financings. All of the Company's portfolio investments were categorized as Level 3 as of March 31, 2021 and December 31, 2020.

The fair value determination of each portfolio investment categorized as Level 3 required one or more of the following unobservable inputs:

- Financial information obtained from each portfolio company, including unaudited statements of operations and balance sheets for the most recent period available as compared to budgeted numbers;
- Current and projected financial condition of the portfolio company;
- Current and projected ability of the portfolio company to service its debt obligations;
- Type and amount of collateral, if any, underlying the investment;
- Current financial ratios (e.g., fixed charge coverage ratio, interest coverage ratio and net debt/EBITDA ratio) applicable to the investment;
- Current liquidity of the investment and related financial ratios (e.g., current ratio and quick ratio);
- Pending debt or capital restructuring of the portfolio company;
- Projected operating results of the portfolio company;
- Current information regarding any offers to purchase the investment;
- Current ability of the portfolio company to raise any additional financing as needed;
- Changes in the economic environment, which may have a material impact on the operating results of the portfolio company;
- Internal occurrences that may have an impact (both positive and negative) on the operating performance of the portfolio company;
- Qualitative assessment of key management;
- Contractual rights, obligations or restrictions associated with the investment; and
- Time to exit.

The use of significant unobservable inputs creates uncertainty in the measurement of fair value as of the reporting date. The significant unobservable inputs used in the fair value measurement of the Company's investments, are (i) earnings before interest, tax, depreciation, and amortization ("EBITDA") and revenue multiples (both projected and historic), and (ii) volatility assumptions. Significant increases (decreases) in EBITDA and revenue multiple inputs in isolation would result in a significantly higher (lower) fair value measurement. Similarly, significant increases (decreases) in volatility inputs in isolation would result in a significantly higher (lower) fair value measurement. On the contrary, significant increases (decreases) in weighted average cost of capital inputs in isolation would result in a significantly lower (higher) fair value measurement. However, due to the nature of certain investments, fair value measurements may be based on other criteria, such as third-party appraisals of collateral and fair values as determined by independent third parties, which are not presented in the tables below.

Debt investments include both secured loans and equipment financing securities. The following table provides a summary of the significant unobservable inputs used to fair value the Level 3 portfolio investments as of March 31, 2021 (dollars in thousands):

Investment Type	Value as of Iarch 31, 2021	Valuation Techniques/ Unobservable Methodologies Inputs (1)		Range	Weighted Average ⁽²⁾
Debt investments	\$ 364,769	Discounted Cash Flows	Hypothetical Market Yield	9.4% - 34.4%	15.4 %
	75,558	Originated within the past three months	Origination Market Yield	12.2% - 24.5%	13.3 %
	21,941	Transactions Precedent ⁽⁶⁾	Transaction Price	n/a	n/a
	1,416	Liquidation Scenario	Probability Weighting of Alternative Outcomes	60.0% - 90.0%	n/a
Equity investments	7,451	Market Approach	Revenue Multiple ⁽³⁾	n/a	0.7 x
			Company Specific Adjustment (4)	n/a	(21.7)%
			Volatility ⁽⁵⁾	n/a	63.1 %
			Risk-Free Interest Rate	n/a	0.1 %
			Estimated Time to Exit (in years)	n/a	1.0
	7,236	Market Approach	Revenue Multiple Only (3)	0.3 - 2.1	0.6
	8,161	Transactions Precedent ⁽⁶⁾	Transaction Price	n/a	n/a
	26,771	Liquidation Scenario	Probability Weighting of Alternative Outcomes	20.0% - 80.0%	n/a
Warrants	18,193	Market Approach	Revenue Multiple ⁽³⁾	0.7x - 12.0x	4.3 x
			Company Specific Adjustment (4)	(33.7)% - (3.9)%	(13.8)%
			Volatility ⁽⁵⁾	30.3% - 126.0%	53.0 %
			Risk-Free Interest Rate	0.0% - 3.0%	0.8 %
			Estimated Time to Exit (in years)	0.3 - 5.2	3.0
	1,085	Black Scholes Option Pricing Model	Volatility (5)	81.6% - 132.3%	85.2 %
			Risk-Free Interest Rate	0.1% - 0.2%	0.1 %
			Estimated Time to Exit (in years)	n/a	2.0
	3,160	Transactions Precedent ⁽⁶⁾	Transaction Price	n/a	n/a
Total Level 3 Investments	\$ 535,741				

⁽¹⁾ The significant unobservable inputs used in the fair value measurement of the Company's debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The significant unobservable inputs used in the fair value measurement of the Company's equity and warrant securities are revenue multiples and portfolio company specific adjustment factors. Additional inputs used in the option pricing model ("OPM") include industry volatility, risk free interest rate and estimated time to exit. Significant increases (decreases) in the inputs in isolation would result in a significantly higher (lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date.

- ⁽²⁾ Weighted averages are calculated based on the fair market value of each investment.
- ⁽³⁾ Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments.
- (4) Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments.

(6) Represents investments where there is an observable transaction or pending event for the investment.

⁽⁵⁾ Represents the range of industry volatility used by market participants when pricing the investment.

Investment Type			Unobservable Inputs ⁽¹⁾	Range	Weighted Average ⁽²⁾	
Debt investments	\$	330,184	Discounted Cash Flows	Hypothetical Market Yield	9.5% - 31.2%	15.1 %
		99,053	Originated within the past three months	Origination Market Yield	12.9% - 15.2%	14.2 %
		11,771	Transactions Precedent ⁽⁶⁾	Transaction Price	n/a	n/a
		2,211	Liquidation Scenario	Probability Weighting of Alternative Outcomes	60.0% - 90.0%	n/a
Equity investments		3,623	Liquidation Scenario	Probability Weighting of Alternative Outcomes	30.0% - 70.0%	n/a
		5,550	Market Approach	Revenue Multiple Only ⁽³⁾	0.5 - 0.9	0.7
		23,481	Market Approach	Revenue Multiple ⁽³⁾	0.36x - 3.0x	1.8 x
				Company Specific Adjustment (4)	(17.5)% - 150.0%	74.9 %
				Volatility ⁽⁵⁾	45.0% - 80.0%	59.8 %
				Risk-Free Interest Rate	0.1% - 0.2%	0.1 %
				Estimated Time to Exit (in years)	0.5 - 2.0	1.1
Warrants		15,133	Market Approach	Revenue Multiple ⁽³⁾	0.3x - 20.75x	3.2 x
				Company Specific Adjustment (4)	(50.0)% - 10.0%	(13.1)%
				Volatility ⁽⁵⁾	20.0% - 104.7%	53.4 %
				Risk-Free Interest Rate	0.1% - 3.0%	0.9 %
				Estimated Time to Exit (in years)	0.2 - 10.0	3.3
		2,645	Black Scholes Option Pricing Model	Volatility ⁽⁵⁾	46.8% - 132.3%	52.0 %
				Risk-Free Interest Rate	0.1% - 0.7%	0.1 %
				Estimated Time to Exit (in years)	0.5 - 7.3	0.8
Total Level 3 Investments	\$	493,651				

The following table provides a summary of the significant unobservable inputs used to fair value the Level 3 portfolio investments as of December 31, 2020 (dollars in thousands):

- ⁽²⁾ Weighted averages are calculated based on the fair market value of each investment.
- ⁽³⁾ Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments.
- ⁽⁴⁾ Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments.
- ⁽⁵⁾ Represents the range of industry volatility used by market participants when pricing the investment.
- ⁽⁶⁾ Represents investments where there is an observable transaction or pending event for the investment.

⁽¹⁾ The significant unobservable inputs used in the fair value measurement of the Company's debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The significant unobservable inputs used in the fair value measurement of the Company's equity and warrant securities are revenue multiples and portfolio company specific adjustment factors. Additional inputs used in the option pricing model ("OPM") include industry volatility, risk free interest rate and estimated time to exit. Significant increases (decreases) in the inputs in isolation would result in a significantly higher (lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date.

The following table provides a summary of changes in the debt, including loans and equipment financings (collectively "Debt"), equity, and warrants fair value of the Company's Level 3 portfolio investments for the three months ended March 31, 2021 (in thousands):

	Type of Investment							
		Debt		Equity		Warrants		Total
Fair Value as of December 31, 2020	\$	443,219	\$	32,654	\$	17,778	\$	493,651
Purchases, net of deferred fees		75,657		10,000		1,037		86,694
Non-cash conversion		_		4,600		(4,600)		
Proceeds from sales and paydowns		(61,093)		(5,892)				(66,985)
Accretion of OID and EOT payments		4,593		-				4,593
Net realized gain/(loss)		(10)		2,942		(337)		2,595
Third party participation ⁽¹⁾		_		(283)		_		(283)
Change in unrealized appreciation/(depreciation)		1,318		5,598		8,560		15,476
Fair Value as of March 31, 2021	\$	463,684	\$	49,619	\$	22,438	\$	535,741
Net change in unrealized appreciation/depreciation on Level 3 investments still held as of March 31, 2021	\$	1,385	\$	6,294	\$	5,286	\$	12,965

(1) Certain third parties had rights to 17,485 shares of Ology Biosciences common stock at a fair value of approximately \$0.6 million as of December 31, 2020. During the three months ended March 31, 2021, these shares were reissued by Ology Biosciences directly to the third parties and the corresponding liability was removed from the Consolidated Statement of Assets and Liabilities. The activity related to these shares and the related liability is recorded against unrealized appreciation/(depreciation).

The following table provides a summary of changes in the debt, including loans and equipment financings (collectively "Debt"), equity, and warrants fair value of the Company's Level 3 portfolio investments for the year ended December 31, 2020 (in thousands):

	Type of Investment						
	Debt	Equity	Warrants	Total			
Fair Value as of January 1, 2020	\$ —	\$ —	\$ —	\$ —			
Formation Transactions acquisitions	375,858	24,066	17,099	417,023			
Purchases, net of deferred fees	234,418	2,170	1,976	238,564			
Non-cash conversion	(10,148)	10,879	532	1,263			
Proceeds from sales and paydowns	(157,046)	(3,855)	_	(160,901)			
Accretion of OID and EOT payments	11,788		_	11,788			
Net realized gain/(loss)	(7,361)	(300)	(1,742)	(9,403)			

Third party participation ⁽¹⁾	_		283	_	283
Change in unrealized appreciation/(depreciation)	(4,290)	_	(589)	 (87)	(4,966)
Fair Value as of December 31, 2020	\$ 443,219	\$	32,654	\$ 17,778	\$ 493,651
Net change in unrealized appreciation/depreciation on Level 3 investments still held as of December 31, 2020	\$ (4,290)	\$	(589)	\$ (87)	\$ (4,966)

(1) Certain third parties had rights to 17,485 shares of Ology Biosciences common stock at a fair value of approximately \$0.6 million as of December 31, 2020. The activity related to these shares and the related liability is recorded against unrealized appreciation/(depreciation).

During the three months ended March 31, 2021 and the year ended December 31, 2020, there were no transfers into or out of Level 3.

Fair Value of Financial Instruments Carried at Cost

As of March 31, 2021 and December 31, 2020, the carrying value of the Credit Facility is approximately \$43.4 million and \$132.9 million, net of unamortized deferred financing costs of \$1.6 million and \$2.1 million, respectively. The carrying value of the Company's Credit Facility as of March 31, 2021 and December 31, 2020 approximates the fair value, which was estimated using a market yield approach with Level 3 inputs.

As discussed in "Note 5 - Borrowings," the 2025 Notes have a fixed interest rate with a carrying value of approximately \$120.6 million and \$120.3 million net of unamortized deferred financing costs of \$4.4 million and \$4.7 million as of March 31, 2021 and December 31, 2020, respectively. The fair value of the 2025 Notes as of March 31, 2021 and December 31, 2020 was \$129.0 million and \$131.4 million, respectively, which was estimated using a relative market yield approach with Level 3 inputs.

As

of March 31, 2021 and December 31, 2020, the carrying value of the Convertible Notes is approximately \$47.1 million and \$46.6 million,

respectively, net of unamortized deferred financing costs and discount of \$2.9 million and \$3.4 million, respectively. The Convertible

Notes have a fixed interest rate as discussed in "Note 5 – Borrowings." The carrying value of the Company's Convertible Notes as of March 31, 2021 and December 31, 2020 approximates the fair value, based on the recent funding.

The fair value amounts have been measured as of the reporting date and have not been reevaluated or updated for purposes of these financial statements subsequent to that date. As such, the fair values of these financial instruments subsequent to the reporting date may be different than amounts reported.

Note 5. Borrowings

Credit Suisse Credit Facility

On January 9, 2020, TF1 and its affiliates borrowed \$190.0 million under the Credit Facility. On January 16, 2020, in connection with the Formation Transactions, through its wholly owned subsidiary, TF1, the Company became a party to, and assumed, the Credit Facility with Credit Suisse. During the year ended December 31, 2020, the Company borrowed an additional \$30.0 million and made repayments of \$85.0 million to Credit Suisse. During the three months ended March 31, 2021, the Company made repayments of \$90.0 million to Credit Suisse. During the year ended December 31, 2020, the Company incurred approximately \$4.0 million of financing costs in connection with the Credit Facility that are capitalized and deferred using the straight-line method over the life of the facility. As of March 31, 2021 and December 31, 2020, unamortized deferred financing costs related to the Credit Facility were \$1.6 million and \$2.1 million, respectively and presented as a direct deduction from the carrying amount of the debt liability on the Consolidated Statements of Assets and Liabilities.

The Credit Facility matures on January 8, 2022, unless extended. Borrowings under the Credit Facility bear interest at a rate of the three-month London Interbank Offered Rate ("LIBOR") plus 3.25%. The Credit Facility is collateralized by all investments held by TF1 and permits an advance rate of up to 65% of eligible investments. The Company has the ability to borrow up to an aggregate of \$300.0 million, and the Credit Facility borrowing base contains certain criteria for eligible investments and includes concentration limits as defined in the Credit Facility. As of March 31, 2021 and December 31, 2020, the Company had approximately \$45.0 million and \$135.0 million, respectively, in borrowings outstanding under the Credit Facility and a borrowing availability of approximately \$72.5 million and \$42.0 million, respectively.

The summary information regarding the Credit Facility is as follows (dollars in thousands):

	Mar	Three Mon ch 31, 2021	ths Ended March 31, 2020		
Stated interest expense	\$	677	\$	1,713	
Amortization of deferred financing costs		528		434	
Total interest and amortization of deferred financing costs	\$	1,205	\$	2,147	
Weighted average effective interest rate		6.2 %		4.6 %	
Weighted average outstanding balance	\$	78,000	\$	149,518	

The Credit Facility contains covenants that, among other things, require the Company to maintain minimum tangible net worth and leverage ratios, minimum cash balance of \$15.0 million, and a cash reserve of 60 days for interest.

2025 Notes

Concurrent with the completion of a private common stock offering, on January 16, 2020, the Company completed the "144A Note Offering" of \$105.0 million in aggregate principal amount of the unsecured 2025 Notes in reliance upon the available exemptions from the registration requirements of the Securities Act. KBW, as the initial purchaser, exercised in full its option to purchase or place additional Notes and on January 29, 2020 the Company issued and sold an additional \$20.0 million in aggregate principal amount of the 2025 Notes. As a result, the Company issued and sold a total of \$125.0 million in aggregate principal amount of the 2025 Notes pursuant to the 144A Note Offering.

The 2025 Notes were issued pursuant to an Indenture dated as of January 16, 2020 (the "Base Indenture"), between the Company and U.S. Bank National Association, as trustee (the "Trustee"), and a First Supplemental Indenture, dated as of January 16, 2020 (the "First Supplemental Indenture" and together with the Base Indenture, the "2025 Notes Indenture"), between the Company and the Trustee. The 2025 Notes mature on January 16, 2025 (the "Maturity Date"), unless repurchased or redeemed in accordance with their terms prior to such date. The 2025 Notes are redeemable, in whole or in part, at any time, or from time to time, at the Company's option, on or after January 16, 2023 at a redemption price equal to 100% of the outstanding principal amount thereof, plus accrued and unpaid interest to, but excluding, the date of redemption. The holders of the 2025 Notes do not have the option to have the notes repaid or repurchased by the Company prior to the Maturity Date.

The 2025 Notes bear interest at a fixed rate of 7.00% per year payable quarterly on March 15, June 15, September 15 and December 15 of each year, commencing on March 15, 2020. The 2025 Notes are direct, general unsecured obligations of the Company and rank pari passu, or equal in right of payment with all of the Company's existing and future unsecured indebtedness or other obligations that are not so subordinated.

Concurrent with the closing of the 144A Note Offering, on January 16, 2020, the Company entered into a registration rights agreement for the benefit of the purchasers of the 2025 Notes in the 144A Note Offering. Pursuant to the terms of this registration rights agreement, the Company filed with the SEC a registration statement, which was declared effective on October 20, 2020, registering the public resale of the 2025 Notes by the holders thereof that elected to include their 2025 Notes in such registration statement.

Aggregate offering costs in connection with the 2025 Notes issuance, including the underwriter's discount and commissions, were approximately \$5.8 million which were capitalized and deferred. As of March 31, 2021 and December 31, 2020, unamortized deferred financing costs related to the 2025 Notes were \$4.4 million and \$4.7 million, respectively.

The components of interest expense and related fees for the 2025 Notes are as follows (in thousands):

	Mare	Ended arch 31, 2020		
Stated interest expense	\$	2,188	\$	1,847
Amortization of deferred financing costs		291		232
Total interest and amortization of deferred financing costs	\$	2,479	\$	2,079
Weighted average effective interest rate		7.9 %	6	5.9 %

Convertible Notes

On December 11, 2020, the Company completed a private offering (the "Private Convertible Note Offering") of \$50 million in aggregate principal amount of its unsecured 6.00% Convertible Notes due 2025 (the "Convertible Notes") in reliance upon the available exemptions from the registration requirements of the Securities Act. KBW acted as the initial purchaser and placement agent in connection with the Private Convertible Note Offering pursuant to a purchase/placement agreement dated December 4, 2020 by and between the Company and KBW.

The Convertible Notes were issued pursuant to the Base Indenture and a Second Supplemental Indenture, dated as of December 11, 2020 (the "Second Supplemental Indenture" and together with the Base Indenture, the "Convertible Notes Indenture"), between the Company and the Trustee. Concurrent with the closing of the Convertible Note Offering, on December 11, 2020, the Company entered into a registration rights agreement for the benefit of the holders of the Convertible Notes and the shares of common stock issuable upon conversion thereof.

The Convertible Notes bear interest at a fixed rate of 6.00% per year, subject to additional interest upon certain events, payable semiannually in arrears on May 1 and November 1 of each year, beginning on May 1, 2021. If an investment grade rating is not maintained with respect to the Convertible Notes, additional interest of 0.75% per annum will accrue on the Convertible Notes until such time as the Convertible Notes have received an investment grade rating of "BBB-" (or its equivalent) or better. The rating remained unchanged as of March 31, 2021 and December 31, 2020. The Convertible Notes mature on December 11, 2025 (the "Convertible Notes Maturity Date"), unless earlier converted or repurchased in accordance with their terms.

Holders may convert their Convertible Notes, at their option, at any time on or prior to the close of business on the business day immediately preceding the Convertible Notes Maturity Date. The conversion rate is initially 66.6667 shares of the Company's common stock, per \$1,000 principal amount of the Convertible Notes (equivalent to an initial conversion price of approximately \$15.00 per share of common stock). The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events, further described in the Convertible Note Indenture, that occur prior to the Convertible Notes Maturity Date, the Company will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances. Upon conversion of the Convertible Notes, the Company will pay or deliver, as the case may be, cash, shares of common stock, or a combination of cash and shares of common stock, at the Company's election, per \$1,000 principal amount of the Convertible Notes, equal to the then existing conversion rate.

At the Company's option, it may cause holders to convert all or a portion of the then outstanding principal amount of the Convertible Notes plus accrued but unpaid interest, at any time on or prior to the close of business on the business day immediately preceding the Convertible Notes Maturity Date, if the closing sale price of the Company's common stock for any 30 consecutive trading days exceeds 120% of the conversion price, as may be adjusted. Upon such conversion, the Company will pay or deliver, as the case may be, cash, shares of common stock, or a combination of cash and shares of common stock, at the Company's election, per \$1,000 principal amount of the Convertible Notes, equal to the then existing conversion rate, and a forced conversion make-whole payment (as defined in the Second Supplemental Indenture), if any, in cash.

The Company may not redeem the Convertible Notes at its option prior to maturity. In addition, if the Company undergoes a fundamental change (as defined in the Second Supplemental Indenture), holders may require the Company

to repurchase for cash all or part of such holders' Convertible Notes at a repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

The Convertible Notes are direct unsecured obligations of the Company and rank pari passu, or equal, in right of payment with all of the Company's existing and future unsecured indebtedness or other obligations that are not so subordinated, including, without limitation, the 2025 Notes, and senior in right of payment to all of the Company's future indebtedness or other obligations that are expressly subordinated, or junior, in right of payment to the Convertible Notes.

Aggregate offering costs in connection with the Convertible Note Offering, including the initial purchaser and placement agent discount and commissions, were approximately \$1.6 million which were capitalized and deferred. As of March 31, 2021 and December 31, 2020, unamortized deferred financing costs related to the Convertible Notes were \$1.8 million and \$1.7 million, respectively.

The Convertible Notes are accounted for in accordance with ASC 470-20 *Debt Instruments with Conversion and Other Options*. In accounting for the Convertible Notes, the Company estimated at the time of issuance that the values of the debt and the embedded conversion feature of the Convertible Notes were approximately 99.1% and 0.9%, respectively. The original issue discount of 0.9%, or approximately \$0.5 million, attributable to the conversion feature of the Convertible Notes was recorded in "capital in excess of par value" in the Consolidated Statements of Assets and Liabilities. As a result, the Company records interest expense comprised of both stated interest expense as well as the original issue discount resulting in an estimated effective interest rate of approximately 7.2% annualized.

In January 2021, the Company early adopted ASU 2020-06, *Debt – Debt with Conversion and Other Options* ("ASU 2020-06"), under which the accounting for convertible instruments was simplified by removing the separate accounting for embedded conversion features. As such approximately \$0.5 million was reversed out of net assets and reduced the original issue discount for the Convertible Notes.

The components of the carrying value of the Convertible Notes were as follows (in thousands):

	Marcl	March 31, 2021		er 31, 2020
Principal amount of debt	\$	50,000	\$	50,000
Unamortized debt issuance cost		(1,760)		(1,672)
Original issue discount related to equity component, net of accretion		_		(468)
Original issue discount, net of accretion		(1,127)		(1,308)
Carrying value of Convertible Notes	\$	47,113	\$	46,552

The components of interest expense and related fees for the Convertible Notes were as follows (in thousands):

	March 3	Three Mor 1, 2021		ths Ended March 31, 2020	
Stated interest expense	\$	742	\$		
Amortization of deferred financing costs and original issue discount		156			
Total interest and amortization of deferred financing costs and original issue discount	\$	898	\$	_	
Weighted average effective interest rate		7.2 %	. <u></u>	— %	

As of March 31, 2020 and December 31, 2020, the Company was in compliance with the terms of the Credit Facility, the 2025 Notes Indenture, and the Convertible Notes Indenture.

Note 6. Commitments and Contingencies

Unfunded Commitments

The Company's commitments and contingencies consist primarily of unused commitments to extend credit in the form of loans or equipment financings to the Company's portfolio companies. A portion of these unfunded contractual commitments as of March 31, 2021 and December 31, 2020 are generally dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available. Furthermore, the Company's credit agreements contain customary lending provisions that allow the Company relief from funding obligations for previously made commitments in instances where the underlying portfolio company experiences materially adverse events that affect the financial condition or business outlook for the Company. Since a portion of these commitments may expire without being withdrawn, unfunded contractual commitments do not necessarily represent future cash requirements. As such, the Company's disclosure of unfunded contractual commitments as of March 31, 2021 and December 31, 2020 includes only those commitments which are available at the request of the portfolio company and are unencumbered by milestones or additional lending provisions.

As of March 31, 2021, the Company had an aggregate of approximately \$8.3 million of unfunded commitments to two portfolio companies, Dandelion, Inc. and Greenlight Biosciences, Inc. As of December 31, 2020, the Company had outstanding unfunded commitments of approximately \$0.1 million to one portfolio company, Dandelion, Inc. These unfunded commitments are available at the request of such portfolio companies and unencumbered by milestones. The fair value of these unfunded commitments is considered to approximate the cost of such commitments as the yields determined at the time of underwriting are expected to be materially consistent with the yields upon funding.

The Company will fund its unfunded commitments from the same sources it uses to fund its investment commitments that are funded at the time they are made (which are typically through existing cash and cash equivalents and borrowings under the Credit Facility).


In the normal course of business, the Company enters into contracts that provide a variety of representations and warranties, and general indemnifications. Such contracts include those with certain service providers, brokers and trading counterparties. Any exposure to the Company under these arrangements is unknown as it would involve future claims that may be made against the Company; however, based on the Company's experience, the risk of loss is remote and no such claims are expected to occur. As such, the Company has not accrued any liability in connection with such indemnifications.

Leases

FASB ASU 2016-02, *Leases (Topic 842)* ("ASU 2016-02") requires that a lessee evaluate its leases to determine whether they should be classified as operating or financing leases. The Company identified one significant operating lease for its office space. The lease commenced February 21, 2017 and expires July 31, 2022. The lease contains a five-year extension option for a final expiration date of July 31, 2027 which the company does not expect to exercise.

The total lease expense incurred related to this lease for the three months ended March 31, 2021 and 2020 was approximately \$0.1 million for each period. As of March 31, 2021 and December 31, 2020, the right of use asset related to the operating lease was \$0.3 million and \$0.4 million, respectively, and the lease liability was \$0.3 million and \$0.4 million, respectively. As of March 31, 2021, the remaining lease term was 1.25 years and the discount rate was 3.25%. The Company has also entered into a lease for new office space with an estimated commencement date in mid-2021 and a lease term of eight years. A right of use asset and corresponding lease liability will be recorded upon commencement of the lease. Future minimum payments under the term of the new lease have been included in the table below.

The following table shows future minimum payments under the Company's operating leases as of March 31, 2021 (in thousands):



Legal Proceedings

The Company may, from time to time, be involved in litigation arising out of its operations in the normal course of business or otherwise. Furthermore, third parties may try to seek to impose liability on the Company in connection with the activities of its portfolio companies. As of March 31, 2021, there are no material legal matters or material litigation pending of which the Company is aware.

Note 7. Stockholder's Equity

The Company authorized 200,000,000 shares of its common stock with a par value of \$0.001 per share. On September 27, 2019, the Company was initially capitalized with the issuance of 10 shares of its common stock for an aggregate purchase price of \$150 to its sole shareholder.

Private Common Stock Offerings

On January 16, 2020, the Company completed the Private Common Stock Offering. As a result, the Company issued and sold a total of 8,333,333 shares of its common stock for aggregate net proceeds of approximately \$114.4 million, net of offering costs of approximately \$10.6 million. Refer to "Note 1 – Organization and Basis of Presentation" for further details.

Concurrent with the closing of the Private Common Stock Offering, on January 16, 2020, the Company entered into a registration rights agreement for the benefit of the purchasers of shares of its common stock in such offering and the Legacy Investors that received shares of its common stock in connection with the Formation Transactions that were not the Company's directors, officers and affiliates. Pursuant to the terms of this registration rights agreement, the Company no longer has any registration obligations with respect to such shares because (i) such shares may be sold by any such stockholder in a single transaction without registration pursuant to Rule 144 under the Securities Act, (ii) the Company has been subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, for a period of at least 90 days and is current in the filing of all such required reports and (iii) such shares have been listed for trading on the Nasdaq Global Select Market.

Formation Transactions

On January 16, 2020, immediately following the initial closings of the Private Offerings, the Company used the proceeds from the Private Offerings to complete the Formation Transactions, pursuant to which the Company acquired the Legacy Funds and Trinity Capital Holdings. In consideration for the Legacy Funds, the Company issued 9,183,185 shares of common stock at \$15.00 per share for a total value of approximately \$137.7 million and paid approximately \$108.7 million in cash to the Legacy Investors. As consideration for all of the equity interests in Trinity Capital Holdings, the Company issued 533,332 shares of its common stock at \$15.00 per share for a total value of approximately \$8.0 million and paid approximately \$2.0 million in cash. Refer to "Note 1 – Organization and Basis of Presentation" for further details regarding the Formation Transactions.

Initial Public Offering

The Company's common stock began trading on the Nasdaq Global Select Market on January 29, 2021 under the symbol "TRIN." On February 2, 2021, the Company completed its initial public offering of 8,006,291 shares of common stock at a price of \$14.00 per share, inclusive of the underwriters' option to purchase additional shares, which was exercised in full. Proceeds from this offering were primarily used to pay down a portion of our existing indebtedness outstanding under the Credit Facility.

Long-Term Incentive Plan

The Board has approved the 2019 Trinity Capital Inc. Long-Term Incentive Plan and the Trinity Capital Inc. 2019 Non-Employee Director Restricted Stock Plan, each to be effective upon receipt of exemptive relief from the SEC and stockholder approval of such plans. The Company has applied for an exemptive order from the SEC to permit us to issue securities under such plans. If such exemptive relief and stockholder approval are obtained, the Compensation Committee may award such securities in such amounts and on such terms as the Compensation Committee determines and consistent with any exemptive order the SEC may issue and the terms of such plans, as applicable. The SEC is not obligated to grant an exemptive order to allow this practice and will do so only if it determines that such practice is consistent with stockholder interests and does not involve overreaching by management or the Board. The Company cannot provide any assurance that it will receive such exemptive relief from the SEC or such stockholder approval will be received.

Distribution Reinvestment Plan

The Company's amended and restated distribution reinvestment plan ("DRIP") provides for the reinvestment of distributions in the form of common stock on behalf of its stockholders, unless a stockholder has elected to receive distributions in cash. As a result, if the Company declares a cash distribution, its stockholders who have not "opted out" of the DRIP by the opt out date will have their cash distribution automatically reinvested into additional shares of the Company's common stock. The share requirements of the DRIP may be satisfied through the issuance of common shares or through open market purchases of common shares by the DRIP plan administrator. Newly issued shares will be valued based upon the final closing price of the Company's common stock on the valuation date determined for each distribution by the Board.

The Company's DRIP is administered by its transfer agent on behalf of the Company's record holders and participating brokerage firms. Brokerage firms and other financial intermediaries may decide not to participate in the Company's DRIP but may provide a similar distribution reinvestment plan for their clients. During the three months ended March 31, 2021, the Company issued 87,710 shares of common stock for a total of approximately \$1.1 million under the DRIP. During the three months ended March 31, 2020, no dividends were declared or paid to stockholders.

Distributions

During the three months ended March 31, 2021, the Company declared a distribution on March 23, 2021 of \$0.28 per share, which was paid on April 16, 2021 to stockholders of record as of March 31, 2021. No distributions were declared or paid during the three months ended March 31, 2020.



8. Earnings Per Share

In accordance with the provisions of ASC Topic 260 – Earnings per Share ("ASC 260"), basic earnings per share is computed by dividing net income available to common stockholders by the weighted-average number of common shares outstanding for the period. Other potentially dilutive common shares, and the related impact to earnings are considered when calculating earnings per share on a diluted basis. Potential common shares associated with the conversion option embedded in the Convertible Notes are anti-dilutive when the Company's average NAV per share / market price per share is below the conversion price. The following table sets forth the computation of the weighted average basic and diluted net increase (decrease) in net assets per share from operations for the three months ended March 31, 2021 and 2020 (in thousands except shares and per share information):

	n.	Three Months Ended March 31, 2021 March 31, 2		
		1arch 51, 2021	IVIO	101 51, 2020
Net increase/(decrease) in net assets resulting from operations	\$	25,324	\$	(35,051)
Weighted average common shares outstanding		23,554,950	1	7,821,790
Net increase/(decrease) in net assets resulting from operations per common share - basic				
and diluted	\$	1.08	\$	(1.97)

For the three months ended March 31, 2021, the effect of the Convertible Notes was anti-dilutive and, accordingly, was excluded from the calculation of diluted earnings per share.

Note 9. Income Taxes

When filing its 2020 tax return, the Company intends to elect to be treated for U.S. federal tax purposes as a RIC under Subchapter M of the Code and operate in a manner so as to qualify annually thereafter for the tax treatment applicable to RICs. As a RIC, the Company generally will not pay corporate-level income tax on the portion of its taxable income distributed to stockholders, generally required to be at least 90% of its investment company taxable income (which is generally its net ordinary taxable income and realized net short-term capital gains in excess of realized net long-term capital losses) and 90% of its tax-exempt income to maintain its RIC status (pass-through tax treatment for amounts distributed). The amount to be paid out as a distribution is determined by the Board each quarter and is based upon the annual earnings estimated by the management of the Company. To the extent the Company's distributions for the fiscal year may be deemed a return of capital for tax purposes to the Company's stockholders.

Because federal income tax regulations differ from accounting principles generally accepted in the United States, distributions in accordance with tax regulations may differ from net investment income and realized gains recognized for financial reporting purposes. Differences may be permanent or temporary in nature. Permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character. Temporary differences arise when certain items of income, expense, gain or loss are recognized at some time in the future. Also, recent tax legislation requires that income be recognized for tax purposes no later than when recognized for financial reporting purposes.

The following table sets forth the tax cost basis and the estimated aggregate gross unrealized appreciation and depreciation from investments for federal income tax purposes as of and for the period ended March 31, 2021 and December 31, 2020 (in thousands):

	March	31, 2021	Decemb	er 31, 2020
The Cost of Investments (1)	¢ ı	576.516	¢	EE0 427
Tax Cost of Investments ⁽¹⁾	Þ.	5/0,510	Ф	559,437

	March	31, 2021	Dec	cember 31, 2020
Unrealized appreciation	\$	35,687	\$	14,879
Unrealized depreciation		(25,177)		(19,845)
Net unrealized appreciation/(depreciation) from investments	\$	10,510	\$	(4,966)

(1) Includes cost of short-term investments, including cash and cash equivalents.

Note 10. Financial Highlights

The following presents financial highlights (in thousands except share and per share information):

	Three Mon March 31, 2021			ths Ended March 31, 2020		
Per Share Data: ⁽¹⁾						
Net asset value, beginning of period	\$	13.03	\$	14.97 (2)		
				(2)		
Net investment income		0.31		0.32 (3)		
Net realized and unrealized gains/(losses) on investments ⁽⁴⁾		0.77		(1.39)		
Costs related to acquisition of Trinity Capital Holdings and Legacy Funds				(0.87)		
Net increase/(decrease) in net assets resulting from operations		1.08		(1.94)		
Offering costs		(0.30)		(0.59)		
Effect of shares issued ⁽⁵⁾		0.18		_		
Equity component of convertible notes		(0.02)		_		
Distributions ⁽⁶⁾		(0.28)				
Total increase/(decrease) in net assets		0.66		(2.53)		
Net asset value, end of period	\$	13.69	\$	12.44		
Shares outstanding, end of period	2	26,415,275		18,049,860		
Weighted average shares outstanding	2	23,554,950		17,821,790 ⁽³⁾		
Total return based on net asset value ⁽⁷⁾ ⁽⁸⁾		7.2 9	%	(16.9)% ⁽⁹⁾		
Total return based on market value ⁽¹⁰⁾		6.6 %	%	na		
Ratio/Supplemental Data:						
Per share market value at end of period	\$	14.92		n/a		
	¢		¢			
Net assets, end of period*	\$	361,563	\$	224,563		
Ratio of total expenses to average net assets ⁽¹¹⁾		13.6 9	%	14.0 %		
Ratio of net investment income to average net assets ⁽¹¹⁾		9.8 9	%	12.2 %		
Ratio of interest and credit facility expenses to average net assets ⁽¹¹⁾ Portfolio turnover rate ⁽⁸⁾ ⁽¹²⁾		6.2 9		9.1 %		
			%	%		

	13.0	9.4
Asset coverage ratio ⁽¹³⁾	264.3 %	188.8 %
*		

Rounded to the nearest thousand.

- ⁽¹⁾ Based on actual number of shares outstanding at the end of the corresponding period or the weighted average shares outstanding for the period, unless otherwise noted, as appropriate.
- (2) The net asset value as of January 16, 2020 (commencement of operations) is calculated based on the initial common stock purchase price of \$15.00 per share less the accumulated loss of \$0.03 per share from August 12, 2019 (the date of inception) through December 31, 2019.

- ⁽³⁾ Calculated based upon weighted average shares outstanding for the period from January 16, 2020 (commencement of operations) through March 31, 2020.
- ⁽⁴⁾ Net realized and unrealized gains/(losses) on investments include rounding adjustments to reconcile the change in net asset value per share.
- (5) Includes the impact of the different share amounts as a result of calculating certain per share data based on the weighted-average basic shares outstanding during the period and certain per share data based on the shares outstanding as of a period end or transaction date.
- ⁽⁶⁾ The per share data reflects the actual amount of distributions declared per share for the applicable period.
- (7) Total return based on net asset value is calculated as the change in net asset value per share during the period plus declared distributions per share during the period, divided by the beginning net asset value per share.
- (8) Not annualized.
- (9) Total return excluding costs related to acquisition of Trinity Capital Holdings and the Legacy Funds would have been (11.1)%.
- (10) Total return based on market value is calculated as the change in market value per share during the period, taking into account dividends, if any, reinvested in accordance with the Company's DRIP. The beginning market value per share is based on the market price of \$14.00 per share on January 29, 2021, the date of the Company's listing on Nasdaq, and not annualized.
- ⁽¹¹⁾ Annualized.
- (12) Portfolio turnover rate is calculated using the lesser of year-to-date cash sales/repayments or year-to-date cash purchases over the average of the total investments at fair value.
- ⁽¹³⁾ Based on outstanding debt of \$220.0 million and \$255.4 million as of March 31, 2021 and 2020, respectively.

Senior Securities

Information about the Company's senior securities (including debt securities and other indebtedness) is shown in the following table as of March 31, 2021 and December 31, 2020. No senior securities were outstanding as of December 31, 2019.

Class and Period	O Ez	Total Amount utstanding cclusive of Treasury ecurities ⁽¹⁾	Asset Coverage per Unit ⁽²⁾	Involuntary Liquidating Preference per Unit ⁽³⁾	Average Market Value per Unit ⁽⁴⁾
Credit Facility				<u></u>	
March 31, 2021	\$	45,000	2,643	_	na
December 31, 2020	Ψ			_	
December 31, 2019		135,000	1,770	-	na
December 51, 2019		-	-	-	na
2025 Notes					
March 31, 2021	\$	125,000	2,643	-	na
December 31, 2020		125,000	1,770	_	na
December 31, 2019		-	-	-	na
Convertible Notes					
March 31, 2021					
	\$	50,000	2,643	-	na
December 31, 2020		50,000			22
December 31, 2019		50,000	1,770	-	na
		-	-	-	na
Total					
March 31, 2021	¢	220,000	D C 4D		
December 31, 2020	\$	220,000	2,643	-	na
		310,000	1,770	-	na
December 31, 2019		-	-	-	na

⁽¹⁾ Total amount of each class of senior securities outstanding at the end of the period presented.

(2) Asset coverage per unit is the ratio of the carrying value of total assets, less all liabilities excluding indebtedness represented by senior securities in this table to the aggregate amount of senior securities representing indebtedness. Asset coverage per unit is expressed in terms of dollar amounts per \$1,000 of indebtedness and is calculated on a consolidated basis.

(3) The amount to which such class of senior security would be entitled upon the Company's involuntary liquidation in preference to any security junior to it. The "-" in this column indicates information that the SEC expressly does not require to be disclosed for certain types of senior securities.

⁽⁴⁾ Not applicable because the senior securities are not registered for public trading.

Note 11. Related Party Transactions

Through the Formation Transactions, the Company acquired 100% of the equity interests of Trinity Capital Holdings and the Legacy Funds were merged with and into the Company. Members of the Company's management, including Steven L. Brown, Kyle Brown, Gerald Harder and Ron Kundich, owned 100% of the equity interests in Trinity Capital Holdings and controlling interests in the general partners/managers of the Legacy Funds.

As a result of the Formation Transactions, Messrs. S. Brown, K. Brown, Harder and Kundich collectively received (i) 533,332 shares of the Company's common stock valued at approximately \$8.0 million and approximately \$2.0 million in cash in exchange for their equity interests in Trinity Capital Holdings, and (ii) 377,441 shares of the Company's common stock valued at approximately \$5.7 million for their limited partner and general partner interests in the Legacy Funds.

During the three months ended March 31, 2021 and the year ended December 31, 2020, certain related parties received distributions from the Company relating to their shares held. Refer to "Note 7 – Stockholder's Equity" for further details on the Company's Distribution Reinvestment Plan and the distributions declared. Additionally, during the Company's IPO certain related parties purchased additional shares of the Company's common stock. These acquisitions were made at the IPO price of \$14.00 per share.

The Company has entered into indemnification agreements with its directors and executive officers. The indemnification agreements are intended to provide the Company's directors and executive officers the maximum indemnification permitted under Maryland law and the 1940 Act. Each indemnification agreement provides that the Company shall indemnify the director or executive officer who is a party to the agreement, or an "Indemnitee," including the advancement of legal expenses, if, by reason of his or her corporate status, the Indemnitee is, or is threatened to be, made a party to or a witness in any threatened, pending, or completed proceeding, to the maximum extent permitted by Maryland law and the 1940 Act.

Note 12. Recent Accounting Pronouncements

In March 2020, the FASB issued ASU 2020-04, "*Reference rate reform (Topic 848) - Facilitation of the effects of reference rate reform on financial reporting.*" The amendments in this update provide optional expedients and exceptions for applying U.S. GAAP to certain contracts and hedging relationships that reference LIBOR or another reference rate expected to be discontinued due to reference rate reform and became effective upon issuance for all entities. ASU 2020-04 is elective and is effective on March 12, 2020 through December 31, 2022. The Company does not plan on adopting, as it expects that the adoption of this guidance will not have a material impact on its consolidated financial statements.

In August 2020, the FASB issued ASU 2020-06, *Debt – Debt with Conversion and Other Options* ("ASU 2020-06") under which the accounting for convertible instruments will be simplified by removing major separation models required under current GAAP. Accordingly, more convertible instruments will be reported as a single liability or equity with no separate accounting for embedded conversion features. Certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception will be removed and, as a result, more equity contracts will qualify for the scope exception. ASU 2020-06 will also simplify the diluted earnings-per-share calculation in certain areas. ASU 2020-06 will be effective for years beginning after December 31, 2021, including interim periods within those fiscal years. Early adoption will be permitted for fiscal periods beginning after December 15, 2020 (including interim periods within the same fiscal year). The Company early adopted ASU 2020-06 on January 1, 2021, with no material impact to the consolidated financial statements other than no longer separately accounting for the embedded conversion feature.

Rule 2a-5 under the 1940 Act was recently adopted by the SEC and establishes requirements for determining fair value in good faith for purposes of the 1940 Act. The Company is evaluating the impact of adopting Rule 2a-5 and intends to comply with the new rule's requirements on or before the compliance date in September 2022.

Note 13. Subsequent Events

The Company's management evaluated subsequent events through the date of issuance of the consolidated financial statements included herein. There have been no subsequent events that occurred during such period that would require recognition or disclosure.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Except where the context suggests otherwise, the terms "we," "us," "our," and "the Company" refer to Trinity Capital Inc. and its consolidated subsidiaries. The information contained in this section should be read in conjunction with our consolidated financial statements and related notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q.

Forward-Looking Statements

This quarterly report contains forward-looking statements that involve substantial risks and uncertainties. Such statements involve known and unknown risks, uncertainties and other factors and undue reliance should not be placed thereon. Any statements about our expectations, beliefs, plans, predictions, forecasts, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but not always, made through the use of words or phrases such as "anticipate," "believes," "can," "could," "may," "predicts," "potential," "should," "will," "estimate," "plans," "projects," "continuing," "ongoing," "expects," "intends" and similar words or phrases. Accordingly, these statements are only predictions and involve estimates, known and unknown risks, assumptions and uncertainties that could cause actual results to differ materially from those expressed in them. Our actual results could differ materially from those anticipated in such forward-looking statements as a result of several factors discussed under Item 1A. "Risk Factors" of Part II of this quarterly report and Item 1A. "Risk Factors" of Part I of our Annual Report on Form 10-K, filed with the SEC on March 4, 2021, including the following factors, among others:

- our limited operating history as a business development company ("BDC");
- our future operating results, including the impact of the SARS-CoV-2 ("COVID-19") pandemic;
- our dependence upon our management team and key investment professionals;
- our ability to manage our business and future growth;
- risks related to investments in growth stage companies, other venture capital-backed companies and generally U.S. companies;
- the ability of our portfolio companies to achieve their objectives, including as a result of the COVID-19 pandemic;
- the use of leverage;
- risks related to the uncertainty of the value of our portfolio investments;
- changes in political, economic or industry conditions, the interest rate environment or conditions affecting the financial and capital markets, including as a result of the COVID-19 pandemic;
- uncertainty surrounding the financial and/or political stability of the United States, the United Kingdom, the European Union and China, including as a result of the COVID-19 pandemic;
- the dependence of our future success on the general economy and its impact on the industries in which we invest;
- risks related to changes in interest rates, our expenses, and other general economic conditions and the effect on our net investment income;
- the effect of changes in tax laws and regulations and interpretations thereof;

- the impact on our business of new or amended legislation or regulations, including the Coronavirus Aid, Relief and Economic Security Act, the stimulus package passed by Congress and signed into law in December 2020 and the American Rescue Plan Act of 2021 signed into law in March 2021;
- risks related to market volatility, including general price and volume fluctuations in stock markets;
- our ability to make distributions, including as a result of the COVID-19 pandemic; and
- our ability to maintain our status as a BDC under the Investment Company Act of 1940, as amended (the "1940 Act"), and qualify annually for tax treatment as a regulated investment company ("RIC") under Subchapter M of the Internal Revenue Code of 1986, as amended (the "Code").

Additionally, there may be other risks that are otherwise described from time to time in the reports that we file with the Securities and Exchange Commission. Any forward-looking statements in this report should be considered in light of various important factors, including the risks and uncertainties listed above, as well as others. All forward-looking statements are necessarily only estimates of future results, and there can be no assurance that actual results will not differ materially from expectations, and, therefore, you are cautioned not to place undue reliance on such statements. Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed throughout this quarterly report. Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. Because we are an investment company, the forward-looking statements and projections contained in this quarterly report are excluded from the safe harbor protections provided by Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995).

Overview

We are a specialty lending company providing debt, including loans and equipment financings, to growth stage companies, including venture-backed companies and companies with institutional equity investors. We are an internally managed, closed-end, non-diversified management investment company that has elected to be regulated as BDC under the 1940 Act. We also intend to elect to be treated, and intend to qualify annually thereafter, as a RIC under Subchapter M of the Code for U.S. federal income tax purposes. As a BDC and a RIC, we are required to comply with certain regulatory requirements.

Our investment objective is to generate current income and, to a lesser extent, capital appreciation through our investments. We seek to achieve our investment objective by making investments consisting primarily of term loans and equipment financings and, to a lesser extent, working capital loans, equity and equity-related investments. In addition, we may obtain warrants or contingent exit fees at funding from many of our portfolio companies, providing an additional potential source of investment returns. We generally are required to invest at least 70% of our total assets in qualifying assets in accordance with the 1940 Act but may invest up to 30% of our total assets in non-qualifying assets, as permitted by the 1940 Act.

We target investments in growth stage companies, which are typically private companies, including venture-backed companies and companies with institutional equity investors. We define "growth stage companies" as companies that have significant ownership and active participation by sponsors, such as institutional investors or private equity firms, and expected annual revenues of up to \$100.0 million. Subject to the requirements of the 1940 Act, we are not limited to investing in any particular industry or geographic area and seek to invest in under-financed segments of the private credit markets.

Our loans and equipment financings may have initial interest-only periods of up to 24 months and generally fully amortize over a total term of up to 60 months. These investments are typically secured by a blanket first position lien, a specific asset lien on mission critical assets and/or a blanket second position lien. We may also make a limited number of direct equity and equity-related investments in conjunction with our debt investments. We target growth stage companies that have recently issued equity to raise cash to offset potential cash flow needs related to projected growth, have

achieved positive cash flow to cover debt service, or have institutional investors committed to providing additional funding. A loan or equipment financing may be structured to tie the amortization of the loan or equipment financing to the portfolio company's projected cash balances while cash is still available for operations. As such, the loan or equipment financing may have a reduced risk of default. We believe that the amortizing nature of our investments will mitigate risk and significantly reduce the risk of our investments over a relatively short period. We focus on protecting and recovering principal in each investment and structure our investments to provide downside protection.

Our History

Trinity Capital Inc. was incorporated under the general corporation laws of the State of Maryland on August 12, 2019 and commenced operations on January 16, 2020. Prior to January 16, 2020, we had no operations, except for matters relating to our formation and organization as a BDC.

On January 16, 2020, through a series of transactions (the "Formation Transactions"), we acquired Trinity Capital Investment, LLC ("TCI, LLC"), Trinity Capital Fund II, L.P. ("Fund II"), Trinity Capital Fund III, L.P. ("Fund III"), Trinity Capital Fund IV, L.P. ("Fund IV") and Trinity Sidecar Income Fund, L.P. ("Sidecar Fund," and collectively, the "Legacy Funds") and all of their respective assets (the "Legacy Assets"), including their respective investment portfolios (the "Legacy Portfolio"), as well as Trinity Capital Holdings, LLC ("Trinity Capital Holdings"), a holding company whose subsidiaries managed and/or had the right to receive fees from certain of the Legacy Funds. In order to complete these transactions we used a portion of the proceeds from our private equity offering and private debt offering that occurred on January 16, 2020 (refer to "Item 8. Consolidated Financial Statements and Supplementary Data - Note 1. Organization and Basis of Presentation" for further discussion of these transactions).

The Legacy Funds were merged with and into the Company, and we issued 9,183,185 shares of our common stock for an aggregate amount of approximately \$137.7 million and paid approximately \$108.7 million in cash to the Legacy Funds' investors, which included the general partners/managers of the Legacy Funds (the "Legacy Investors"), to acquire the Legacy Funds and all of their respective assets, including the Legacy Portfolio. Our senior management team, led by Steven L. Brown, comprises the majority of the senior management team that managed the Legacy Funds and sourced the Legacy Portfolio.

As part of the Formation Transactions, we also acquired 100% of the equity interests of Trinity Capital Holdings for an aggregate purchase price of \$10.0 million, which was comprised of 533,332 shares of our common stock, totaling approximately \$8.0 million, and approximately \$2.0 million in cash. In connection with the acquisition of such equity interests, the Company also assumed a \$3.5 million severance related liability with respect to a former member of certain general partners of certain Legacy Funds. In connection with the acquisition of Trinity Capital Holdings, approximately \$13.5 million (consisting of the aggregate purchase price and severance related liability assumed) was expensed to Costs related to the acquisition of Trinity Capital Holdings and Legacy Funds in the Consolidated Statements of Operations. As a result of the Formation Transactions, Trinity Capital Holdings became a wholly owned subsidiary of the Company.

On February 2, 2021, we completed our initial public offering of 8,006,291 shares of our common stock at a price of \$14.00 per share, inclusive of the underwriters' option to purchase additional shares, which was exercised in full. Our common stock began trading on the Nasdaq Global Select Market on January 29, 2021 under the symbol "TRIN." Proceeds from this offering were primarily used to pay down a portion of our existing indebtedness outstanding under the Credit Facility.

Critical Accounting Policies

The Company's financial statements are prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and pursuant to Regulation S-X under the Securities Act of 1933, as amended (the "Securities Act"). The Company follows accounting and reporting guidance as determined by the Financial Accounting Standards Board ("FASB"), in FASB Accounting Standards Codification ("ASC") 946, *Financial Services — Investment Companies*.

The preparation of our financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Changes in the economic environment, financial markets and any other parameters used in determining such estimates could cause actual results to differ materially. Valuation of investments, income recognition, realized / unrealized gains or losses and U.S. federal income taxes are considered to be our critical accounting policies and estimates. –For additional information, please refer to "Note 2 - Summary of Significant Accounting Policies" in the notes to the consolidated financial statements included with this Quarterly Report on Form 10-Q.

Reclassification

Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. Included in interest income for the three months ended March 31, 2020 is the acceleration of OID and EOT of approximately \$0.4 million, which was reclassified from net realized gain/(loss) on investments. Included in one-time fee income for the three months ended March 31, 2020 is non-recurring fees of approximately \$1.4 million for the three months then ended of which \$0.9 million were reclassified from net realized gain/(loss) on investment and \$0.5 million were reclassified from interest income. These reclassifications had no effect on the previously reported net increase (decrease) in net assets.

Valuation of Investments

The most significant estimate inherent in the preparation of the Company's consolidated financial statements is the valuation of investments and the related amounts of unrealized appreciation and depreciation of investments recorded. The Company's investments are carried at fair value in accordance with the 1940 Act and ASC 946 and measured in accordance with ASC 820, *Fair Value Measurements and Disclosures* ("ASC 820"). ASC 820 defines fair value, establishes a framework for measuring fair value, establishes a fair value hierarchy based on the observability of inputs used to measure fair value, and provides disclosure requirements for fair value measurements. ASC 820 requires the Company to assume that each of the portfolio investments is sold in a hypothetical transaction in the principal or, as applicable, most advantageous market using market participant assumptions as of the measurement date. Market participants are defined as buyers and sellers in the principal market that are independent, knowledgeable and willing and able to transact. The Company values its investments at fair value as determined in good faith by the Company's Board of Directors (the "Board") in accordance with the provisions of ASC 820 and the 1940 Act.

While the Board is ultimately and solely responsible for determining the fair value of the Company's investments, the Company has engaged independent valuation firms to provide the Company with valuation assistance with respect to its investments. The Company engages independent valuation firms on a discretionary basis. Specifically, on a quarterly basis, the Company will identify portfolio investments with respect to which an independent valuation firm will assist in valuing certain investments. The Company selects these portfolio investments based on a number of factors, including, but not limited to, the potential for material fluctuations in valuation results, size, credit quality and the time lapse since the last valuation of the portfolio investment by an independent valuation firm.

Investments recorded on our Consolidated Statements of Assets and Liabilities are categorized based on the inputs to the valuation techniques as follows:

- Level 1 Investments whose values are based on unadjusted quoted prices for identical assets in an active market that the Company has the ability to access (examples include investments in active exchange-traded equity securities and investments in most U.S. government and agency securities).
- Level 2 Investments whose values are based on quoted prices in markets that are not active or model inputs that are observable either directly or indirectly for substantially the full term of the investment.
- Level 3 Investments whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement (for example, investments in illiquid securities issued by privately held companies). These inputs reflect management's own assumptions about the assumptions a market participant would use in pricing the investment.

Given the nature of lending to venture capital-backed growth stage companies, substantially all of the Company's investments in these portfolio companies are considered Level 3 assets under ASC 820 because there is no known or accessible market or market indexes for these investment securities to be traded or exchanged. The Company uses an internally developed portfolio investment rating system in connection with its investment oversight, portfolio management and analysis and investment valuation procedures. This system takes into account both quantitative and qualitative factors of the portfolio companies. Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company's investments may fluctuate from period to period. Because of the inherent uncertainty of valuation, these estimated values may differ significantly from the values that would have been reported had a ready market for the investments existed, and it is reasonably possible that the difference could be material.

Fair value estimates are made at discrete points in time based on relevant information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. The carrying amounts of the Company's financial instruments, consisting of cash, investments, receivables, payables and other liabilities approximate the fair values of such items due to the short-term nature of these instruments.

Income Recognition

Interest Income

The Company recognizes interest income on an accrual basis and recognizes it as earned in accordance with the contractual terms of the loan agreement to the extent that such amounts are expected to be collected. Original issue discount ("OID") initially includes the estimated fair value of detachable warrants obtained in conjunction with the origination of debt securities, and is accreted into interest income over the term of the loan as a yield enhancement based on the effective yield method. In addition, the Company may also be entitled to an end-of-term ("EOT") fee. Debt EOT fees to be paid at the termination of the financing arrangements are accreted into interest income over the contractual life of the debt based on the effective yield method. As of March 31, 2021 and December 31, 2020, the Company had an EOT payment receivable of approximately \$36.1 million and \$37.9 million, respectively, which is included as a component of the cost basis of the Company's current debt securities.

Income related to application or origination payments, net of related expenses, and generally collected in advance, includes loan commitment and facility fees for due diligence, as well as fees for transaction services rendered by the Company to borrowers. Loan and commitment fees in excess of the related expenses are amortized into interest income over the contractual life of the loan. In certain loan arrangements, warrants or other equity interests are received from the borrower as additional origination fees. The Company recognizes nonrecurring fees over the remaining term of the loan commencing in the quarter relating to specific loan modifications.

When a portfolio company pays off their outstanding indebtedness prior to the scheduled maturity date, then the acceleration of the accretion of the OID and EOT is recognized as interest income.

Fee Income

The

Company recognizes one-time fee income, including, but not limited to, structuring fees, prepayment penalties, and exit fees related to

a change in ownership of the portfolio company, as other income when earned. These fees are generally earned when the portfolio company

enters into an equipment financing arrangement or pays off their outstanding indebtedness prior to the scheduled maturity.

Portfolio Composition and Investment Activity

Portfolio Composition

Through the Formation Transactions, we acquired the Legacy Assets, including the Legacy Portfolio, from the Legacy Funds, as well as Trinity Capital Holdings. The Legacy Portfolio became our investment portfolio. As of March

31, 2021, our investment portfolio had an aggregate fair value of approximately \$535.7 million and was comprised of approximately \$335.7 million in secured loans, \$128.0 million in equipment financings, and \$72.0 million in equity and equity-related investments, including warrants, across 80 portfolio companies. As of December 31, 2020, our investment portfolio had an aggregate fair value of approximately \$493.7 million and was comprised of approximately \$320.7 million in secured loans, \$122.5 million in equipment financings, and \$50.5 million in equity and equity-related investments, including warrants, across 80 portfolio secured loans, \$122.5 million in equipment financings, and \$50.5 million in equity and equity-related investments, including warrants, across 80 portfolio secured loans, \$122.5 million in equipment financings, and \$50.5 million in equity and equity-related investments, including warrants, across 80 portfolio secured loans, \$122.5 million in equipment financings, and \$50.5 million in equity and equity-related investments, including warrants, across 80 portfolio secured loans, \$122.5 million in equipment financings, and \$50.5 million in equity and equity-related investments, including warrants, across 80 portfolio secured loans, \$122.5 million in equipment financings, and \$50.5 million in equity and equity-related investments, including warrants, across 80 portfolio secured loans, \$120.5 million in equipment financings, and \$50.5 million in equity and equity-related investments, including warrants, across 80 portfolio secured loans, \$100.5 million in equipment financings, and \$50.5 million in equity and equity-related investments, including warrants, across 80 portfolio secured loans, \$100.5 million in equipment financings, and \$50.5 millio

A summary of the composition of our investment portfolio at cost and fair value as a percentage of total investments are shown in following table as of March 31, 2021 and December 31, 2020:

	March 3	March 31, 2021		31, 2020
Туре	Cost	Fair Value	Cost	Fair Value
Secured Loans	64.5%	62.6%	65.1%	65.0%
Equipment Financings	24.3%	23.9%	24.7%	24.8%
Equity	8.5%	9.3%	6.6%	6.6%
Warrants	2.7%	4.2%	3.6%	3.6%
Total	100.0%	100.0%	100.0%	100.0%

The following table shows the composition of our investment portfolio by geographic region at cost and fair value as a percentage of total investments as of March 31, 2021 and December 31, 2020. The geographic composition is determined by the location of the corporate headquarters of the portfolio company.

	March 31, 2021		December	er 31, 2020	
Geographic Region	Cost	Fair Value	Cost	Fair Value	
United States					
West	46.2%	49.3%	49.6%	48.8%	
Northeast	29.5%	26.7%	26.4%	25.9%	
Midwest	9.8%	8.7%	9.5%	8.9%	
Mountain	7.6%	7.8%	6.8%	6.9%	
Southeast	2.0%	2.3%	2.2%	3.6%	
South	0.1%	0.3%	0.1%	0.4%	
Canada	4.8%	4.9%	5.4%	5.5%	
Total	100.0%	100.0%	100.0%	100.0%	

	March 31, 2021		December 31, 2020	
Industry	Cost	Fair Value	Cost	Fair Value
Manufacturing	23.3%	26.5%	20.8%	20.2%
Retail Trade	18.4%	16.2%	15.7%	15.4%
Professional, Scientific, and Technical Services	12.3%	12.7%	15.6%	16.0%
Finance and Insurance	7.0%	7.0%	7.0%	7.2%
Information	6.5%	6.4%	6.4%	6.2%
Rental and Leasing Services	6.3%	6.3%	5.8%	5.9%
Utilities	4.9%	4.8%	5.4%	5.5%
Real Estate	4.1%	4.0%	3.5%	3.5%
Agriculture, Forestry, Fishing and Hunting	3.7%	3.7%	4.2%	4.2%
Pharmaceutical	3.1%	3.2%	3.5%	4.9%
Educational Services	2.6%	2.6%	1.9%	2.0%
Wholesale Trade	2.5%	2.4%	4.8%	4.8%
Health Care and Social Assistance	2.8%	2.2%	2.9%	2.3%
Construction	2.1%	1.6%	2.0%	1.4%
Administrative and Support and Waste Management				
and Remediation Services	0.4%	0.4%	0.5%	0.5%
Total	100.0%	100.0%	100.0%	100.0%

Set forth below is a table showing the industry composition of our investment portfolio at cost and fair value as a percentage of total investments as of March 31, 2021 and December 31, 2020:

As of March 31, 2021 and December 31, 2020, the debt, including loans and equipment financings, in our portfolio had a weighted average time to maturity of approximately 3.0 years. Additional information regarding our portfolio is set forth in the schedule of investments and the related notes thereto included with this Quarterly Report on Form 10-Q.

Concentrations of Credit Risk

Credit risk is the risk of default or non-performance by portfolio companies, equivalent to the investment's carrying amount. The top three industries of the Company's portfolio companies as of December 31, 2020, are in the "Manufacturing," "Professional, Scientific, and Technical Services" and "Retail Trade" sectors. Industry and sector concentrations will vary from period to period based on portfolio activity.

As of March 31, 2021 and December 31, 2020, the Company's ten largest portfolio companies represented approximately 40.9% and 42.5%, respectively, of the total fair value of the Company's investments in portfolio companies. As of March 31, 2021 and December 31, 2020, the Company had 9 and 14 portfolio companies that represented 5% or more of the Company's net assets, respectively.

Investment Activity

During the three months ended March 31, 2021, we made an aggregate of approximately \$44.5 million of investments in 6 new portfolio companies and approximately \$42.6 million of investments in 13 existing portfolio companies, excluding fees. During the three months ended March 31, 2021, we received an aggregate of \$67.0 million in proceeds from repayments of our investments, including proceeds of approximately \$40.8 million from early repayments.

During the year ended December 31, 2020, in addition to \$417.0 million in investments we acquired in connection with the Formation Transactions, we made an aggregate of approximately \$144.3 million of investments in 18 new portfolio companies and approximately \$95.7 million of investments in 18 existing portfolio companies. During the year ended December 31, 2020, we received an aggregate of \$160.9 million in proceeds from repayments of our investments including proceeds of approximately \$108.8 million from early repayments.

The following table provides a summary of the changes in the investment portfolio for the three months ended March 31, 2021 and the year ended December 31, 2020 (in thousands):

	ree Months Ended rch 31, 2021	Year Ended December 31, 2020	
Beginning Portfolio	\$ 493,651	\$	
Formation Transactions acquisitions	_		417,023
Purchases, net of deferred fees	86,694		238,564
Non-cash conversion	_		1,263
Proceeds from Paydowns and Sales	(26,157)		(52,111)
Proceeds from early debt repayments	(40,828)		(108,790)
Accretion of OID and EOT payments	4,593		11,788
Net realized gain/(loss)	2,595		(9,403)
Third party participation ⁽¹⁾	(283)		283
	(200)		200
Change in unrealized appreciation/(depreciation)	 15,476		(4,966)
Ending Portfolio	\$ 535,741	\$	493,651

(1) Certain third parties had rights to 17,485 shares of Ology Biosciences common stock at a fair value of approximately \$0.6 million as of December 31, 2020. During the three months ended March 31, 2021, these shares were reissued by Ology Biosciences directly to the third parties and the corresponding liability was removed from the Consolidated Statement of Assets and Liabilities. The activity related to these shares and the related liability is recorded against unrealized appreciation/(depreciation).

The level of our investment activity can vary substantially from period to period depending on many factors, including the amount of debt, including loans and equipment financings, and equity capital required by growth stage companies, the general economic environment and market conditions and the competitive environment for the types of investments we make.

Portfolio Asset Quality

Our portfolio management team uses an ongoing investment risk rating system to characterize and monitor our outstanding loans and equipment financings. Our portfolio management team monitors and, when appropriate, recommends changes to the investment risk ratings. Our Investment Committee reviews the recommendations and/or changes to the investment risk ratings, which are submitted on a quarterly basis to the Board and its Audit Committee.

For our investment risk rating system, we review seven different criteria and, based on our review of such criteria, we assign a risk rating on a scale of 1 to 5, as set forth in the following illustration.

INVESTMENT RISK RATING



We review 7 different criteria on a scale of 1-5 against specific benchmarks

Risk Rating Score	Designation
4.0-5.0	Very Strong Performance
1.0 - 1.9	Strong Performance
2.0-2.9	Performing
1.6-1.9	Watch
1.0-1.5	Default / Workout

The following table shows the distribution of our loan and equipment financing investments on the 1 to 5 investment risk rating scale range at fair value as of March 31, 2021 and December 31, 2020 (dollars in thousands):

		March 31, 2021				December 31, 2020		
Investment Risk Rating		Inv	vestments at	Percentage of	In	vestments at	Percentage of	
Scale Range	Designation	I	Fair Value	Total Portfolio	Fair Value		Total Portfolio	
4.0 - 5.0	Very Strong Performance	\$	110,278	23.8%	\$	92,519	20.9%	
3.0 - 3.9	Strong Performance		164,709	35.4%		212,969	48.0%	
2.0 - 2.9	Performing		148,691	32.1%		116,895	26.4%	
10.10	X + Z + 1		20.404	0 =0/		10.000	4.00/	
1.6 - 1.9	Watch		39,194	8.5%		19,230	4.3%	
1.0 - 1.5	Default/Workout		812	0.2%		1,606	0.4%	
Total		\$	463,684	100.0%	\$	443,219	100.0%	

At March 31, 2021 and December 31, 2020, our loan and equipment financing investments had a weighted average risk rating score of 3.2.

Debt Investments on Non-Accrual Status

When a debt security becomes 90 days or more past due, or if our management otherwise does not expect that principal, interest, and other obligations due will be collected in full, we will generally place the debt security on non-accrual status and cease recognizing interest income on that debt security until all principal and interest due has been paid or we believe the borrower has demonstrated the ability to repay its current and future contractual obligations. Any uncollected interest is reversed from income in the period that collection of the interest receivable is determined to be doubtful. However, we may make exceptions to this policy if the investment has sufficient collateral value and is in the process of collection.

At March 31, 2021, loans to three portfolio companies were on non-accrual status with a total cost of approximately \$2.3 million, and a total fair market value of approximately \$1.4 million, or 0.3%, of the fair value of the Company's investment portfolio. As of December 31, 2020, loans to three portfolio companies were on non-accrual status with a total cost of approximately \$3.4 million, and a total fair market value of approximately \$2.2 million, or 0.5%, of the fair value of the Company's investment portfolio.

Results of Operations

The following discussion and analysis of our results of operations encompasses our consolidated results for the three months ended March 31, 2021 and 2020. We were formed on August 12, 2019 and commenced operations on



January 16, 2020. Prior to January 16, 2020, we had no operations, except for immaterial matters relating to our formation and organization as a BDC.

Investment Income

The following table sets forth the components of investment income (in thousands):

	Mare	Three Mont ch 31, 2021	ths Ended <u>March 31, 2020</u>		
Stated interest income	\$	11,752	\$	8,710	
Amortization of original issue discount		3,447		1,676	
Acceleration of amortization of original issue discount		1,146		428	
Prepayment penalty and related fees		706		957	
Other fee income		269		477	
Total investment income	\$	17,320	\$	12,248	

We generate revenues primarily in the form of investment income from the investments we hold, generally in the form of interest income from our debt securities. Investment income represents interest income recognized as earned in accordance with the contractual terms of the loan agreement. Interest income from original issue discount ("OID") represents the estimated fair value of detachable warrants obtained in conjunction with the origination of debt securities, including loans and equipment financings and is accreted into interest income over the term of the loan as a yield enhancement. Interest income from payment-in-kind ("PIK") represents contractually deferred interest added to the loan balance recorded on an accrual basis to the extent such amounts are expected to be collected.

Loan and commitment fees in excess of related expenses are amortized into interest income over the contractual life of the loan. The Company also recognizes certain fees as one-time fee income, including, but not limited to, prepayment penalties, fees related to select covenant default, late-payment fees, structuring fees and exit fees related to a change in ownership of the portfolio company.

For the three months ended March 31, 2021, total investment income was approximately \$17.3 million, which represents an approximate effective yield of 15.5% on the average investments during such period. For the three months ended March 31, 2020, total investment income was approximately \$12.2 million, which represents an approximate yield of 15.0% on the investments during the period. The increase in investment income for the three months ended March 31, 2021 is due to higher stated interest income and amortization of OID and EOT based on an increased principal value of income producing debt investments and partially offset by decreased fee income.

Operating Expenses

Our operating expenses are comprised of interest and fees on our borrowings, employee compensation, professional fees and general and administrative expenses. Our operating expenses totaled approximately \$10.1 million and \$6.6 million for the three months ended March 31, 2021 and 2020, respectively.

Interest Expense and Other Debt Financing Costs

Interest expense and other debt financing costs on our borrowings totaled approximately \$4.6 million and \$4.3 million for the three months ended March 31, 2021 and 2020, respectively, which is primarily comprised of interest and fees related to the Credit Facility, the 2025 Notes and the Convertible Notes. Our weighted effective interest rate, comprised of interest and amortization of fees and discount was approximately 7.2% and 6.4% for the three months ended March 31, 2021 and 2020, respectively. The increase in interest expense for the three months ended March 31, 2021 was primarily due to the issuance of the Convertible Notes in December 2020 and partially offset by paydowns in the Credit Facility.

Employee Compensation and Benefits

Employee compensation and benefits totaled approximately \$4.0 million and \$1.4 million for the three months ended March 31, 2021 and 2020, respectively. The increase in employee compensation related expenses during the three months ended March 31, 2021 relates primarily to the accrual of bonuses expected to be paid at the discretion of management or upon approval of the Board, as applicable. As of March 31, 2021 and 2020, the Company had 39 and 29 employees, respectively.

The Board has approved the 2019 Trinity Capital Inc. Long-Term Incentive Plan and the Trinity Capital Inc. 2019 Non-Employee Director Restricted Stock Plan, each to be effective upon receipt of exemptive relief from the SEC and stockholder approval of such plans. We have applied for an exemptive order from the SEC to permit us to issue certain securities under such plans. If such exemptive relief and stockholder approval are obtained, the Compensation Committee may award such securities in such amounts and on such terms as the Compensation Committee determines and consistent with any exemptive order the SEC may issue and the terms of such plans, as applicable. The SEC is not obligated to grant an exemptive order to allow this practice and will do so only if it determines that such practice is consistent with stockholder interests and does not involve overreaching by management or our Board. We cannot provide any assurance that we will receive such exemptive relief from the SEC or such stockholder approval.

Professional Fees Expenses

Professional fees expenses include legal fees, accounting fees, third-party valuation fees, and talent acquisition fees. Our professional fees expenses totaled approximately \$0.6 million and \$0.5 million for the three months ended March 31, 2021 and 2020, respectively.

General and Administrative Expenses

General and administrative expenses include insurance premiums, rent, taxes and other various expenses related to our ongoing operations. Our general and administrative expenses totaled approximately \$0.8 million and \$0.4 million for the three months ended March 31, 2021 and 2020, respectively. The increase in general and administrative expenses for the three months ended March 31, 2021 is primarily due to a higher D&O insurance premiums.

Net Investment Income

As a result of approximately \$17.3 million in total investment income as compared to approximately \$10.0 million in total expenses, net investment income for the three months ended March 31, 2021 was approximately \$7.3 million. As a result of approximately \$12.2 million in total investment income as compared to approximately \$6.5 million in total expenses, net investment income for the three months ended March 31, 2020 was approximately \$5.7 million.

Net Realized Gains and Losses

Realized gains or losses are measured by the difference between the net proceeds from the sale or redemption of an investment or a financial instrument and the cost basis of the investment or financial instrument, without regard to unrealized appreciation or depreciation previously recognized, and includes investments written-off during the period. For the three months ended March 31, 2021, we realized a net gain on investments of approximately \$2.6 million. For the three months ended March 31, 2020, we realized a net loss on investments of approximately \$0.9 million.

The net realized gains (losses) from the sales, repayments, or exits of investments were comprised of the following (in thousands):

Net realized gain (loss) on investments:	Mar	Three Mo ch 31, 2021	 Ended rch 31, 2020
Gross realized gains	\$	2,967	\$ 794
Gross realized losses		(372)	 (1,676)
Total net realized gains/(losses) on investments	\$	2,595	\$ (882)

Net Change in Unrealized Appreciation / (Depreciation) from Investments

Net change in unrealized appreciation/(depreciation) from investments primarily reflects the net change in the fair value of the investment portfolio and financial instruments and the reclassification of any prior period unrealized appreciation or depreciation on exited investments and financial instruments to realized gains or losses.

Net unrealized appreciation and depreciation on investments for the three months ended March 31, 2021 and 2020 is comprised of the following (in thousands):

	Ma	Three Moi rch 31, 2021	
Gross unrealized appreciation	\$	34,066	\$ 1,296
Gross unrealized depreciation		(18,081)	(25,599)
Third party participation ⁽¹⁾		283	13
		205	15
Net unrealized appreciation/depreciation reclassified related to net realized gains or losses ⁽²⁾		(792)	
Total net unrealized gains (losses) on investments	\$	15,476	\$ (24,290)

⁽¹⁾ Certain third parties had rights to 17,485 shares of Ology Biosciences common stock at a fair value of approximately \$0.6 million as of December 31, 2020. During the three months ended March 31, 2021, these shares were reissued by Ology Biosciences directly to the third parties and the corresponding liability was removed from the Consolidated Statement of Assets and Liabilities. The activity related to these shares and the related liability is recorded against unrealized appreciation/(depreciation).

⁽²⁾ Investments were recorded at their fair values in the Formation Transactions on January 16, 2020, therefore no reclassification of unrealized appreciation (depreciation) was recorded during the three months ended March 31, 2020.

⁷⁴

The significant changes in net unrealized appreciation (depreciation) from investments during the three months ended March 31, 2021 consisted of the following (in thousands):

Portfolio Company	Net Unrealized Appreciation (Depreciation)		
Atieva, Inc.	\$	22,193	
Matterport, Inc.		3,403	
Convercent, Inc.		1,027	
AyDeeKay LLC		954	
Madison Reed, Inc.		794	
Store Intelligence, Inc.		(564)	
WorkWell Prevention & Care Inc.		(673)	
Incontext Solutions, Inc.		(916)	
Ology Biosciences, Inc.		(5,748)	
Birchbox, Inc.		(7,970)	
Other, net		2,976	
Total	\$	15,476	

The significant changes in net unrealized appreciation (depreciation) from investments during the three months ended March 31, 2020 consisted of the following (in thousands):

Portfolio Company	Net Unrealized Appreciation (Depreciation)				
Vertical Communications, Inc.	\$ (3,868	5)			
Workwell Prevention & Care Inc.	(2,544	.)			
Altierre, Inc.	(2,110))			
UnTuckIt, Inc.	(1,558	5)			
Project Frog, Inc.	(1,507)			
Vidsys, Inc.	(1,502	.)			
Birchbox, Inc.	(938	5)			
Atieva, Inc.	(849))			
BaubleBar, Inc.	(844	.)			
Edeniq, Inc.	(716	5)			
SQL Sentry LLC	(578	5)			
STS Media, Inc.	(500))			
Other, net	(6,776	5)			
Total	\$ (24,290	<u>)</u>			

Net Increase (Decrease) in Net Assets Resulting from Operations

Net increase in net assets resulting from operations during the three months ended March 31, 2021 was approximately \$25.3 million. Net decrease in net assets resulting from operations before formation costs during the three months ended March 31, 2020 was approximately \$19.5 million.

Net Increase (Decrease) in Net Assets Resulting from Operations and Earnings Per Share

For the three months ended March 31, 2021 basic and fully diluted net increase in net assets per common share were \$1.08. For the three months ended March 31, 2020, basic and diluted net decrease in net assets per common share were \$1.97. Costs related to the acquisition of Trinity Capital Holdings was approximately \$13.5 million, and the cost related to the acquisition of the Legacy Funds was approximately \$2.1 million. The total cost of \$15.6 million, when added to

the net decrease in net assets resulting from operations before formation costs, resulted in a net decrease in net assets resulting from operations during the three months ended March 31, 2020 of approximately \$(35.1) million.

Financial Condition, Liquidity and Capital Resources

Our liquidity and capital resources are generated primarily from the net proceeds of offerings of our securities, including the Private Offerings and the Convertible Notes offering, borrowings under the Credit Facility and cash flows from our operations, including investment sales and repayments, as well as income earned on investments and cash equivalents. Our primary use of our funds includes investments in portfolio companies, payments of interest on our outstanding debt, and payments of fees and other operating expenses we incur. We also expect to use our funds to pay distributions to our stockholders. We have used, and expect to continue to use, our borrowings, including under the Credit Facility or any future credit facility, and proceeds from the turnover of our portfolio to finance our investment objectives and activities.

We may, from time to time, enter into additional credit facilities, increase the size of our existing Credit Facility, or issue additional securities in private or public offerings. Any such incurrence or issuance would be subject to prevailing market conditions, our liquidity requirements, contractual and regulatory restrictions, and other factors.

For the three months ended March 31, 2021, we experienced a net decrease in cash and cash equivalents in the amount of \$9.8 million, which is the net result of \$19.2 million of cash used in operating activities and \$0.5 million of cash used in investing activities partially offset by \$9.9 million of cash provided by financing activities. During the three months ended March 31, 2020, we experienced a net increase in cash and cash equivalents in the amount of \$79.5 million, which is the net result of \$170.1 million of cash provided by financing activities and \$1.1 million of cash from operating activities partially offset by \$91.7 million of cash used in investing activities.

As of March 31, 2021 and December 31, 2020, we had cash, cash equivalents and restricted cash of \$51.3 million and \$61.1 million, respectively, of which \$39.7 and \$60.3 million, respectively, is held in the Goldman Sachs Financial Square Government Institutional Fund. Cash held in demand deposit accounts may exceed the Federal Deposit Insurance Corporation ("FDIC") insured limit and therefore is subject to credit risk. All of the Company's cash deposits are held at large established high credit quality financial institutions, and management believes that the risk of loss associated with any uninsured balances is remote. As of March 31, 2021 and December 31, 2020, restricted cash consisted of approximately \$15.3 million and \$15.7 million, respectively, related to the Credit Facility covenants (See "Note 5 – Borrowings"), and an additional amount of approximately \$0.7 million at December 31, 2020 was held in escrow related to the payout of a severance related liability assumed as part of the Formation Transactions with respect to a former member of certain general partners of certain Legacy Funds. As of March 31, 2021 and December 31, 2020, we had approximately \$72.5 million and \$42.0 million, respectively, of available borrowings under the Credit Facility, subject to its terms and regulatory requirements. Cash, cash equivalents and restricted cash, taken together with available borrowings under the Credit Facility, as of March 31, 2021, are expected to be sufficient for our investing activities and to conduct our operations in the near term.

On January 16, 2020, in connection with the Formation Transactions, we became a party to, and assumed, the Credit Facility through our wholly owned subsidiary, Trinity Funding 1, LLC. The Credit Facility matures on January 8, 2022, unless extended, and we have the ability to borrow up to an aggregate of \$300.0 million. In addition, borrowings under the Credit Facility are subject to floating interest rates based on LIBOR, generally bearing interest at a rate of the three-month LIBOR plus 3.25%. We may utilize the leverage available under the Credit Facility to finance future investments. We used a portion of the proceeds from the Private Offerings to repay a portion of the aggregate amount outstanding under the Credit Facility in amount of approximately \$60 million. As of March 31, 2021 and December 31, 2020, approximately \$45.0 million and \$135.0 million, respectively, was outstanding under the Credit Facility. During the three months ended March 31, 2021 and 2020, we repaid \$85.0 million and \$60.0 million, respectively, of borrowings under the Credit Facility.

In January 2020, we completed the Private Common Stock Offering in reliance upon the available exemptions from the registration requirements of the Securities Act, pursuant to which we issued and sold 8,333,333 shares of our common stock for aggregate gross proceeds of approximately \$125.0 million. A portion of the proceeds of the Private

Common Stock Offering were used to complete the Formation Transactions and repay a portion of the outstanding borrowings under the Credit Facility.

In January 2020, concurrent with the completion of the Private Common Stock Offering, we completed the 144A Note Offering in reliance upon the available exemptions from the registration requirements of the Securities Act, pursuant to which we issued and sold \$125.0 million in aggregate principal amount of the unsecured 2025 Notes that mature on January 16, 2025, unless repurchased or redeemed in accordance with their terms prior to such date and bear interest at a fixed rate of 7.00% per year payable quarterly on March 15, June 15, September 15 and December 15 of each year. A portion of the proceeds of the 144A Note Offering were used to complete the Formation Transactions and repay a portion of the outstanding borrowings under the Credit Facility. Aggregate estimated offering expenses in connection with the transaction, including the fees and commissions, were approximately \$4.8 million. As of March 31, 2021 and December 31, 2020, we had \$125 million in aggregate principal amount of 2025 Notes outstanding.

In December 2020, we issued \$50.0 million in aggregate principal amount of the Convertible Notes. The sale generated net proceeds of \$47.0 million, including \$1.7 million of debt issuance costs and \$1.3 million of original issue discount. The Convertible Notes bear interest at a rate of 6.00% per year, payable semiannually in arrears on May 1 and November 1, of each year. The Convertible Notes mature on December 11, 2025, unless earlier converted by noteholders or purchased by the Company at the noteholders option upon the occurrence of a fundamental change, as defined in the indenture governing the Convertible Notes. As of March 31, 2021 and December 31, 2020, we had \$50.0 million in aggregate principal amount of Convertible Notes outstanding.

Refer to "Item 2. Financial Statements and Supplementary Data – Note 5 – Borrowings" included in the notes to our consolidated financial statements appearing elsewhere in this report for a discussion of our borrowings.

Reduced Asset Coverage Requirements

In accordance with the 1940 Act, with certain limited exceptions, we are only allowed to incur borrowings, issue debt securities or issue preferred stock, if immediately after the borrowing or issuance, the ratio of total assets (less total liabilities other than indebtedness) to total indebtedness plus preferred stock, is at least 150%. On September 27, 2019, the Board, including a "required majority" (as such term is defined in Section 57(0) of the 1940 Act) and our initial stockholder approved the application to us of the 150% minimum asset coverage ratio set forth in Section 61(a)(2) of the 1940 Act. As a result, effective September 28, 2019, the asset coverage ratio under the 1940 Act applicable to us decreased from 200% to 150%, permitting us to potentially borrow \$2 for investment purposes of every \$1 of investor equity. As of March 31, 2021, our asset coverage ratio was approximately 264.3% and our asset coverage ratio per unit was approximately \$2,643. As of December 31, 2020, our asset coverage ratio was approximately 177.0% and our asset coverage ratio per unit was approximately \$1,770. We target a leverage range of between 1.15x and 1.35x.

Commitments and Off-Balance Sheet Arrangements

Other than contractual commitments with respect to our portfolio companies and other legal contingencies incurred in the normal course of our business, we do not have any off-balance sheet financings or liabilities as of March 31, 2021 or December 31, 2020.

The Company's commitments and contingencies consist primarily of unfunded commitments to extend credit in the form of loans to the Company's portfolio companies. A portion of these unfunded contractual commitments as of March 31, 2021 and December 31, 2020 are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available. Furthermore, the Company's credit agreements with its portfolio companies generally contain customary lending provisions that allow the Company relief from funding obligations for previously made commitments in instances where the underlying portfolio company experiences materially adverse events that affect the financial condition or business outlook for the company. Since a portion of these commitments may expire without being withdrawn, unfunded contractual commitments do not necessarily represent future cash requirements. As such, the Company's disclosure of unfunded contractual commitments includes only those which are available at the request of the portfolio company and unencumbered by milestones. As of March 31, 2020, the Company had outstanding unfunded commitments of approximately \$8.3 million to two portfolio companies, Dandelion, Inc. and Greenlight Biosciences,

Inc. As of December 31, 2020, the Company had outstanding unfunded commitments of approximately \$0.1 million to one portfolio company, Dandelion, Inc. The Company will fund its future unfunded commitments from the same sources it uses to fund its investment commitments that are funded at the time they are made (which are typically through existing cash and cash equivalents and borrowings under the Credit Facility).

In the normal course of business, the Company enters into contracts that provide a variety of representations and warranties, and general indemnifications. Such contracts include those with certain service providers, brokers and trading counterparties. Any exposure to the Company under these arrangements is unknown as it would involve future claims that may be made against the Company; however, based on the Company's experience, the risk of loss is remote and no such claims are expected to occur. As such, the Company has not accrued any liability in connection with such indemnifications.

Contractual Obligations

A summary of our contractual payment obligations as of March 31, 2021, is as follows:

	 Payments Due by Period							
	s than 1 year	1 - 3 years		years 4 - 5 year		ars After 5 years		 Total
Credit Facility	\$ _	\$	45,000	\$	_	\$	_	\$ 45,000
7.00% Notes			_		125,000		_	125,000
Convertible Notes			_		50,000		_	50,000
Operating Leases ⁽¹⁾	 168		845		751		1,619	 3,383
Total Contractual Obligations	\$ 168	\$	45,845	\$	175,751	\$	1,619	\$ 223,383

(1) Relates to lease for the Company's office, which expires on July 31, 2022 and is subject to a five-year extension option, plus the lease the Company signed for a new space in downtown Phoenix, Arizona with an estimated commencement date in mid-2021. The Company has recorded the current lease as a right-of-use asset and lease liability in its financial statements, and will record the new lease as such upon its commencement date in mid-2021. No right of use asset or corresponding lease liability has been recorded on the new lease as the lease has not commenced.

Distributions

We intend to pay quarterly distributions to our stockholders out of assets legally available for distribution. All distributions will be paid at the discretion of the Board and will depend on our earnings, financial condition, maintenance of our tax treatment as a RIC, compliance with applicable BDC regulations and such other factors as the Board may deem relevant from time to time.

During the three months ended March 31, 2021, the Company declared a distribution on March 23, 2021 of \$0.28 per share, which was paid on April 16, 2021 to stockholders of record as of March 31, 2021. No distributions were declared or paid during the three months ended March 31, 2020.

Related Party Transactions

As discussed herein, the Legacy Funds were merged with and into the Company and we issued 9,183,185 shares of our common stock at \$15.00 per share for a total value of approximately \$137.7 million and paid approximately \$108.7 million in cash to the Legacy Investors, which include the general partners/managers of the Legacy Funds. In addition, as part of the Formation Transactions, we acquired 100% of the equity interests of Trinity Capital Holdings for shares of our common stock and cash. Members of our management, including Steven L. Brown, Kyle Brown, Gerald Harder and Ron Kundich, owned 100% of the equity interests in Trinity Capital Holdings and controlling interests in the general partners/managers of the Legacy Funds.

As a result of the Formation Transactions, Messrs. S. Brown, K. Brown, Harder and Kundich collectively received (i) 533,332 shares of the Company's common stock valued at approximately \$8.0 million and approximately \$2.0 million in cash in exchange for their equity interests in Trinity Capital Holdings, and (ii) 377,441 shares of the Company's common stock valued at approximately \$5.7 million for their limited partner and general partner interests in the Legacy Funds.

We have entered into indemnification agreements with our directors and executive officers. The indemnification agreements are intended to provide our directors and executive officers with the maximum indemnification permitted under Maryland law and the 1940 Act. Each indemnification agreement provides that we shall indemnify the director or executive officer who is a party to the agreement, or an "Indemnitee," including the advancement of legal expenses, if, by reason of his or her corporate status, the Indemnitee is, or is threatened to be, made a party to or a witness in any threatened, pending, or completed proceeding, to the maximum extent permitted by Maryland law and the 1940 Act.

Recent Developments

Subsequent to the quarter ended March 31, 2021 and through the date of filing of this Quarterly Report on Form 10-Q, no material events or developments occurred that require reporting.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are subject to financial market risks, including valuation risk and interest rate risk. Uncertainty with respect to the economic effects of the COVID-19 pandemic has introduced significant volatility in the financial markets, and the effect of the volatility could materially impact our market risks, including those listed below.

Valuation Risk

Our investments may not have a readily available market price, and we value these investments at fair value as determined in good faith by the Board of Directors in accordance with our valuation policy. There is no single standard for determining fair value in good faith. As a result, determining fair value requires that judgment be applied to the specific facts and circumstances of each portfolio investment while employing a consistently applied valuation process for the types of investments we make. Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of our investments may fluctuate from period to period, including as a result of the impact of the COVID-19 pandemic on the economy and financial and capital markets. Because of the inherent uncertainty of valuation, these estimated values may differ significantly from the values that would have been used had a ready market for the investments existed, and it is possible that the difference could be material.

Interest Rate Risk

Interest rate sensitivity and risk refer to the change in earnings that may result from changes in the level of interest rates. To the extent that we borrow money to make investments, including under the Credit Facility or any future financing arrangement, our net investment income will be affected by the difference between the rate at which we borrow funds and the rate at which we invest these funds. In periods of rising interest rates, our cost of borrowing funds would increase, which may reduce our net investment income. As a result, there can be no assurance that a significant change in market interest rates will not have a material adverse effect on our net investment income.

As of March 31, 2021, approximately 32.1% of our debt investments at fair value represented floating-rate investments based on PRIME, and approximately 67.9% of our debt investments based on outstanding principal balance represented fixed-rate investments. In addition, borrowings under the Credit Facility are subject to floating interest rates based on LIBOR, generally bearing interest at a rate of the three-month LIBOR plus 3.25%.

Based on our Consolidated Statements of Operations as of March 31, 2021, the following table shows the annualized impact on net income of hypothetical base rate changes in the PRIME rate on our debt investments

(considering interest rate floors for floating rate instruments) and the hypothetical base rate changes in the three-month LIBOR on our Credit Facility and there are no changes in our investment and borrowing structure (in thousands):

	Interest	Interest	Net
	Income	Expense	Income/(Loss)
Up 300 basis points	\$ 3,826	\$ 1,350	\$ 2,476
Up 200 basis points	\$ 2,325	\$ 900	\$ 1,425
Up 100 basis points	\$ 1,011	\$ 450	\$ 561
Day m 100 basis points	\$ —	\$ (120)	\$ 120
Down 100 basis points	3 —	\$ (120)	\$ 120
Down 200 basis points	\$ —	\$ (120)	\$ 120
Down 300 basis points	\$ —	\$ (120)	\$ 120

Currency Risk

In addition, any investments we make that are denominated in a foreign currency will be subject to risks associated with changes in currency exchange rates. These risks include the possibility of significant fluctuations in the foreign currency markets, the imposition or modification of foreign exchange controls and potential illiquidity in the secondary market. These risks will vary depending upon the currency or currencies involved. As of March 31, 2021, we had two foreign domiciled portfolio companies. Our exposure to currency risk related to the debt investments is minimal as payments from such portfolio companies are received in U.S. dollars. Our equity investments in such portfolio companies are also settled using U.S. dollars. No other investments at March 31, 2021 were subject to currency risk.

Hedging

We do not currently engage in any hedging activities. However, we may, in the future, hedge against interest rate and currency exchange rate fluctuations by using standard hedging instruments such as futures, options and forward contracts subject to the requirements of the 1940 Act. While hedging activities may insulate us against adverse changes in interest rates, they may also limit our ability to participate in benefits of lower interest rates with respect to our portfolio of investments with fixed interest rates. We may also borrow funds in local currency as a way to hedge our non-U.S. denominated investments.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

In accordance with Rules 13a-15(b) and 15d-15(b) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), we, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, carried out an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q and determined that our disclosure controls and procedures are effective as of the end of the period covered by this Quarterly Report on Form 10-Q.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period ended March 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II OTHER INFORMATION

Item 1. Legal Proceedings

We are not currently subject to any material legal proceedings, nor, to our knowledge, are any material legal proceedings threatened against us. From time to time, we may be a party to certain legal proceedings in the ordinary course of business, including proceedings relating to the enforcement of our rights under contracts with our portfolio companies. Furthermore, third parties may seek to impose liability on us in connection with the activities of our portfolio companies. Our business is also subject to extensive regulation, which may result in regulatory proceedings against us. While the outcome of these legal or regulatory proceedings cannot be predicted with certainty, we do not expect that these proceedings will have a material effect upon our financial condition or results of operations.

Item 1A. Risk Factors

Investing in our securities involves a number of significant risks. In addition to the other information set forth in this quarterly report

on Form 10-Q, including the risk factors set forth below, you should carefully consider the risk factors discussed in "Item 1A. Risk Factors" of Annual Report on Form 10 K filed with the SEC on March 4, 2021, all of which could materially affect our business,

financial condition and/or results of operations. Although the risks described below and in our other SEC filings referenced above represent

the principal risks associated with an investment in us, they are not the only risks we face. Additional risks and uncertainties not currently

known to us, or that we currently deem to be immaterial, might materially and adversely affect our business, financial condition and/or

results of operations.

Other than as described below, during the three months ended March 31, 2021, there have been no material changes to the risk factors discussed in our SEC filings referenced above.

We are exposed to risks associated with changes in interest rates.

Because we may borrow money to make investments, our net investment income will depend, in part, upon the difference between the rate at which we borrow funds and the rate at which we invest those funds. As a result, we can offer no assurance that a significant change in market interest rates will not have a material adverse effect on our net investment income. A reduction in the interest rates on new investments relative to interest rates on current investments could have an adverse impact on our net investment income. However, an increase in interest rates could decrease the value of any investments we hold which earn fixed interest rates and also could increase our interest expense, thereby decreasing our net income. Also, an increase in interest rates available to investors could make an investment in our common stock less attractive if we are not able to increase our distribution rate, which could reduce the value of our common stock. Further, rising interest rates could also adversely affect our performance if such increases cause our borrowing costs to rise at a rate in excess of the rate that our investments yield.

In periods of rising interest rates, to the extent we borrow money subject to a floating interest rate, our cost of funds would increase, which could reduce our net investment income. Further, rising interest rates could also adversely affect our performance if we hold investments with floating interest rates, subject to specified minimum interest rates (such as a LIBOR floor), while at the same time engaging in borrowings subject to floating interest rates not subject to such minimums. In such a scenario, rising interest rates may increase our interest expense, even though our interest income from investments is not increasing in a corresponding manner as a result of such minimum interest rates.

If general interest rates rise, there is a risk that the portfolio companies in which we hold floating rate securities will be unable to pay escalating interest amounts, which could result in a default under their loan documents with us. Rising interest rates could also cause portfolio companies to shift cash from other productive uses to the payment of interest, which may have a material adverse effect on their business and operations and could, over time, lead to increased defaults. In addition, rising interest rates may increase pressure on us to provide fixed rate loans to our portfolio companies, which could adversely affect our net investment income, as increases in our cost of borrowed funds would not be accompanied by increased interest income from such fixed-rate investments. On July 27, 2017, the United Kingdom's Financial Conduct Authority (the "FCA"), which regulates LIBOR, announced that it intends to phase out LIBOR by the end of 2021. On November 30, 2020, ICE Benchmark Administration ("IBA"), the administrator of LIBOR, with the support of the United States Federal Reserve and the FCA, announced plans to consult on ceasing publication of USD LIBOR on December 31, 2021 for only the one week and two month USD LIBOR tenors, and on June 30, 2023 for all other USD LIBOR tenors, which the FCA subsequently confirmed on March 5, 2021. The United States Federal Reserve concurrently issued a statement advising banks to stop new USD LIBOR issuances by the end of 2021. Such announcements indicate that the continuation of LIBOR on the current basis cannot and will not be guaranteed after 2021. It appears highly likely that LIBOR will be discontinued or modified by 2021.

The U.S. Federal Reserve, in conjunction with the Alternative Reference Rates Committee, a steering committee comprised of large U.S. financial institutions, is considering replacing U.S. dollar LIBOR with a new index calculated by short term repurchase agreements, backed by Treasury securities called the Secured Overnight Financing Rate ("SOFR"). The first publication of SOFR was released in April 2018. Whether or not SOFR attains market traction as a LIBOR replacement remains a question and the future of LIBOR at this time is uncertain. Although SOFR appears to be the preferred replacement rate for U.S. dollar LIBOR, at this time, it is not possible to predict the effect of any such changes, any establishment of alternative reference rates or any other reforms to LIBOR that may be enacted. The elimination of LIBOR or any other changes or reforms to the determination or supervision of LIBOR could have an adverse impact on the market for or value of any LIBOR-linked securities, loans, and other financial obligations or extensions of credit held by or due to us or on our overall financial condition or results of operations. In addition, if LIBOR ceases to exist, we may need to renegotiate credit agreements extending beyond 2021 with our portfolio companies that utilize LIBOR as a factor in determining the interest rate, in order to replace LIBOR with the new standard that is established, which may have an adverse effect on our overall financial condition or results of operations. Following the replacement of LIBOR, some or all of these credit agreements may bear interest a lower interest rate, which could have an adverse impact on our results of operations. Furthermore, under the Credit Facility with Credit Suisse, borrowings generally will bear interest at a rate of the three-month LIBOR plus 3.25%. If LIBOR ceases to exist, we will need to renegotiate certain terms of the Credit Facility. If we are unable to do so, amounts drawn under the Credit Facility may bear interest at a higher rate, which would increase the cost of our borrowings and, in turn, affect our results of operations.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On January 15, 2021, pursuant to its restated and amended distribution reinvestment plan, the Company issued 87,710 shares of its common stock, at a price of \$13.01 per share, to stockholders of record as of December 30, 2020 that did not opt out of the Company's distribution reinvestment plan in order to satisfy the reinvestment portion of the Company's distribution. This issuance was not subject to the registration requirements of the Securities Act.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

Item 6. Exhibits

The following exhibits are filed as part of this Quarterly Report on Form 10-Q or hereby incorporated by reference to exhibits previously filed with the SEC:

Exhibit	
Number	Description of Exhibits
3.1	Articles of Amendment and Restatement (incorporated by reference to Exhibit 3.1 to the Company's
	Registration Statement on Form 10 filed on January 16, 2020).
3.2	Bylaws (incorporated by reference to Exhibit 3.2 to the Company's Registration Statement on Form 10 filed on
	<u>January 16, 2020).</u>
<u>4.1</u>	Amended and Restated Registration Rights Agreement dated December 15, 2020 (Common Stock)
	(incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed December 16,
	<u>2020).</u>
4.2	Registration Rights Agreement, dated January 16, 2020 (Notes) (incorporated by reference to Exhibit 4.2 to the
	Company's Registration Statement on Form 10 filed on January 16, 2020).
4.3	Registration Rights Agreement, dated December 11, 2020 (Convertible Notes) (incorporated by reference to
	Exhibit 10.1 to the Company's Current Report on Form 8-K, filed on December 14, 2020).
4.4	Indenture, dated as of January 16, 2020, by and between Trinity Capital Inc. and U.S. Bank National
	Association, as trustee (incorporated by reference to Exhibit 4.3 to the Company's Registration Statement on
	Form 10 filed on January 16, 2020).
4.5	First Supplemental Indenture, dated as of January 16, 2020, relating to the 7.00% Notes due 2025, by and
	between Trinity Capital Inc. and U.S. Bank National Association, as trustee (incorporated by reference to
	Exhibit 4.4 to the Company's Registration Statement on Form 10 filed on January 16, 2020).
4.6	Form of 7.00% Note due 2025 (included as part of and incorporated by reference to Exhibit 4.5 hereto).
4.7	Second Supplemental Indenture, dated January 16, 2020, relating to the 6.00% Convertible Notes due 2025,
	between Trinity Capital Inc. and U.S. Bank National Association, as trustee (incorporated by reference to
	Exhibit 4.1 to the Company's Current Report on Form 8-K, filed on December 14, 2020).
4.8	Form of 6.00% Convertible Notes due 2025 (included as part of and incorporated by reference to Exhibit 4.7
	<u>hereto).</u>
10.1	Amended and Restated Distribution Reinvestment Plan (incorporated by reference to Exhibit 10.1 to the
	Company's Current Report on Form 8-K, filed on March 29, 2021).
31.1*	Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities
	Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities
	Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to
	Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*	Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to
	Section 906 of the Sarbanes-Oxley Act of 2002.

* Filed herewith

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

TRINITY CAPITAL INC.

By: /s/ Steven L. Brown Steven L. Brown Chairman and Chief Executive Officer (Principal Executive Officer)

Dated: May 6, 2021

Dated: May 6, 2021

By: /s/ David Lund

David Lund Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer)